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Summary 
A positive affection of human health by nutrition is of high interest, especially for food 
being daily consumed in high amounts. This is the case for coffee, one of the most 
consumed beverages worldwide. In epidemiological studies a reduced risk of type II 
diabetes, cognitive, cardiovascular and certain cancer disorders were associated with 
a lifelong daily intake. These positive health effects are partially associated with the 
high polyphenol content (especially chlorogenic acids) in coffee. Numerous in vitro 
studies using this class of polyphenols are also indicating an association. These 
chlorogenic acids (CGA), consisting essentially of a hydroxycinnamic acid esterified 
with D-(-)-quinic acid (QA), are therefore suggested to be nutraceuticals. However, so 
far their accurate bioefficacy with daily consumption of CGA by coffee is not well 
understood. The decisive basis for this is a precise knowledge of CGA bioavailability 
after oral application as it describes the amount of CGA which is available at the site 
of action.  
The bioavailability of a molecule can be influenced by various factors. These can be 
widely classified by the dosage form, the proband´s physiology and the physico-
chemical properties of the ingested molecule. Series of studies describes a 
somewhat controversial and inconsistent bioavailability data for CGA, especially in 
the upper GIT. Since different dosages in matrices and doses, with partially different 
CGA compositions and different analytical strategies were used, it is not possible to 
take these differences into account with overall bioavailability.  
The objective of the present study was to investigate the influence of individual 
factors on bioavailability of CGA in the upper parts of the GIT. For that purpose we 
used two different study designs.  
First we monitored dose-response effects in vivo for the total absorption, metabolic 
pattern in the upper gastro intestinal tract and colonic availability of CGA and QA 
after oral coffee application. Especially the effect of the ingested dose on the sites 
where absorption occurs within the GIT were here of interest. For this, we performed 
a randomized, double-blinded, crossover study with five probands with a terminal 
ileostomy. After a two day polyphenol free diet, the ileostomists consumed, in three 
separate occasions, instant coffee with different CGA contents (HIGH 4,525 µmol; 
MEDIUM 2,219 µmol; LOW 1,053 µmol) and different amounts of free QA (HIGH 
2,457 µmol; MEDIUM 1,373 µmol, LOW 695 µmol). Plasma, urine and ileal fluid 
Summary   XVII 
samples were collected. Except for plasma samples, we used an analytical strategy 
for all samples without enzymatic cleavage of CGA conjugates. CGA and 
corresponding metabolites were identified and quantified by HPLC-DAD, -ESI-MS 
and -ESI-MS/MS. QA was quantified by stable isotope dilution analysis. 
 
Additionally, the influence of molecular properties of CGA and QA from coffee on 
bioavailability was assessed (structure-absorption relation). Due to the extensive 
biotransformation of CGA in the human body such investigations were performed ex 
vivo with pig jejunal mucosa using the Ussing chamber model. For this purpose 
we used QA and individual CGA from coffee, namely: caffeoylquinic acids (CQA), 
feruloylquinic acids (FQA), caffeic acid (CA), dicaffeoylquinic acids (diCQA). These 
compounds were incubated using individual experiments at physiological 
concentrations from 0.2 up to 3.5 mM. We also investigated a possible secretion and 
the mechanism of absorption (dose-absorption relation) of the main CGA from 
coffee, 5-caffeoylquinic acid. The mucosa and individual supernatants of Ussing 
chamber halves were analyzed by HPLC-DAD and -ESI-MS/MS. 
 
After the consumption of different, increasing doses of coffee the following AUC0-8h 
for CGA and metabolites were determined in plasma (after treatment with 
glucuronidase and sulfatase): 4,412 ± 751 nM*h0-8-1 (HIGH), 2,394 ± 637 nM*h0-8-1 
(MEDIUM) and 1,782 ± 731 nM*h0-8-1 (LOW) respectively. The renal excretion 
accounted for CGA and metabolites 8.0 ± 4.9% (HIGH), 12.1 ± 6.7% (MEDIUM) and 
14.6 ± 6.8% (LOW) of the ingested dose. About ⅔ of the CGA from coffee 
consumption was available in the colon dose independent: Therefore, we assumed 
the sites of absorption within the GIT were not influenced by dose. Higher ingested 
CGA doses lead to an accelerated ileal excretion. Interindividual difference in 
gastrointestinal transit times of coffee were probably related to the systemic 
availability of CGA. This is corroborated ex vivo by a direct proportional relationship 
of incubation time with absorbed CGA amounts. Consequently the interindividual 
differences of proband´s physiology are a decisive bioavailability factor for CGA 
uptake. New metabolites in ileal and renal excretion were detected and therefore a 
much more extensive metabolism of CGA than recently expected. For instance, CGA 
with a caffeic acid moiety were predominantly sulfated at position 3´ instead of CGA 
with ferulic acid moiety predominantly renally excreted as glucuronide. In the ileal 
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effluent samples, sulfation of both structural units dominated. However, 
glucuronidation of CGA slightly was increased with increasing consumed coffee 
dose.  
We conclude that the consumption of high CGA doses via coffee might influence the 
gastrointestinal transit time and consequently affect CGA absorption in vivo. 
Nevertheless, the dose-response studies concluded that different CGA and QA 
doses from coffee have only minor effects on absorption in the upper GIT. This is 
also corroborated ex vivo by a non-saturable absorption (linear dose-flux 
relationship) of 5-CQA, indicating passive diffusion as major mechanism of 
absorption.  
Due to the extensive biotransformation of CGA in the human body after consumption 
of coffee, the conclusion of influence of molecular properties on absorption is limited. 
However, no diCQA were determined in vivo but for the first time significant amounts 
of FQA, CQA and QA in plasma and urine were present. These observations were 
corroborated ex vivo in the Ussing chamber model. According to the subgroup of 
CGA different amounts were transferred through the jejunal pig mucosa in increasing 
order: diCQA, trace amounts; CQA, ≈ 1%; CA, ≈ 1.5%; FQA, ≈ 2%; and QA, ≈ 4%. 
No differences were observed within the CGA subgroups. Thus we conclude that the 
mechanism of CGA absorption is governed by its physico-chemical properties.  
Furthermore, we identified an active efflux secretion for 5-CQA in the pig jejunum ex 
vivo and we are postulating an active efflux for hydrophilic CGA metabolites such as 
CQA-sulfates or FQA-glucuronides which might decrease total CGA bioavailability.  
 
In the course of this PhD thesis the influence of several factors on bioavailability of 
CGA from coffee was shown. The increased consumption of CGA doses by coffee 
had a minor effect on oral bioavailability in ileostomists. This was approved ex vivo 
since CGA absorption is governed by diffusion. Consequently, the consumption of 
high amounts of CGA from coffee with the daily diet is not limiting its bioavailability. 
However, the systemic availability of CGA is associated with the different proband´s 
physiology, especially the interindividual gastrointestinal transit time which is possibly 
influenced by dose and the physico-chemical properties of CGA. Hence, 
bioavailability of CGA also depends on the CGA composition of the food consumed.  
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Zusammenfassung 
Eine Verringerung des Erkrankungsrisikos von sogenannten Zivilisationskrankheiten 
durch die Ernährung ist in den industrialisierten Ländern von großer Bedeutung. Eine 
solche potentielle Wirkung wird dem Kaffee Getränk nachgesagt. Eines der weltweit 
meist konsumierten Getränke. Ein reduziertes Risiko für Type II Diabetes-, 
Kognitiver-, Herzkreislauf- und bestimmte Krebs- Erkrankungen werden in 
epidemiologischen Untersuchungen mit einem täglichen, lebenslangen Konsum in 
Zusammenhang gebracht. Die beschriebenen Effekte auf die Gesundheit werden 
zum Teil der hohen Polyphenol Menge im Kaffee (insbesondere den 
Chlorogensäuren) zugeschrieben. Zahlreiche in vitro Studien mit dieser 
Polyphenolklasse weisen ebenfalls auf einen derartigen Zusammenhang hin. Daher 
werden die Chlorogensäuren (CGA), bestehend aus einer Hydroxyzimtsäure 
verestert mit D-(-)-Chinasäuren (QA), auch als sogenannte “Nutraceuticals” 
bezeichnet. Allerdings ist bis jetzt deren exakte biologische Wirkung bei täglichem 
Verzehr von CGA durch Kaffee nicht eingehend erfasst. Die entscheidende 
Grundlage dafür ist ein präzises Verständnis der Bioverfügbarkeit nach oraler 
Applikation, da diese die Menge an CGA beschreibt, welche am Wirkort verfügbar ist. 
Die Bioverfügbarkeit eines Moleküls kann von verschiedenen Faktoren beeinflusst 
werden. Diese können in die Art der Dosis, die Physiologie des Probanden und der 
physikalisch-chemischen Eigenschafften des Moleküls unterteilt werden. Durch eine 
Vielzahl von Studien ist ein etwas kontroverser und unzureichender Kenntnisstand 
der Bioverfügbarkeit von CGA beschrieben, besonders bezüglich deren Absorption 
im oberen Gastrointestinaltrakt. Da unterschiedliche Dosierungen in Matrix und 
Menge, teilweise mit unterschiedlichen CGA Profil und verschiedenen analytischen 
Strategien (mit oder ohne enzymatischer Spaltung von CGA Metaboliten) verwendet 
wurden, ist die Bedeutung einzelner Parameter auf die Bioverfügbarkeit nicht 
erfassbar. Ziel dieser Arbeit war es, einen Einfluss individueller Parameter auf die 
Bioverfügbarkeit der CGA im oberen Gastrointestinaltrakt zu untersuchen. Dazu 
verwendeten wir zwei unterschiedliche Ansätze.  
Zunächst überprüften wir in vivo den Einfluss der applizierten Dosis auf die 
Absorption und den Metabolismus im oberen Gastrointestinaltrakt und die 
Verfügbarkeit im Kolon von CGA und QA nach oraler Applikation von Kaffee (Dosis-
Wirkungs Studie). Von besonderem Interesse war dabei der Einfluss der 
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aufgenommenen Dosis auf den Ort der Absorption innerhalb des 
Gastrointestinaltraktes. Dazu führten wir eine randomisierte, crossover 
Doppelblindstudie mit fünf Probanden mit einem Stoma des terminalen Ileums 
durch. Nach einer zwei Tage dauernden Polyphenol-freien Ernährung konsumierten 
die Ileostomie-Probanden an drei separaten Gelegenheiten, Instant-Kaffee mit 
unterschiedlichen CGA-Gehalt (HOCH 4.525 µmol; MITTEL 2.219 µmol, NIEDRIG 
1.053 µmol) und unterschiedlichen Gehalten an freier QA (HOCH 2.457 µmol; 
MITTEL 1.373 µmol, NIEDRIG 695 µmol). Es wurden Plasma Proben, sowie der 
gesamte Urin und Stoma-ausfluss entnommen. Mit Ausnahme der Plasma Analyse 
wurde für alle Proben eine analytische Strategie gewählt, welche keinerlei 
enzymatische Spaltung von Metaboliten der CGA vorsah. CGA und deren Metabolite 
wurden mittels HPLC-DAD, -ESI-MS und -ESI-MS/MS identifiziert und quantifiziert. 
Für die Quantifizierung der QA wurde eine Isotopenverdünnungs Analyse 
angewandt. 
Zusätzlich wurde die Bedeutung der molekularen Eigenschaften auf die 
Bioverfügbarkeit der CGA des Kaffees und der QA bestimmt (Struktur-Absorptions-
Beziehung). Bedingt durch die intensive Biotransformation (der CGA) im 
menschlichen Körper wurden derartige Überlegungen ex vivo mittels der Mukosa 
des Schweinejejunums im Ussing Kammer Model durchgeführt. Dafür wurden QA 
und einzelne CGA des Kaffees verwendet; und zwar: Kaffeoylchinasäuren (CQA), 
Feruloylchinasäuren (FQA), Kaffeesäure (CA) und diKaffeoylchinasäuren (diCQA). 
Diese Verbindungen wurden in einzelnen Experimenten in physiologischen 
Konzentrationen von 0.2 bis 3.5 mM verwendet. Weiterhin wurde auch eine mögliche 
Sekretion und der Mechanismus der Absorption (Dosis-Absorptions Beziehung) 
anhand der bedeutendsten CGA aus Kaffee, der 5-Kaffeoylchinasäure, untersucht. 
Die Mukosa und die einzelnen Überstände der Ussing Kammer Hälften wurden 
analysiert mittels HPLC-DAD und -ESI-MS/MS. 
 
Nach Verzehr unterschiedlicher Dosen Kaffee wurde folgende AUC0-8h für CGA und 
deren Metaboliten im Plasma bestimmt (nach Behandlung mit Glucuronidase und 
Sulfatase): 4412 ± 751 nM*h0-8-1 (HOCH), 2394 ± 637 nM*h0-8-1 (MITTEL) und 
1782 ± 731 nM*h0-8-1 (GERING). Die renale Ausscheidung betrug 8,0 ± 4,9% 
(HOCH), 12,1 ± 6,7% (MITTEL) und 14,6 ± 6,8% (GERING) der konsumierten CGA 
Dosis. Etwa ⅔ der CGA des applizierten Kaffees waren im Kolon Dosis-unabhängig 
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verfügbar, somit scheint der Ort der Absorption innerhalb des Gastrointestinaltraktes 
nicht durch die Dosis beeinflussbar zu sein. Eine größere aufgenommene CGA 
Menge führte zu einer beschleunigten ilealen Exkretion. Durch interindividuelle 
Unterschiede der gastrointestinalen Transitzeit des Kaffees konnte ein 
wahrscheinlicher Zusammenhang zur systemisch verfügbaren CGA Menge 
hergestellt werden. Dies konnte, durch einen direkt proportionalen Zusammenhang 
von Inkubationszeit und absorbierter CGA Menge, ex vivo bestätigt werden. Folglich 
sind die interindividuellen Unterschiede in der Physiologie der Probanden ein 
entscheidender Faktor für die Bioverfügbarkeit der CGA. Es wurden neuartige 
Metabolite in den ilealen und renalen Ausscheidungen charakterisiert und somit ein 
intensiver Metabolismus der CGA. Beispielsweise wurden CGA mit 
Kaffeesäureresten bevorzugt an Position 3´ sulfatiert, während CGA mit 
Ferulasäureresten renal zu einem größeren Anteil als Glucuronid ausgeschieden 
wurden. In der ilealen Flüssigkeit dominierten Sulfate beider struktureller Einheiten. 
Allerdings gewann der Anteil der CGA-Glucuronide mit größerer, verzehrter Kaffee 
Dosis an Bedeutung. 
Es wurde beobachtet, dass der Verzehr einer hohen Dosis CGA durch Kaffee die 
gastrointestinale Transitzeit beeinflussen kann und dadurch die CGA Absorption in 
vivo beeinflusst wird. Dennoch konnte durch Dosis-Wirkungs-Studien gezeigt 
werden, dass unterschiedliche CGA- und QA-Dosen aus Kaffee nur einen 
geringen Einfluss auf die Absorption im oberen Gastrointestinaltrakt haben. Dies 
konnte ebenfalls ex vivo, durch eine nicht sättigbare Absorption (linearen Dosis-
Fluss) von 5-CQA, welches auf eine passive Diffusion als Haupt-Mechanismus der 
Absorption hinweist, bestätigt werden. 
Durch die intensive Biotransformation der CGA im menschlichen Körper, nach dem 
Verzehr von Kaffee, konnte nur bedingt eine Aussage über den Einfluss der 
molekularen Eigenschaften auf die Absorption getroffen werden. Allerdings konnte in 
vivo keine diCQA, aber zum ersten Mal signifikante Mengen von FQA, CQA und QA 
in Plasma und Urin erfasst werden. Diese Beobachtung wurde ex vivo im Ussing-
Kammer-model bekräftigt. Die einzelnen Untergruppen der CGA wurden 
unterschiedlich durch die Mukosa des Schweine-jejunums transportiert, in 
aufsteigender Reihenfolge: diCQA, Spuren; CQA ≈ 1%; CA ≈ 1.5%; FQA ≈ 2%; und 
QA ≈ 4%. Innerhalb der CGA-Untergruppen wurden keine Unterschiede beobachtet. 
Somit kamen wir zu dem Schluss, dass die Absorption der CGA und QA durch 
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deren physikalisch-chemischen Eigenschaften bestimmt wurde. Weiterhin 
identifizierten wir eine aktive Sekretion der 5-CQA im Jejunum des Schweins ex vivo 
und postulieren eine aktive Sekretion für weitere CGA und deren hydrophilen 
Metabolite wie CQA-Sulfate oder FQA-Glucuronide, welche die gesamte 
Bioverfügbarkeit der CGA verringern könnte. 
Im Verlauf dieser Arbeit konnte der Einfluss verschiedener Faktoren auf die 
Bioverfügbarkeit der CGA aus Kaffee aufgezeigt werden. Der Verzehr von 
zunehmenden Mengen CGA mittels Kaffee hatte geringen Einfluss auf die orale 
Bioverfügbarkeit in Ileostomie-Probanden. Dies wurde ex vivo durch eine passive 
Diffusion als bestimmenden Mechanismus der Absorption bestätigt. Folglich wirkt 
sich der Verzehr hoher Mengen CGA durch die tägliche Ernährung nicht limitierend 
auf deren Bioverfügbarkeit aus. Allerdings scheint die systemische Verfügbarkeit der 
CGA von den unterschiedlichen Physiologien der Probanden abzuhängen. 
Insbesondere der gastrointestinalen Transitzeit. Ebenso wie von den 
unterschiedlichen physikalisch-chemischen Eigenschaften der einzelnen CGA 
Verbindungen. Somit ergibt sich eine unterschiedliche Bioverfügbarkeit aus 
Lebensmitteln mit gleichem Gehalt an CGA aber einem unterschiedlichen CGA Profil. 
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1  Introduction and motivation 
Coffee is a popular beverage especially in western countries and it is consumed for 
its stimulating effects and aromatic flavour. Furthermore, coffee is one of the most 
consumed beverages worldwide, with increasing consumption (IOC, 2012a). In 2011 
up to 149 L per person was consumed in Germany (Kaffeeverband, 2012). 
In the past coffee consumption was associated with harmful effects on human health 
whereas recent epidemiological investigations associated long-term effects of coffee 
consumption with a reduced risk of type II diabetes, neurodegenerative-, 
cardiovascular- and certain cancer disorders (Michels et al., 2005; Larsson and Wolk, 
2007; Powers et al., 2008; Tunnicliffe and Shearer, 2008; Bravi et al., 2009; 
Eskelinen et al., 2009; Wu et al., 2009). Coffee is a complex mixture with more than 
1000 compounds generating the unique taste and aroma (Hatzold, 2012a). 
Numerous bioactive compounds such as caffeine, CGA and coffee diterpenes may 
be associated with the described epidemiological health effects. As in vitro and in 
vivo studies observed positive acute effects of CGA such as antioxidant activity 
(Natella et al., 2002) and an activation of enzymes involved in detoxification and 
antioxidant defense (Boettler et al., 2011), this molecular class from coffee will be 
focused on here.  
CGA are a subclass of polyphenols and are predominantly esters of D-(-)-quinic acid 
(QA) (10a1) with either ferulic acid (FA) (7a) forming feruloylquinic acids (FQA) or 
caffeic acid (CA) (5a) forming caffeoylquinic acids (CQA) (Manach et al., 2004). CGA 
shows a wide distribution among edible plants but coffee is the richest source of CGA 
in the western diet. A common coffee (200 mL) serves between 70 and 350 mg CGA 
(Clifford, 1999; Farah and Donangelo, 2006). As coffee drinkers are normally 
consuming coffee several times daily over a decade, coffee is an interesting mediator 
for the bioactive CGA. Taking the consumption of CGA from coffee into account with 
the reported health effects, the understanding of CGA concentration at the site of 
molecule action in the human body is of decisive relevance. In detail, CGA 
composition in consumed coffee and bioavailability data of CGA such as absorption 
                                            
1 Bold numbers in brackets are chemical structures of CGA being of relevance in this thesis 
(see chapter 8). 
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in the gastro intestinal mucosa, the subsequent metabolization and distribution in the 
body are of interest. Controversial data on the total bioavailability of these 
compounds has been generated in various human intervention studies with healthy 
volunteers or volunteers with an ileostomy (without a colon), mostly by single dose 
consumption with various study designs summarized by (Olthof et al., 2001; Kahle et 
al., 2007; Stalmach et al., 2010; Hagl et al., 2011; Williamson et al., 2011). The 
dosage form (such as different CGA composition from various food matrices) or dose 
were different in these studies. These are factors that can have an important 
influence on the oral bioavailability of molecules (Chereson, 1996; El-Kattan and 
Varma, 2012). 
We pose the question if the total bioavailability in the upper GIT and colonic 
availability of CGA and QA from coffee is affected by consumption of different doses? 
Especially, QA bioavailability as this has not been considered up to now.  
Moreover, an influence of different ingested CGA compositions from various food 
matrices on oral bioavailability might be possible since the physico-chemical 
properties of a molecule can influence its oral bioavailability (Lipinski et al., 1997). 
Due to the extensive metabolism, hydrolyzation and interesterification of CGA in the 
human body (Kahle et al., 2005; Stalmach et al., 2009), an influence of individual 
physico-chemical properties of CGA could not be detected in vivo. Up to now only a 
few in vitro and ex vivo CGA bioavailability studies have investigated such a 
structure-absorption relation (SAR) of CGA (Konishi and Kobayashi, 2004; Deußer, 
2010; Farrell et al., 2011), but no SAR data of the major coffee CGA is available so 
far.  
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2 State of knowledge 
2.1 Coffee 
The seeds (beans) of the coffee tree which belongs to the Rubiaceae family, genus 
Coffea, are used to prepare a beverage known as coffee (Eisenbrand and Schreier, 
2005; Farah, 2012). This beverage has been the most consumed one in the world for 
decades. Therefore, coffee is one of the most important primary products in world 
trade. Approximately eight million tons (representing 500 billion cups or 134 million 
coffee bags) were produced worldwide in 2010 (IOC, 2012a) with an increasing 
production over the last five years. Countries with the highest production are Brazil 
(48 million bags), Vietnam (18 million bags), Indonesia (9.5 million bags) followed by 
Colombia (9 million bags) (IOC, 2012a). The reasons for this popularity are the 
unique aromatic taste, stimulating effects and most recently the changed image of 
coffee as health benefits from long-term coffee consumption have been observed 
(see chapter 2.3.) (Hatzold, 2012a). 
The production of coffee from the coffee fruit to cup is a complex task involving 
several steps (Hatzold, 2012b). First of all, the production of coffee starts with 
cultivation and harvesting the coffee fruits (coffee cherry) containing the coffee 
beans. In order to extract the green coffee beans from the cherries the pulp and skin 
has to be removed by a dry or wet extraction method (Crozier et al., 2009; Hatzold, 
2012b). After extraction the green beans are ready for roasting, but as 10% of the 
produced coffee is for decaffeinated consumption a part of the produced green beans 
is treated with an organic solvent (such as dichloromethane or ethyl acetate) and 
water for caffeine removal.  
During the roasting process at maximum temperatures of + 210 to + 240°C coffee 
beans change color to almost black and gain their characteristic aroma and flavor by 
chemical changes of bean constituents (see chapter 2.1.2 and 2.2.6.2). According to 
the roasting degree the color of coffee varies from light to very dark. The roasted 
coffee beans were ground and marketed or used for instant coffee production.  
Typically instant coffee production follows a treatment of ground-roast coffee with hot 
water and pressure for extraction of water-soluble compounds. This kind of brew is 
then cooled, sometimes centrifuged and dried by a freeze-drying or spray-drying 
process.  
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For the brewing of coffee hot water is used normally at a temperature of + 90 to 
+ 95°C with various brewing methods such as simple percolation, boiled coffee or 
espresso machine. 
More than 80 coffee species have been identified, but only Coffea Arabica also 
known as Arabica coffee (approximately 70% of trading volume) and Coffea 
canephora also known as Robusta coffee (approximately 30% of trading volume) are 
economically important (IOC, 2012b).  
 
2.1.1 Chemical composition of green coffee 
The green coffee bean is the processed seed from the coffee cherry (Crozier et al., 
2009). Its chemical composition is dominated by carbohydrates and fiber, proteins, 
lipids, minerals and chlorogenic acids (CGA) (see Table 2-1) (Farah, 2012). CGA and 
other minor components present in green coffee beans such as caffeine, trigonelline, 
soluble fiber and diterpenes (cafestol and kahweol from the lipid fraction) are 
probably bioactive compounds (see Table 2-1) (Farah, 2012).
 
Table 2-1: Chemical composition of green coffee [in g*100 g-1] beans from Coffea 
Arabica and Coffea Canephora, copied from (Farah, 2012). 
  
Concentration [g*100 g-1] 
Compounds 
 
Coffea 
arabica 
Coffea 
canephora 
    Carbohydrates/fiber 
Sucrose  6.0 - 9.0 0.9 - 4.0 
Reducing sugars  0.1 0.4 
Polysaccharides  34 - 44 45 - 55 
Lignin  3.0 3.0 
Pectin  2.0 2.0 
    
Nitrogenous compounds    
Protein/peptides  10.0 - 11.0 11.0 - 15.0 
Free amino acids  0.5 0.8 - 1.0 
Caffeine  0.9 - 1.3 1.5 - 2.5 
Trigonelline  0.6 - 2.0 0.6 - 0.7 
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Concentration [g*100 g-1] 
Compounds 
 
Coffea 
arabica 
Coffea 
canephora 
    Lipids   
Coffee oil (triglycerides with     
unsaponifiables, sterols, tocopherols) 
 15.0 - 17.0 7.0- 10.0 
Diterpenes (free and esterified)  0.5 - 1.2 0.2 - 0.8 
    
Minerals  3.0 - 4.2 4.4 - 4.5 
    
Acids and Esters    
Chlorogenic acids  4.1 -7.9 6.1 - 11.3 
Aliphatic acids  1.0 1.0 
Quinic acid  0.4 0.4 
     
2.1.2 Chemical composition of roasted coffee and coffee brew 
During coffee bean roasting the bean composition changes and new compounds and 
a complex aroma are formed due to pyrolysis, Strecker degradation and Maillard 
reactions. The roasting process is performed at a temperature of + 230°C for a few 
minutes or alternatively for + 180°C up to approximately 20 min (Crozier et al., 2009). 
The final composition of compounds depends on factors such as raw material, 
roasting degree, roasting type, time, temperature and air-flow speed in the roasting 
chamber (Farah, 2012). Melanoidins, proteins, lipids and reducing sugars such as 
arabinogalactan are the major non volatile compounds in the roasted coffee bean 
(see Table 2-2). 
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Table 2-2: Chemical composition of non volatile compounds in roasted coffee [in 
g*100 g-1] beans from Coffea Arabica and Coffea Canephora, copied from 
(Farah, 2012). 
  
Concentration [g*100 g-1] 
Compounds 
 
Coffea 
arabica 
Coffea 
canephora 
    Carbohydrates/fiber 
Sucrose  4.2 1.6 
Reducing sugars  0.3 0.3 
Polysaccharides (arabinogalactans, 
mannans, and glucans) 
 31 - 33 37 
Lignin  3.0 3.0 
Pectins  2.0 2.0 
   
Free amino acids  ND ND 
Caffeine  1.1 - 1.3 2.4 - 2.5 
Trigonelline  0.2 - 1.2 0.3 - 0.7 
Nicotinic acid  0.016 - 0.026 0.014 - 0.025 
    
Lipids    
Coffee oil (triglycerides with     
unsaponifiables) 
 17.0 11.0 
Diterpene esters  0.9 0.2 
    
Minerals  4.5 4.7 
    
Acids and Esters    
Chlorogenic acids  1.9 - 2.5 3.3 - 3.8 
Aliphatic acids  1.6 1.6 
Quinic acid  0.8 1.0 
    
Melanoidines  25 25 
    ND = not detected 
 
More than 950 volatile compounds have been identified in roasted coffee. These 
volatile compounds can be divided into the following classes: furans and pyrans, 
pyrazines, pyrroles, ketones and phenols, hydocarbons, alcohols, aldehydes, acids 
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and anhydrides, esters, lactones, thiophenes, oxazoles, thiazoles, pyridines, amines 
and various sulfur and nitrogen compounds (Farah, 2012). 
According to different coffee preparation conditions the amount of roasted been 
components in the coffee brew varies. These factors are: grid, brewing method, 
proportion of coffee to water, hardness and temperature of water, length of time 
coffee is in contact with water and the filter material (Farah, 2012). Several 
compounds pass into the brew such as CGA, caffeine, trigonelline, nicotinic acid, 
minerals and polysaccharides (predominantly galactomannans and type II 
arabinogalactans) (see Table 2-3). Whereas most of the lipid fraction remains in the 
solid material after brewing (Farah, 2012). 
 
Table 2-3: Representive chemical composition of coffee brew in [mg*100 mL-1], copied 
from (Farah, 2012). 
Compounds 
 
Concentration 
  
   Caffeine 50 - 380 
Chlorogenic acid  35 - 500 
Trigonelline  40 - 50 
Soluble fiber  200 - 800 
Protein  100 
Lipids  0.8 
Minerals  250 - 700 
Niacin  10 
Melanoidins  500 – 1,500 
Volatiles  ND 
     ND = not detected 
 
Due to inappropriate harvesting, weather conditions during primary processing, or 
improper storage of coffee, the brew can contain minor incidental constituents such 
as ochratoxin A (a mycotoxin), biogenic amines (e.g. putrescine, spermindine), 
β-carbolines (e.g. harman, norharman), acrylamide and polycyclic aromatic 
hydrocarbons (e.g. Benzo[α]pyrene) (Farah, 2012).  
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2.2 Chlorogenic acids (CGA), esters of hydroxycinnamic acids (HCA) and 
D-(-)-quinic acid (QA) 
2.2.1 Chemical class and nomenclature 
Chlorogenic acids (CGA) are part of the phenolic acid family which is a member of 
the widespread chemical structure of polyphenols (several hydroxyl groups on 
aromatic rings) (Manach et al., 2004). In the past CGA were recognized as an ester 
of D-(-)-quinic acid (QA) (10a) and the hydroxycinnamic acid (HCA) caffeic acid (CA) 
(Clifford, 1999). Up to now it is known that several cinnamic acids are conjugated 
with QA (Clifford, 1999). Classically, CGA is a family of esters formed of 
trans-cinnamic acid with one of the hydroxyl groups of QA 
(1L-1(OH),3,4,5-tetrahydroxycyclohexane carboxylic acid, according to IUPAC 
(IUPAC, 1976)), which has axial hydroxyls on carbons 1 and 3 and equatorial 
hydroxyls on carbons 4 and 5 (Clifford, 1999) (Figure 2-1). 
 
 
Figure 2-1: Chemical structure of 5-caffeoylquinic acid (1d), an ester of D-(-)-QA (10a) 
and the hydroxycinnamic acid caffeic acid (5a); with IUPAC numbering (IUPAC, 
1976).  
 
CGA can be divided into different subgroups depending on the number and chemical 
structure of cinnamic acids at the QA molecule. Clifford et al. is subdividing four 
groups of “classical” CGA (Clifford, 1999):  
• mono esters of cinnamic acids, e.g. caffeoyl- (CQA (1a-d)), feruloyl- (FQA (3a-
c)) and p-coumaroylquinic acid esters (p-CoQA) 
• di-esters, tri-esters and tetra-esters, e.g. diCQA (4a-c), triCQA and tetraCQA 
• mixed di-esters of caffeic- (CA) and ferulic acid (FA), e.g. CFQA 
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• mixed esters with varying number of CA and a dibasic aliphatic acid, e.g. 
succinic acid 
Chemical structures of CGA being of relevance in our investigation are shown in 
chapter 8, Overview of chemical structures. 
 
2.2.2 Physico-chemical properties of CGA 
Several reactions of CGA depending on their physico-chemical properties are 
described in literature. The pH has a major influence on CGA properties. 
For instance, an interesterification (acyl migration) is reported at a pH higher than 6 
for mono esters or at the beginning of coffee roasting process. The cinnamic acid 
moiety is able to change its position in the space of the three hydroxyl positions, 3-, 
4- and 5- at the QA molecule (see Figure 2-1) (Trugo and Macrae, 1984a; Farah et 
al., 2006). 
Furthermore, the lipophilicity (log P) is affected by pH depending on the dissociated 
or non dissociated free carboxylic group of a quinic acid moiety or a free cinnamic 
acid. The microspecies distribution (dissociated-, non dissociated carboxylic group, 
according to Marvin-sketch 5.3.1) of the ionic or neutral form varies according to the 
pH (see Figure 2-2). For instance, log P of 5-CQA (1d) changes from - 0.27 in the 
neutral form (COOH) to - 3.8 in the dissociated ionic form (COO-) (calculated with 
Marvin-sketch 5.3.1). This may play a pivotal role in a potential passive permeability 
of CGA across different GI compartments such as the stomach with a low pH in 
contrast to the small intestine with a higher pH (El-Kattan and Varma, 2012). 
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Figure 2-2: Graph of relationship between pH and the different microspecies 
(dissociated-, non dissociated carboxylic group (COOH)) of 5-caffeoylquinic 
acid (1d) (calculated with Marvin-sketch 5.3.1). 
 
During processing of food total amount and chemical structure of CGA are affected. 
The high temperature of coffee roasting in particular leads to hydrolysis or formation 
of an intramolecular ester of CGA. While hydrolysis releases the esterified 
compounds (QA (10a) and cinnamic acid) (Scholz and Maier, 1990; Farah and 
Donangelo, 2006) lactonization forms an intramolecular ester of QA, the quinide 
(1,5-γ-quinolactone). This esterification takes place between the hydroxyl group at 
carbon 5 and the carboxylic group at carbon 1 of the QA molecule (see Figure 2-1) 
(Bennat et al., 1994; Farah et al., 2005a; Farah et al., 2005b). 
During the roasting process CGA also contribute to the formation of polymeric 
compounds such as melanoidins in a covalent or non-covalent way (Nunes and 
Coimbra, 2010).  
 
2.2.3 Biosynthesis of HCA and QA and its functions in plants 
CGA are formed via the phenylpropanoid (C6 – C3 compounds) and shikimate (C6 – 
C1) pathway (Dixon et al., 2002; Crozier et al., 2009) as secondary metabolites 
induced by environmental stress. Stress factors could include mechanical wounding, 
infection by microbial pathogens, excessive UV or high visible light levels (Herrmann, 
1995; Farah and Donangelo, 2006). Phenolic acids in higher plants are formed from 
L-phenylalanine and tyrosine via the shikimic acid pathway (Figure 2-3). Hereby 
State of knowledge  11 
 
 
carbohydrate precursors, derived from glycolysis and pentose phosphate shunt 
(phospho-enolpyruvate and D-erythrose-4-phosphate) are synthesized into aromatic 
acids. A key enzyme in the biosynthesis of CGA is phenylalanine ammonialyase, 
which forms the parent trans-cinnamic acid from L-phenylalanine. 
QA (10a) is formed by the shikimic acid pathway intermediate 3-dehydroquinate 
(Figure 2-3). Maybe on the basis of cinnamic acid hydroxylation or by the action of  
 
 
Figure 2-3: Biosynthesis of hydroxycinnamic acids (HCA) and quinic acid (QA) in 
plants via the shikimic acid pathway according to (Farah and Donangelo, 2006). 
 
tyrosine aminolyase from tyrosine the hydroxycinnamic acids (CA (5a), FA (7a), 
p-CoA) are produced. Formation of the mono ester 5-CGA (5-CQA (1d), 5-FQA (3c), 
5-p-CoQA) may start with binding of trans-cinnamic acid to coenzyme A (CoA) by a 
CoA lyase, followed by a transfer to quinic acid by cinnamoyl transferase (Gross, 
1981; Farah and Donangelo, 2006). Cinnamic acids at positions 3- and 4- of the 
quinic acid moiety may be based on acyl migration (Gross, 1981; Farah and 
Donangelo, 2006). The functions of CGA in plants are numerous. Via specific 
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enzymes CGA can be transformed into polymerization products and lignin 
contributing to defense mechanisms and the synthesis of plant cell wall constituents 
(Mazzafera and Robinson, 2000; Takahama, 2004; Farah and Donangelo, 2006). 
High levels of CGA found in coffee seeds lead to the assumption that CGA have 
specific plant physiological functions (Farah and Donangelo, 2006). It may contribute 
to seed germination and cell growth, through regulation of indolacetic acid, a 
hormone being involved in plant growth (Clifford, 1985; Farah and Donangelo, 2006). 
 
2.2.4 Occurrence in agricultural crops 
HCA in the free form or esterified with QA (CGA) are extremely widespread in the 
plant kingdom (Clifford, 1999), summarized by (Neveu et al., 2010). A ranking of 
agricultural crops in terms of CGA and HCA content is difficult, due to different 
amounts in plants depending on seasonal influences (Manach et al., 2004). 
Due to the positive health effects attributed to CGA consumption, plants which are 
consumed in large amounts and are rich in HCA and CGA are of high interest. For 
instance, a single cup of coffee may contain 70 – 500 mg CGA (Clifford, 1999; Farah, 
2012). Plants such as fruits, vegetables and especially herbs are contributing in lower 
amounts to the daily CGA and HCA intake and are therefore of lower interest, despite 
the partially high HCA amounts (Crozier et al., 2009; Neveu et al., 2010). Fruits with 
the highest HCA contents are blueberries, kiwi, cherries, plum and apple with 
0.5 - 2 g HCA per kg fresh weight. Amounts are summarized in Table 2-4. 
 
Table 2-4: Hydroxycinnamic acid content (free or esterified compounds such as CGA) 
in selected foods, summarized by (Trugo and Macrae, 1984a; Clifford, 1999; 
Manach et al., 2004; Farah, 2012). 
Source (serving size) mg*kg-1 fresh wt (or mg*L-1) mg per serving 
   Blueberry (100 g) 2,000 - 2,200 200 - 220 
Kiwi (100 g) 600 - 1,000 60 - 100 
Cherry (200 g) 180 - 1,150 36 - 230 
Plum (200 g) 140 - 1,150 28 - 230 
Eggplant (200 g) 600 - 660 120 - 132 
Apple (200 g) 50 - 600 10 - 120 
Pear (200 g) 15 - 600 3 - 120 
Chicory (200 g) 200 - 500  40 - 100 
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Source (serving size) mg*kg-1 fresh wt (or mg*L-1) mg per serving 
   Artichoke (100 g) 450 45 
Potato (200 g) 100 - 190 20 - 38 
Corn flour (75 g) 310 23 
Flour: wheat, rice, oat (75 g) 70 - 90 5 - 7 
Cider (200 mL) 10 - 500 2 - 100 
Coffee (200 mL) 350 - 1,750  70 - 500  
    
Generally, HCA are bound as glycosylated derivatives or in esterified forms (quinic-, 
tartaric-, shikimic acid). Caffeic acid is the most abundant phenolic acid in free form 
as well as in esterified form, especially in coffee. Furthermore it represents 
75% - 100% of the total HCA content of most fruits (Manach et al., 2004). CA can be 
found in all parts of fruits with the highest content in the outer parts of ripe fruits. The 
concentrations decrease during maturation, but total amounts increase with 
increasing size of fruit (Manach et al., 2004).  
The main dietary source of ferulic acid (7a) is cereal grain with an estimated amount 
of ≈ 0.8 – 2 g per kg dry weight for wheat grain. This may represent up to 90% of total 
polyphenols (Sosulski et al., 1982; Lempereur et al., 1997; Manach et al., 2004). Rice 
and oat flours contain the same amount of FA (7a) as wheat flour (63 mg per kg), 
whereas the concentration of maize flour is three times as high (Shahidi and Naczk, 
2003). Only 10% of ferulic acid is found in soluble free form in wheat bran, mostly 
esterified with arabinoxylans and hemicelluloses in the aleurone and pericarb 
(Lempereur et al., 1997). 
 
2.2.5 Daily dietary burden of HCA and CGA 
Due to missing biomarkers for HCA exposure an estimation of long-term intake is 
very difficult. Furthermore, data of HCA composition of commodities after processing, 
such as cooking, baking, etc. and consumption of these food throughout the world is 
inconsistent (Clifford, 1999; Manach et al., 2004). 
Based on literature data and a seven day dietary protocol, Radtke et al. estimated a 
daily HCA intake of 211 mg in the Bavarian population (Radtke et al., 1998). In Japan 
dietary intake of HCA was estimated to be double for coffee drinkers (426 mg a day) 
(Fukushima et al., 2009). Different food content and especially different food 
preferences lead to high differences in HCA incorporation (Manach et al., 2004).  
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Thus, Clifford (Clifford, 1999) divided the UK population into three categories 
according to their food consumption. Coffee drinkers which have the highest dietary 
burden of CGA (500 – 800 mg), followed by people consuming bran and people 
consuming mainly citrus. Those who drink several cups of coffee, consume bran and 
consume citrus might have an intake of 1 g HCA a day, in contrast to people 
consuming none or low amounts of these foods. HCA intake of these people is 
estimated to be 25 mg a day (Clifford, 1999). 
 
2.2.6 CGA profile and amount of coffee 
As coffee is reported to be a major HCA dietary source being usually consumed daily 
and lifelong by coffee drinkers, the precise CGA profile and amount of this beverage 
is of high interest. 
 
2.2.6.1 CGA composition of green coffee beans 
In green coffee beans CGA are the dominating fraction of phenolic acids and have 
been studied for more than a century (Clifford, 1979; Trugo and Macrae, 1984b; 
Farah and Donangelo, 2006). The values of CGA on dry matter based (see Table 
2-5) in green coffee beans is affected by many factors (species, cultivar, degree of 
maturation, agricultural practices, soil, climate) and varies from 4.0 to 8.4% for Coffea 
Arabica and 7.0 to 14.4% for Coffea Canephora (so-called, Robusta), summarized by 
(Farah and Donangelo, 2006). 
The dominating part is the esterified HCA, especially the CGA: CQA (3-CQA (1b), 
4-CQA (1c), 5-CQA (1d)); FQA (3-FQA (3a), 4-FQA (3b), 5-FQA (3c)); diCQA 
(3,4-diCQA (4a), 3,5-diCQA (4b), 4,5-diCQA (4c)), p-CoQA (3-p-CoQA, 4-p-CoQA, 
5-p-CoQA) and six mixed diesters of CFQA (Clifford et al., 2003). The 5-CQA (1d) 
isomer is by far the dominating CGA accounting for 56 – 62% of the total (Farah and 
Donangelo, 2006). Additionally, the described CGA compounds were detected in 
Robusta coffee in trace amounts, e.g. diferuloylquinic-, dimethoxycinnamoylquinic-, 
caffeoyl-dimethoxycinnamoylquinic- and feruloyl-dimethoxycinnamoylquinic acid 
(Clifford et al., 2006). 
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Table 2-5: Chlorogenic acid (CGA) profiles and contents of green coffee beans 
expressed in [g % dry matter basis], summarized by (Farah and Donangelo, 
2006). CQA = caffeoylquinic acid (1a-d); FQA = feruloylquinic acid (3a-c); 
diCQA = dicaffeoylquinic acid (4a-c). 
Samples CQA FQA diCQA Total CGA References 
      
C. arabica      
C. arabica 5.76 0.25 0.87 6.88 (Trugo and Macrae, 1984b) 
var. Caturra 4.63 0.33 0.66 5.62 (Clifford and Ramirez-
Martinez, 1991) 
Wild* 3.26 0.19 0.60 4.10 (Ky et al., 2001) 
Angola 4.30 0.57 1.23 6.10 (Correia et al., 1995) 
Brazil 4.20 0.28 0.77 5.25 (Farah et al., 2005b) 
      
C. canephora      
cv. Robusta 6.82 0.60 1.37 8.80 (Trugo and Macrae, 1984b) 
cv. Robusta 5.33 0.79 1.05 7.17 (Clifford and Ramirez-
Martinez, 1991) 
Wild* 7.66 1.43 2.31 11.3 (Ky et al., 2001) 
cv. Robusta 
 
3.43 0.54 1.20 6.08 (Correia et al., 1995) 
var. Robusta 
 
5.77 0.47 1.34 7.58 (Farah et al., 2005b) 
      
*average 
 
Besides the dominating cinnamoylquinic acid conjugates, a second group of HCA 
with amino acid conjugation such as tryptophan and tyrosine conjugates was 
identified in green coffee beans summarized by (Farah and Donangelo, 2006). 
Furthermore, a small part of phenolic glycosides were estimated in the past (Clifford, 
1985). Additionally, the free HCA (caffeic- (5a), ferulic- (7a), p-coumaric acid) and 
quinic acid (10a) were found in only minor amounts in the green coffee beans 
(Clifford, 1985; Farah and Donangelo, 2006). Compounds different to CGA have also 
been identified in green coffee beans in small amounts: anthocyanidins (cyanidins, 
pelargonidines, and one peonidin) as a residue of the red skin fruit, lignans 
(secoisolariciresinol, lariciresinol, matairesinol, pinoresinol) as summarized by 
(Clifford, 1985; Farah and Donangelo, 2006).  
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2.2.6.2 CGA composition of roasted coffee and coffee beverages 
During roasting of green coffee beans the amount and profile of CGA dramatically 
changes. With every 1% loss of coffee bean dry matter there is a simultaneous 
reduction of 8 - 10% of the total CGA amount (Crozier et al., 2009). Especially, 
interesterification (acyl-migration), epimerization, hydrolysis, lactonization and 
incorporation into melanoidins occur during roasting (see chapter 2.2.2). Total CGA 
content in commercial roasted coffees ranges from 0.5 up to 7% (Table 2-6), 
depending on the type of processing, degree of roasting and coffee blend (Farah and 
Donangelo, 2006). 
Due to interesterifications during the roasting process, the amount of dominating 
5-CQA (1d) decreases whereas the 3- (1b) and 4-CQA (1c) substitutes substantially 
increases (Trugo and Macrae, 1984b; Farah et al., 2005b). 
A further consequence of the roasting process is the formation of lactones. About 7% 
of CGA in regular Arabica coffee and about 5.5% in Robusta coffee is transformed to 
a quinide (1,5-γ-quinolactone) (Table 2-6) (Farah and Donangelo, 2006). The major 
quinide formed is the 3-caffeoylquinide (3-CQL, (2a)) followed by the 
4-caffeoylquinide (4-CQL, (2b)) (Farah et al., 2005b). Other quinides are present only 
in minor levels (Table 2-6). Via thermal syn-elimination further low molecular 
degradation products of CGA are formed, e.g.: catechol, 4-ethylcatechol, 
4-methylcatechol, pyrogallol and hydroxyhydroquinone (Muller et al., 2006; Farah, 
2012). 
 
Table 2-6: Chlorogenic acid profiles of ground roasted and instant coffees expressed 
in [g % dry matter basis], summarized by (Farah and Donangelo, 2006). 
CQA = caffeoylquinic acid (1a-d); FQA = feruloylquinic acid (3a-c); 
diCQA = dicaffeoylquinic acid (4a-c); CQL = caffeoylquinide (2a-b); 
FQL = feruloylquinide; diCQL = dicaffeoylquinide; CoQL = Cumaroylquinide. 
Coffee samples CQA FQA diCQA CQL FQL diCQL CoQL References 
         
Ground roasted:         
Commercial 1.62   0.23    (Bennat et al., 
1994)* 
 2.26 0.21 0.19 0.31    (Schrader et al., 
1996)* 
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Coffee samples CQA FQA diCQA CQL FQL diCQL CoQL References 
         
 0.94 0.15 0.14     (Monteiro and 
Trugo, 2005)* 
C. arabicaa Bourbon 2.15 0.17 0.14 0.36 0.04 0.01 0.01 (Farah et al., 
2005b) 
C. arabicaa Longberry 1.65 0.15 0.13 0.33 0.04 0.01 0.01 (Farah et al., 
2005b) 
C. arabica 3.23   0.32    (Bennat et al., 
1994) 
C. canephoraa cv. 
robusta 
2.76 0.34 0.23 0.39 0.03 0.03  (Farah et al., 
2005b) 
         
Instant coffee:         
Non-decaffeinated 3.00 0.61 0.28     (Trugo and 
Macrae, 1984b)* 
 1.90 0.21 0.07     (Nogueira and 
Trugo, 2003)* 
 6.40 < 1 < 1     (Renouf et al., 
2013) 
Decaffeinated 4.03 0.72 0.23     (Nogueira and 
Trugo, 2003)* 
         
* average; a Laboratory roast (light medium) 
 
Extraction of coffee polyphenols during coffee preparation is affected by numerous 
factors like grind of coffee, proportion of coffee to water relation, brewing method, 
water temperature and contact time with water. Nevertheless, significant amounts are 
transferred into domestic brews and commercial soluble coffee powders (Crozier et 
al., 2009). During domestic brewing of coffee normally 80 – 100% of total CGA is 
extracted, resulting in 70 – 350 mg CGA per 200 mL cup of coffee (Clifford, 1999; 
Farah and Donangelo, 2006).  
 
2.3 Health effects associated with coffee consumption (focus on CGA)  
The lifelong daily exposure of food containing CGA, especially coffee and its 
potentially beneficial effects on human health generates a growing interest in them. 
Despite the numerous compounds in coffee, it is caffeine, diterpenes and the 
polyphenol fraction that are suggested to contribute to health effects, depending on 
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coffee preparation (Bonita et al., 2007). In vitro and in vivo studies considered acute 
health effects such as increasing plasma antioxidative capacity and decreasing LDL 
oxidizability after coffee consumption (Natella et al., 2002; Yukawa et al., 2004).  
The coffee constituent quinic acid was not supposed to be bioactive in the past. But 
QA supports the synthesis of tryptophan and nicotinamide in the GI. This increased 
production is linked to DNA repair enhancement and NF-ĸB inhibition (Pero et al., 
2009; Pero and Lund, 2011). Hence, it is suggested that QA consumption is 
associated with health benefits. 
Nevertheless, some coffee constituents such as acrylamide or furan are associated 
with potential harmful effects on human health. However, these potential harmful 
effects could not be confirmed by epidemiological data on long term ingestion. 
Moreover, epidemiological studies reviewed a reduced risk for certain cancer-, 
cardio-vascular-, neurodegenerative- and Type II diabetes diseases.  
 
2.3.1 Increasing plasma antioxidant activity 
Due to the presence of its π-electron system the catechol group of HCA shows the 
ability to scavenge reactive oxygen species. Thus, oxidative degradation processes 
at biological structures are decelerated or hindered (Lemańska et al., 2001; 
Eisenbrand and Schreier, 2005). Stalmach et al. identified caffeoylquinic acids as the 
most abundant antioxidants in roasted coffee by HPLC analysis and additionally 
supposed a contribution of Maillard reaction products to the coffee antioxidant activity 
(Stalmach et al., 2006). Also catabolites of CA (5a) such as DHCA (6a) showed an 
antioxidant capacity in vitro, summarized by (Bonita et al., 2007).  
The in vivo antioxidant capacity of coffee was investigated after the consumption of a 
single dose of coffee showing a significant increase of plasma antioxidant activity 
(Natella et al., 2002) and in a short term study (5 cups a day) showing a significant 
increase of plasma glutathione (16%) (Esposito et al., 2003). Bakuradze and 
coworkers identified decreased DNA oxidative damage and an elevated glutathione 
level as well as glutathione reductase activity after consumption of a coffee rich in 
green bean and roasted coffee constituents (Bakuradze et al., 2011). 
Nevertheless, low CGA levels reaching the circulatory system implies that its 
mechanisms of action might be beyond the modulation of oxidative stress (Crozier et 
al., 2009).  
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Potential molecular targets and corresponding cellular signaling pathways 
contributing to chemo preventive health effects have been recently identified in vitro 
and in vivo (Volz et al., 2012). More specifically, coffee constituents such as 5-CQA 
are activators of the NF erythroid 2-related factor (Nrf) protein (Boettler et al., 2011). 
This protein induces the antioxidant response element (ARE) mediated expression of 
Phase II enzymes involved in detoxification and antioxidant defense (Venugopal and 
Jaiswala, 1998).  
 
2.3.2 Cardiovascular disease (CVD) and coffee consumption 
An indication of positive effects on the cardiovascular system for coffee drinkers has 
long been suggested (Bidel and Tuomilehto, 2012). Nevertheless, existing literature 
is inconsistent. A protective heart mechanism was found in healthy Japanese males 
after coffee consumption (3 cups a day) as LDL oxidizability significantly decreased 
and returned to baseline after cessation of coffee (Yukawa et al., 2004). Moreover, 
Bonita et al. associated the coffee polyphenols with cardiovascular benefits via 
lowering blood pressure (Bonita et al., 2007). In a recent meta analysis of 21 
prospective cohort studies the coronary heart disease risk by coffee consumption 
was tested and an increased long term risk, as previously assumed, was not 
observed (Wu et al., 2009). In addition, habitual coffee consumption was correlated 
with a risk decrease of 18% in female and 13% in male subjects. Positive effects on 
cardiovascular health were corroborated as well as by other epidemiological and 
cohort studies (Greenberg et al., 2008; Mukamal et al., 2009). 
Regarding the compounds from coffee responsible for the described effects, caffeine 
and CGA are in focus. Caffeine has acute cardiovascular effects such as increasing 
blood pressure, circulating catecholamine levels, arterial stiffness and endothelium 
dependent vasodilation (Smits et al., 1985; Mahmud and Feely, 2001; Papamichael 
et al., 2005), but it is also associated with the development of CVD (Bidel and 
Tuomilehto, 2012). In vitro CA was shown to inhibit LDL oxidation (Nardini et al., 
1995) and CGA stabilized membranes and improved the cell energy status in a study 
on cardiomyocytes (Chlopčíková et al., 2004). 
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2.3.3 Lower risk of Type II diabetes disease 
Recent reviews highlighted a dose-response relationship between coffee 
consumption and a substantially lower risk of type 2 diabetes which is characterized 
by insulin resistance (Van Dam and Hu, 2005; Tunnicliffe and Shearer, 2008). 
Numerous physiological mechanisms are involved in this effect, such as a hindered 
glucose absorption in the gut and a reduced gluconeogenesis in the liver. It is 
assumed in epidemiological and in vitro studies that a coffee polyphenol fraction 
causes this anti diabetic effect (Tunnicliffe and Shearer, 2008). More specifically, the 
coffee quinides seemed to enhance the insulin activity in rats directly (Shearer et al., 
2003; Shearer et al., 2007). 5-Caffeoylquinic acid is modulating carbohydrate 
absorption in vitro as inhibition of porcine α-amylase preparations (Stümpel et al., 
2001; Rohn et al., 2002; Narita and Inouye, 2009; Matusheski et al., 2012) and 
inhibition of glucose-6-phosphatase (which might be important for carbohydrate 
absorption at the enterocyte) was observed.  
 
2.3.4 Reduced cancer risk 
Associations of coffee consumption with a reduced cancer risk is discussed as 
epidemiological studies suggest a reduced risk of liver, kidney, uterine, head, neck, 
breast and colorectal cancers (Michels et al., 2005; Larsson and Wolk, 2007; Bravi et 
al., 2009; Nkondjock, 2012). Several bioactive compounds from coffee can be 
associated with the lower cancer risk. The diterpenes from coffee namely cafestol 
and kahweol shows anticarcinogenic properties such as inducing phase II enzymes 
involved in carcinogen detoxification in animal and cell studies (Cavin et al., 2002; 
Huber et al., 2003) and inhibition of phase I enzymes responsible for carcinogen 
activation was observed in rat liver and primary hepatocytes (Cavin et al., 2008). The 
CGA fraction of coffee shows antioxidant effects (Rodriguez de Sotillo et al., 2006) 
and is associated with a lower risk of type II diabetes disease (see chapter above) 
which is a marker for certain cancer diseases (Renehan et al., 2008). Furthermore, 
CA inhibits DNA methylation in cultured human cancer cells (Vucic et al., 2008). DNA 
hypermethylation is a mechanism for silencing genes such as tumor-suppressor 
proteins, DNA-repair enzymes and receptors in tumor cells (Nkondjock, 2012). 
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2.3.5 Liver health 
Beneficial effects on liver health has been observed according to coffee consumption 
with effects such as reducing blood levels of liver enzymes, potential benefits at risk 
for cirrhosis and hepatocellular carcinoma (La Vecchia, 2005; Muriel and Arauz, 
2012). According to epidemiological data, coffee appears to have a moderate effect 
in reducing risk of cirrhosis as a relationship between coffee consumption and a 
reduced risk was observed (Gallus et al., 2002; Klatsky et al., 2006). The increase of 
plasma antioxidant capacity after coffee consumption as already described in chapter 
2.3.1. may be responsible for a reduced risk of cirrhosis for coffee drinkers (Muriel 
and Arauz, 2012). Coffee is a complex mixture of compounds therefore, no definite 
evidence is available for an individual compound responsible for the described liver 
effects (Muriel and Arauz, 2012). 
 
2.3.6 Neuroprotective effects of coffee consumption  
Acute effects of coffee consumption on better cognitive function are well known, 
specially the effect of caffeine (Hatzold, 2012c). Furthermore, epidemiological 
evidence suggests that long term ingestion of coffee seems to have positive 
influences on a reduced risk of cognitive decline, dementia, and Alzheimer´s and 
Parkinson´s disease (Quintana et al., 2007; Tan et al., 2007; Powers et al., 2008; 
Eskelinen et al., 2009; Lindsay et al., 2012). Although several bioactive compounds 
are present in coffee, caffeine and CGA are specifically associated with the described 
effects (Lim and Tan, 2012; Lindsay et al., 2012). 
 
2.3.7 Adverse health effects of coffee consumption 
Some of the compounds from coffee, mostly formed during roasting such as furan 
and acrylamide, are also associated with potential harmful effects on human health. 
The total amount of these compounds is influenced by the type of roasting and 
preparation of the brew. 
Furan in coffee is formed during roasting of beans (Guenther, 2012). Although the 
levels of furan are decreased during processing, coffee is an important source of 
furan for adults (Morehouse et al., 2008). In animal studies furan was shown to be 
carcinogenic to the liver of mice or rats (National Toxicology Program, 1993; 
Guenther, 2012), however, epidemiological studies revealed no evidence of a 
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possible carcinogenic effect in humans (Bakhiya and Appel, 2010) (see chapter 
2.3.5.).  
In 1994 acrylamide was classified as a group 2A carcinogen (“probably carcinogenic 
to humans”) based on data of genotoxictiy and carcinogenicity in rodents (IARC, 
1994). Furthermore, Wilson and coworkers found an increased risk of endometrial 
cancer among high acrylamide consumers (Wilson et al., 2010). As well as furan the 
coffee contaminant acrylamide is also formed during roasting of coffee beans. The 
Maillard reaction is the major pathway for acrylamide formation during roasting with 
the precursor amino acid asparagine as a backbone of the acrylamide molecule 
(Stadler et al., 2002). Although the acrylamide levels drop approximately 2 min into 
roasting and during storage (Hoenicke and Gatermann, 2005) coffee is a rich source 
of acrylamide in the daily diet (World Health Organization, 2011).  
Coffee is the most important source for exogenous heterocyclic ß-carboline alkaloids 
namely norharman and harman (Herraiz and Chaparro, 2006). About 4 to 20 µg per 
100 mL were present in the coffee brew (Herraiz, 2002; Herraiz and Chaparro, 2006) 
since these compounds are formed during roasting by Pictet-Spengler condensation 
of indolethylamins and carbonylic compounds followed by oxidation and 
decarboxylation (Farah, 2012). An association of norharman and harman intake with 
effects on human health is inconclusive. However, adverse health effects have been 
suggested such as an involvement in addictions and in vivo genotoxicity (Herraiz, 
2000; Farah, 2012). 
Polycyclic aromatic hydrocarbons (PAH) are formed at high roasting temperatures. 
Hence, these compounds are mostly detected in very dark roasts (Orecchio et al., 
2009; Farah, 2012). PAH such as benzo[α]pyrene or phenanthrene are carcinogens 
with low water solubility (Houessou et al., 2005). So the major parts present in 
roasted ground coffee are not present in the same amount (less than 35%) in the 
coffee brew (Houessou et al., 2007; Farah, 2012). 
Not only the type of roasting but also the type of coffee preparation is important for 
potentially harmful components in the brew, because only boiled unfiltered coffee 
contains the diterpenes cafestol and kahweol in significant amounts. These 
diterpenes are associated with both positive effects (as already described above) and 
adverse effects. The diterpenes from coffee are also suggested to increase serum 
cholesterol and extracellular accumulation of LDL which promotes atherosclerosis 
(Bønaa et al., 1988; Rustan et al., 1997; Bonita et al., 2007).  
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2.4 Physiology of the gastrointestinal tract (GIT) 
The GIT (digestive system) has various functions such as food ingestion, propulsion, 
digestion and absorption of nutrients, water and vitamins (Corwin, 2008). Due to the 
different compartments of the GIT with specialized conditions, such as enzyme 
concentration and corresponding pH, it is possible to degrade non absorbable large 
molecules to molecules which can be absorbed. Thereby location of absorption is 
dependent on factors such as the molecular properties, the different conditions in the 
compartments and by the anatomical structure of the compartment such as surface 
organization. Thus, physiological factors of the gastrointestinal compartments such 
as anatomy, pH, bacterial microflora, residence time of food and presence of 
transport proteins impact molecule absorption (El-Kattan and Varma, 2012). 
 
2.4.1 The human GIT 
2.4.1.1 Anatomy and function 
The human GIT extends from the oral cavity to the anus. It is divided into the 
following different specialized compartments: oral cavity, esophagus, stomach, small 
intestine and large intestine. The outcomes of this compartmentalization are different 
physiological and chemical conditions along the GIT (Rehner and Daniel, 2002). 
Figure 2-4 gives a detailed schematic overview of the GIT structure. 
 
2.4.1.2 Upper GIT 
Once food has been ingested into the oral cavity its particle size will be reduced 
through the process of chewing and afterwards reaches the esophagus by 
swallowing. Here the bolus is transported via peristaltic contractions into the 
stomach. Hereby salivary secretion in the oral cavity facilitates the lubrication and 
stirs food with two digestive enzymes: α-amylase (cleaves internal α-1,4-glycoside 
bonds present in starch) and lingual lipase (hydrolysis of dietary lipid) (Johnson, 
2007; Weisbrodt, 2007). 
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Figure 2-4: Schematic detailed overview of the human GIT (copied from (Corwin, 2008). 
 
2.4.1.2.1 Stomach 
In the stomach the bolus is stirred with gastric juice and particle size is decreased 
again. The major constituents of gastric juice are pepsin, mucus, hydrogen ions and 
the intrinsic factor. Despite the activity of saliva enzymes and the proteolytic activity 
of pepsin in the stomach, gastric digestion plays only a minor role in the degradation 
of macromolecules (Rehner and Daniel, 2002). In a fasted state, the pH of gastric 
fluid ranges from 1 to 3.5 and can rise in fed state up to 4.5 and higher (Fallingborg, 
1999; Rehner and Daniel, 2002) (see Figure 2-5).  
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Figure 2-5: Changing of gastric pH (A) and gastric emptying rate (B), after 
consumption of a meal (400 mL, half viscous, pH 6, 40% carbohydrates, 40% 
fat, 20% protein). Modified according to (Malagelada et al., 1976). 
 
Gastric emptying is accomplished by coordinated contractile activity of the stomach, 
pylorus and proximal small intestine (Weisbrodt, 2007). Solid food passes the 
stomach only after a reduction of its particle size which requires an adequate 
resistance time of such foods in the stomach. Only particles with 1 mm3 or less are 
easily emptied by gastric motility, whereas liquids passes the stomach immediately 
(Weisbrodt, 2007) (see Figure 2-5). 
Furthermore, the chemical composition of foods affects the rate of gastric emptying. 
For instance, foods that are high in lipids, H+ or that differ considerably from 
isotonicity pass the stomach at a slower rate than observed for near-isotonic saline 
solutions (Rehner and Daniel, 2002; Weisbrodt, 2007). Receptors in the upper small 
intestine regulate the gastric emptying. These receptors respond to physical 
properties (osmotic pressure) and chemical composition (H+, lipids) of the bolus 
(Weisbrodt, 2007). In addition to the type of meal, other factors such as body 
position, emotional state, and activity (exercise) can affect the rate of gastric 
emptying (Chereson, 1996). 
Thereupon the motility is influencing the amount of bolus reaching the small intestine. 
More specifically, in a study which observed the gastric emptying time after 
consumption of different breakfasts, the following emptying times were reported: high 
carbohydrate 120 ± 75 min; high fat and protein content 580 ± 375 min; and 150 mL 
water 45 ± 110 min (measured by a radio capsule) (Zimmermann and Leitold, 1992). 
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2.4.1.2.2 Small intestine 
Anatomically the small intestine extends from the gastroduodenal junction (pylorus) 
to the duodenum, followed by the jejunum to the ileum. It ends at the ileocecal 
junction (Figure 2-4). In the duodenum, pancreas and gallbladder effluent are 
excreted to the chyme. As a consequence of the hydrogen carbonate content of 
pancreas secretion and duodenal gland efflux, the pH is raised in the aboral direction 
of the small intestine (pH in fed state: duodenum 5.4, jejunum 5.2 – 6.0, ileum 7.5) 
(Hörter and Dressman, 2001; Rehner and Daniel, 2002). 
Furthermore, pancreas effluent contains important enzymes for digestion, especially 
for carbohydrate digestion, proteolysis and lipolysis. The major function of the 
gallbladder is to emulsify the fat in the chyme by bile acids. These acids are 
produced by hepatocytes in the liver and are stored within the gallbladder until 
excretion. So the liver and gallbladder are also important for digestion because bile 
acids increase the absorption of fats and consequently high lipophilic drugs (El-
Kattan and Varma, 2012). Additionally, once molecules are absorbed in the small 
intestine they can be transformed in the liver and excreted via the gallbladder into 
small intestine (enterohepatic circulation). More specifically, the liver plays a major 
role in detoxification and excretion of xenobiotics. Absorbed molecules undergo a 
biotransformation and can be excreted in the liver as well as in the small intestine 
itself which can lead to a limited oral bioavailability (see chapter 2.6.2.4) (Dietrich et 
al., 2003; El-Kattan and Varma, 2012).  
The motility of the small intestine homogenizes the chyme with digestive fluids and 
enzymes, facilitating contact with the intestinal mucosa of the entire chyme and 
propulsion in an aboral direction (Weisbrodt, 2007). Thus, the small intestine is the 
part of the GIT where most digestion and absorption take place. For this, the small 
intestine has a specialized mucosa in order to maximize the intestinal absorptive 
surface area (Rehner and Daniel, 2002) with circular folds, villi and microvilli at the 
enterocyte. These structures create an absorptive surface area of 300 to 400 m2 in 
the small intestine. In Figure 2-6 the anatomy and different tissue layers of the small 
intestine are shown. The villi and the tunica mucosa are situated at the luminal side 
of the small intestine, followed by the thin muscle layer of muscularis mucosa. The 
tela submucosa, the longitudinal and circular muscle layers of lamina muscularis 
follow which regulate the motility of the small intestine. The tunica serosa (a tissue 
nerved with blood vessels) completes the small intestine wall at the serosal side. 
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Besides the enterocytes, other specialized cells are occurring in the small intestine 
such as paneth and microfold cells.  
 
Figure 2-6: Anatomy and surface enlarging factors of the small intestine on the left 
and architecture of the different tissue layers with vasculature on the right. 
According to (Rehner and Daniel, 2002). 
 
Furthermore, the small intestinal microbiota is also involved in the process of 
digestion, as shown by Knaup et al. investigating the degradation of several 
quercetin glycosides in the ileal fluid (Knaup et al., 2007). Colonization of microbiota 
in the small intestine varies within the different parts and increases from the 
duodenum with 103 cfu*mL-1 to the jejunum and ileum with 104 – 108 cfu*mL-1 (Blaut 
and Clavel, 2007) . 
The total transit time of chyme in the small intestine varies from 2.8 up to 6.3 hours 
(Ibekwe et al., 2006). Hereby the flow from the small intestine to the large intestine is 
partly regulated by the ileocecal junction at the end of the small intestine (Weisbrodt, 
2007).  
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2.4.1.3 Large intestine 
The large intestine can anatomically be divided into the cecum, ascending-, 
transverse-, and descending colon and the rectum (Figure 2-4). The major function of 
the large intestine is to absorb water and electrolytes. In total the absorptive surface 
area of the large intestine is not important. Typical surface anatomy present in the 
small intestine such as villi and microvilli cannot be observed (Rehner and Daniel, 
2002). 
Because of the high amount of microbiota in the colon (109 – 1012 cfu*mL-1(Blaut and 
Clavel, 2007)) it is a compartment where chyme compounds, which were not 
absorbed in the upper GIT, are fermented forming short chain fatty acids such as 
butyrate from non absorbed carbohydrates. The metabolic activity of these bacterial 
microflora can play a major role in liberation of drugs by hydrolysis, dehydroxylation, 
deamidation, decarboxylation, and reduction of acid groups (see chapter 2.6.2.1) (El-
Kattan and Varma, 2012). The pHs of the colon are: cecum 5.7; ascending colon 5.6; 
transverse colon 5.7 and descending colon 6.6 (Fallingborg, 1999). Contractions 
organize the aboral movement of contents via the colon and evacuation of feces 
(Weisbrodt, 2007). A colonic transit time of 25 up to 30 hours is reported (Silbernagl 
and Despopoulos, 2003). 
 
2.4.1.4 Unstirred water layer 
Adjacent to the intestinal membrane an unstirred water layer is present with a 
thickness of 25 µm in humans. The effect of this polar unstirred water layer is 
insignificant on the extent of absorption, even on high lipophilic molecules (Chiou, 
1994; El-Kattan and Varma, 2012). 
 
2.4.2 Stoma of the terminal ileum 
A stoma of the terminal ileum is a surgical resection of the colon, where a port 
between the ileum and the abdominal wall is created (Figure 2-7). The reasons for 
this surgery can be colorectal cancer or other bowl diseases (such as Crohn´s 
disease and ulcerative colitis). Via the artificial stoma the ileal effluent is flushed into 
a bag (external appliance connected with the terminal ileum). 
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After the resection the remaining part of the GIT undergoes an adaption since the 
ileostomy effluent decreases from 1.5 – 2.0 L*d-1 within a few weeks after resection 
to about 0.4 - 0.6 L*d-1 (Ladas et al., 1986; Fallingborg, 1999). 
Different studies, summarized by (Fallingborg, 1999), demonstrate that a stoma does 
not affect the pH of the remaining gut, although small changes can be observed after 
surgery. For instance, the bacterial count in the neoterminal ileum is higher (105 up to 
107 cfu*g-1) than in healthy subjects (with normal gut) and the microbiota composition 
is sometimes different with higher aerobic and fewer anaerobic species present 
(Fallingborg, 1999). Furthermore, in ileostomists a possible slightly increased small 
intestinal transit time, when compared to normal subjects, was observed (Ladas et 
al., 1986; Fallingborg et al., 1990; Fallingborg, 1999).  
The ileostomy model became a suitable tool for investigations of colonic availability of 
various compounds as well as for absorption studies focusing on the upper GIT and 
small intestine. Nevertheless, the above mentioned deviations have to be taken into 
account. 
 
 
Figure 2-7: Schematic detailed overview of the human GIT with a stoma at the terminal 
ileum. The large intestine was resected by surgery. Modified according to 
(Corwin, 2008).  
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2.4.3 Mechanisms of absorption in the GIT 
The selective permeability and surface area of the different GI membranes (located in 
the stomach, small intestine, and large intestine) regulate the absorption of molecules 
from the chyme. The characteristic of this barrier function is mostly governed by the 
properties of the lipid bilayer. According to the physico-chemical properties and the 
potential affinity to transport proteins of a molecule and the occurrence of specific 
transport proteins along the GIT, several mechanism of absorption are possible 
(Figure 2-8) (Rehner and Daniel, 2002; El-Kattan and Varma, 2012): (a) simple 
diffusion, (b) facilitated diffusion and (c) carrier mediated active transport. Overall, the 
absorption process through the cell membrane is divided into three partial events: 
entrance of substrates through the luminal cell membrane, traversion of a metabolic 
active intracellular space and exit through the serosal membrane into the blood 
(Daniel, 1986).  
(a): Passive simple diffusion describes the molecule spread into an available space 
(e.g. intracellular space) through random motion (Brownian motion). It is driven by a 
concentration gradient and is leading to a concentration balance in both 
compartments at ideal conditions (net flux = 0).  
So via the transcellular diffusion a spread from the luminal side (high molecule 
concentration) through the lipid bilayers to the serosal side (low molecule 
concentration) occurs. Furthermore, because of the lipid bilayer´s hydrophobicity this 
way of absorption is governed by the physico-chemical properties of the diffusing 
molecules. For instance, lipophilic molecules (e.g. benzene) diffuse very fast, 
followed by small uncharged polar molecules (e.g. H2O, glycerine) and huge 
uncharged polar molecules (e.g. glucose). In contrast, for inorganic ions and charged 
organic molecules (charged amino acids) overcoming of the lipid bilayer is limited, 
because of its polar properties and the hydration shell. In summary, compounds 
which are absorbed via the transcellular pathway are unionized, with lipophilicity of 
Log P > 0 and MW > 300 g*mol-1(Rehner and Daniel, 2002; El-Kattan and Varma, 
2012). 
Other than transcellular diffusion, paracellular diffusion can also take place (Figure 
2-8). In cell membranes forming an impermeable barrier (such as enterocytes), tight 
junctions (TJ) connect cells and enclose the paracellular space. Thus the properties 
of TJ determine the passive diffusion of this transport process. They revealed a 
selective permeability for cations and became tighter in aboral direction. In general, 
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molecules that are small (e.g. MW < 250 g*mol-1) and hydrophilic in nature (log P < 0) 
are absorbed via paracellular diffusion (Rehner and Daniel, 2002; El-Kattan and 
Varma, 2012). 
 
(b): Equally to simple diffusion the facilitated diffusion leads to a concentration 
balance in both compartments. Due to the uptake of molecules showing adverse 
diffusion properties, several transport systems of facilitated diffusion are located in 
the membrane. These transport systems are crossing the lipid bilayer and facilitating 
permeability based on the reaction mechanisms of catalysis. The specialized 
membrane proteins are able to decrease the high activation energy which is 
necessary for passing the bilayer of e.g. polar or charged molecules (Figure 2-8). 
 
(c) Whereas diffusion mechanisms are accompanied by an increase of entropy, 
active transport mechanisms can accumulate a molecule in one compartment. This 
means a decrease of entropy and therefore energy is required for the transport. So 
active transport can lead to an increased absorption of a drug (active uptake) or a 
 
Figure 2-8: Possible mechanism of intestinal absorption from luminal side to the 
serosal side according to (Deußer, 2010). ATP = Adenosine triphosphate.   
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reduced bioavailability (active efflux) with or against the direction of an 
electrochemical gradient (see Figure 2-9). Two different carrier mediated active 
transport ways are described.  
 
The primary active transport requires energy which is generated by exergonic 
reactions such as cleavage of adenosine triphosphate (ATP). Primary active 
transporters have an ATP binding cassette (ABC-transporters) and include a variety 
of transporters in the GIT. Nevertheless, only a few play a key role in intestinal drug 
absorption such as p-glycoprotein (P-gp), multidrug resistance protein (MRP) and 
breast cancer proteins (BCRP). These transport proteins can be located at the 
luminal or serosal membrane of the enterocyte (see Figure 2-8). 
P-gp (MDR1) is a transmembrane efflux pump which shows an affinity to a wide 
range of compounds. Therefore, it is speculated that it plays a major physiological 
role in the absorption of xenobiotics. Unlike P-gp, the expression of BCRP along the 
small intestine does not vary significantly. It is highly expressed on the luminal side of 
enterocytes and it transports substrates back into the lumen. Due to this and the 
broad substrate specificity, BCRP has been noted as an important efflux transporter 
which limits drug absorption along the GIT. While P-gp and BCRP are localized on 
the luminal side of the brush border membrane (luminal efflux), certain MRPs are 
localized on the luminal and serosal membrane of the enterocyte. MRP 2 and 4 
(luminal efflux) are located on the luminal membrane and MRP 1 and 3 (serosal 
efflux) on the serosal membrane of the enterocyte.  
 
Secondary active transport processes via the solute carrier (SLC) superfamilies 
require the concentration gradient generated by primary active transport processes 
as an energy source (H+, Na+, Ca2+ gradients). Relevant intestinal SLC transporters 
are sodium dependent glucose transporter (SGLT1, uptake of glucose), 
monocarboxylic acid transporter (especially MCT1), peptide transporter (PepT1) and 
organic anion polypeptide transporter (OATP1A2) (Rehner and Daniel, 2002; El-
Kattan and Varma, 2012). MCT1 is highly expressed in the intestine and is known as 
a low affinity, high capacity transporter for unbranched aliphatic monocarboxcylates 
on the apical membrane of enterocytes (e.g. uptake of ferulic acid (Poquet et al., 
2008)). The PepT1 transporter is also a low affinity, high capacity transporter 
localized on the apical side mainly in the duodenum and plays a major role in 
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intestinal uptake of peptidomimetics that include β-lactam antibiotics. In the OATPs 
solute carrier family OATP2B1 and OATP1A2 play a key role in the intestinal uptake 
of xenobiotics which are both located on the luminal membrane of the enteroycte. 
Due to an inhibition of OATP1A2 attributed to grapefruit juice ingestion, the uptake of 
talinolol was reduced. This illustrates that transporters might be potential sites for 
diet-drug interactions (El-Kattan and Varma, 2012). 
 
As both active transport ways (primary and secondary) are dependent in a direct or 
indirect way on the hydrolysis of ATP, their inhibition by a metabolic inhibitor such as 
NaN3 is possible (Konishi and Shimizu, 2003; Poquet et al., 2008). Overall, according 
to the orientation of a transporter protein (efflux or uptake) the uptake of a substrate 
is reduced or increased (El-Kattan and Varma, 2012). 
 
Furthermore, an absorption in the gastrointestinal tract of molecules via specialized 
microfold cells (M-cells) is possible. These special cells are located at the peyer´s 
patches in the intestine. M-cells are lacking of mucus and microvilli but therefore 
provide broader microfolds. This allows accessibility of particles to the luminal 
surface so macromolecules or particles can be absorbed (e.g. proteins) by 
endocytosis (Hussain et al., 2001; Rehner and Daniel, 2002). 
 
2.4.4 Transport kinetics 
For simple passive diffusion the transport rate (flux) of a molecule is defined by the 
concentration difference. Thus it cannot be saturated and molecule flux vs. molecule 
concentration have a linear relationship (first order transport kinetics) (Figure 2-9) 
(Rehner and Daniel, 2002; Silbernagl and Despopoulos, 2003). 
Facilitated diffusion or active transport processes are characterized by non linear 
transport kinetics. Reasons for this are factors limiting the transport. In detail, the 
facilitated diffusion is influenced by a limited number of binding sites at the transport 
protein. Consequently, the transport kinetics (molecular flux vs. molecule 
concentration) depends on the luminal drug concentration and shows a hyperbole 
relation (Figure 2-9) with a limited maximum flux (second order kinetics) (Rehner and 
Daniel, 2002; El-Kattan and Varma, 2012). 
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Figure 2-9: Transport kinetics of simple passive diffusion and facilitated diffusion 
displayed as concentration vs. flux. Only facilitated diffusion reaches a flux 
maximum (Vmax). According to (Rehner and Daniel, 2002). 
 
2.5 The pig as intestinal absorption model  
Men and pigs are omnivorous and show physiological and anatomical similarities of 
the GIT and the intestinal barrier (Vodicka et al., 2005). Despite the different lengths 
of the small intestine (pig 15 - 22 meters, men 5 – 6 meters) the lengths per kg*BW 
are very similar for both species with around 0.1 m*kg-1*BW-1(Patterson et al., 2008). 
Most similarities are observable in the upper part of the GIT (Figure 2-10). In 
particular, the pig GIT can also be divided into stomach, duodenum, jejunum and 
ileum. However, comparative considerations of the large intestine of both species are 
possible concerning its functionality. The large intestine of a pig is found in a spiral 
conformation (Figure 2-10), but can also be divided into colon ascendens, colon 
transversum, colon descendens and rectum.  
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Figure 2-10: Schematic detailed overview of the pig GIT (Charalambakis, 2008). The 
stomach and small intestine of pig shows strong similarities to the upper GIT of 
man. Comparative considerations of the large intestine is possible concerning 
the functionality (Patterson et al., 2008). 
 
Microscopically structures of human and pig intestines are comparable as well 
(Crump, 1975; Cooper et al., 1997). The morphology of the small intestine is divided 
into several tissues like the human mucosa: tunica serosa, tunica muscularis, tela 
submucosa and tunica mucosa (see Figure 2-11). The tunica serosa is a connective 
tissue and is affiliated to the smooth muscle tissue of tunica muscularis. Next to this, 
the tela submucosa (a lax connective tissue) is located, along with blood vessels, 
nerves and adenoid tissue. Following this is the tunica mucosa which consists of 
three tissue parts: tela submucosa, lamina muscularis mucosae (a thin smooth 
muscle tissue) and lamina propria mucosae (a lax connective tissue). The wall of the 
small intestine ends up with the epithelium mucosae at the luminal side (Mosimann 
and Kohler, 1990). 
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Figure 2-11: Cross section of the pig jejunum (Mosimann and Kohler, 1990). 
 
Beyond anatomical similarities, the associated metabolic processes are similar as 
well (Patterson et al., 2008). However, literature data on this issue is not coherent. As 
previous literature reported a limitation of phase II conjugation in pig (missing 
sulfation) (Williamson et al., 2000), more recent data indicated methylation and 
glucuronidation of polyphenols as major phase II metabolism besides sulfation (Wu et 
al., 2005; Espín et al., 2007; Deußer, 2010). 
 
Because of the strong similarities in the physiology of digestion as well as the 
associated metabolic processes (Crump, 1975; Rowan et al., 1994; Patterson et al., 
2008), pig is reported as the best non-primate human-nutrition model (Wu et al., 
2005; Patterson et al., 2008). 
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2.6 Bioavailability 
Oral bioavailability describes the absorbed amount of an ingested drug (such as 
CGA) which becomes available at the site of drug action. However, the drug 
concentration cannot be readily measured at the direct site of drug action. Based on 
the premise that the drug concentration at the site of action is in equilibrium with its 
concentration in blood, the bioavailability can be determined by the concentration of 
the drug in the systemic circulation or urine (Chereson, 1996). 
 
2.6.1 Factors influencing bioavailability 
Various factors are able to influence the bioavailability of a drug. These factors can 
be widely classified in the dosage form, the proband’s physiology and the molecular 
properties of the ingested drug (see Table 2-7). The molecular properties of the drug 
(physico-chemical properties) and the dosage form have a major influence on 
bioavailability. Whereas interindividual differences in proband´s physiology can lead 
to interindividual differences in bioavailability. Such differences in bioavailability can 
be attributed to physiological differences such as GI motility, gastric emptying rate or 
different disease states (see Table 2-7). Especially the gastric emptying rate can be 
affected by several factors (see chapter 2.4.1.2) and can have a major influence on 
acid-resistant drugs (Chereson, 1996). 
Furthermore, bioavailability of drugs can be decreased when the drug is a substrate 
of efflux transporters situated along the apical side of the GIT such as MDR 1 or MRP 
2 (Dietrich et al., 2003). 
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Table 2-7: Summary of eminent factors that can influence the bioavailability of a drug (such as CGA) after oral ingestion. These factors 
can be widely classified in the dosage form, the proband’s physiology and the molecule property, according to (Chereson, 1996; 
Lipinski et al., 1997; Dietrich et al., 2003; Williamson et al., 2011; El-Kattan and Varma, 2012). 
Factors related to oral bioavailability 
Dosage form 
  
Proband (physiological factors) 
  
Molecule property 
  
   Concentration, amount Variations in absorption power along GI tract Physico-chemical properties 
Size of ingested load Variations in pH of GI fluids - Molecule weight 
Interactions with other substances Gastric emptying rate - Hydrophobicity (log P) 
- Food Intestinal motility - pKa 
- Fluid volume Perfusion of the GIT Substrate of efflux transporters? 
- Other drugs/xenobiotics Presystemic and first-pass metabolism Mechanism of absorption 
Formulation: e.g. solutions, capsules Age, sex, weight 
   Disease states   
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2.6.2 Bioavailability of CGA 
The bioavailability of CGA was elucidated by numerous in vitro and in vivo 
experiments showing its complexity, with partially contradictory outcomes. Therefore, 
the individual steps of CGA bioavailability must be taken into account, such as 
liberation, absorption, distribution, metabolization and elimination (LADME) with 
consideration of the methodical differences used in the individual studies. Specifically 
metabolization of CGA was determined with different analytical methodologies in the 
past and therefore needs detailed consideration. In Figure 2-12 a schematic overview 
of 5-CQA (1d) LADME profile is given.  
 
 
Figure 2-12: Ingestion, liberation, absorption, metabolization, distribution and 
excretion pathways of 5-CQA (LADME) in a healthy human (with colon) and 
ileostomists (without colon, ileal excretion), modified according to (Scalbert 
and Williamson, 2000; Stalmach et al., 2009; Stalmach et al., 2010; Williamson et 
al., 2011). Bold arrows indicate major pathways. CQA = caffeoylquinic acid, 
CA = caffeic acid, QA = quinic acid, DHCA = dihydrocaffeic acid, 
DHFA = dihydroferulic acid; FA = ferulic acid, IFA = isoferulic acid, 
Sulf = sulfate, GlucA = glucuronide. 
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2.6.2.1 Degradation of CGA and liberation of HCA during GI passage 
Observing the way food passes through the GIT (see Figure 2-12), degradation of 
CGA and liberation of HCA from CGA increases from stomach to colon.  
The liberation of free phenolic acids and QA (10a) from CGA plays only a minor role 
in the upper GIT. More specifically, Rechner et al. showed that the acidic 
environment of the gastric lumen did not affect coffee CGA composition (Rechner et 
al., 2001). Additionally, a recent study investigated a high stability of CA and 5-CQA 
in simulated gastric juice and saliva (Kahle et al., 2011). Only a reduced liberation of 
CA (< 1%) was detected in vivo in a ligated rat stomach for 5-CQA (Lafay et al., 
2006) as well as a limited liberation of HCA from coffee CGA in vitro in a gastric cell 
layer study via an esterase most likely located on the apical side (Farrell et al., 2011). 
In vitro a degradation of 5-CQA was observed in a simulated duodenal juice. In this 
assay (pH 7.2) caffeic acid methylester, CA (5a), QA (10a), FA (7a), DHCA (6a) and 
3- and 4-CQA (1b-c) were formed within 24 hours of incubation (Kahle et al., 2011). 
As the conditions of this study are not physiological (extended incubation time and 
increased pH, cf. chapter 2.4.1.2) the data cannot be transmitted to the in vivo 
situation. In another incubation with human duodenal fluid (in vitro, 4 h of incubation) 
(Olthof et al., 2001; Lafay et al., 2006) or ileal effluent (ex vivo, 2 h of incubation) 
5-CQA (1d) was not degraded (Olthof et al., 2001; Lafay et al., 2006). In literature a 
cinnamoyl esterase is described as being located along the human small intestine 
(Andreasen et al., 2001) so a moderate liberation of CGA into QA (10a) and HCA is 
conceivable as already detected in human intervention studies with ileostomists 
(Kahle et al., 2007; Stalmach et al., 2010).  
It is well known that considerable amounts of ingested CGA reach the colon (Olthof 
et al., 2001; Kahle et al., 2007; Stalmach et al., 2010; Hagl et al., 2011). In this 
compartment the microbial metabolism leads to the liberation of QA and HCA and 
further numerous degradation products, respectively (see Figure 2-13) (Olthof et al., 
2003). In particular the microorganisms Escherichia coli, Bifidobacterium lactis, and 
Lactobacillus gasseri are reported to be able to express cinnamoyl esterase activity 
(Rechner et al., 2004) and therefore are partly responsible for the observed 
degradation. 
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Figure 2-13: Proposed cleavage of 5-caffeoylquinic acid to 3,4-dihydroxycinnamic acid 
(CA) and QA and subsequent microbial degradation in the colon, according to 
(Olthof et al., 2003; Rechner et al., 2004). 
 
CGA are rapidly cleaved into QA (10a) and HCA (e.g. 3,4-dihydroxycinnamic acid, 
(CA)) with a subsequent degradation via reduction at the aliphatic double bond, 
dehydroxylation and aromatization (Olthof et al., 2003; Rechner et al., 2004). Hereby 
benzoic- and 3-phenylhydroxypropionic acid are the major metabolites of human 
colonic microbiota (Gonthier et al., 2006). Until now it is not known if different 
subgroups of CGA (CQA (1a-d), FQA (3a-c), CQL (2a-b), diCQA (4a-c)) show 
differences in kinetics and affinity to a cinnamoyl esterase (liberation of CQA, HCA 
and QA (10a) and further degradation) during the GI – passage.  
 
2.6.2.2 Absorption 
In vivo investigations of individual coffee CGA absorption rates are limited because 
CGA undergo large interesterification- and biotransformation reactions in the human 
body. Thus, different research groups have performed in vitro and ex vivo studies to 
achieve reliable individual absorption data, summarized in Table 2-8. 
Small amounts of CGA and HCA were absorbed in the experiments performed (Table 
2-8). The absorption of the HCA seems by trend to be higher in comparison to the 
esterified ones (CGA) in vitro and ex vivo (Table 2-8). In most in vivo studies higher 
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plasma levels of free HCA and only low plasma levels of intact CGA (FQA (3a-c), 
CQA (1b-d), CQL (2a-b)) after consumption of CGA were reported, affirming these 
observations (Nardini et al., 2002; Wittemer et al., 2005; Azzini et al., 2007; Matsui et 
al., 2007; Bergmann et al., 2009; Stalmach et al., 2009).  
Farrell et al. investigated the permeability of coffee CGA in cell monolayer 
experiments (gastric cell line, Caco-2) and therefore used coffee with its natural CGA 
composition and varying CGA concentrations. In the Caco-2 cell line they figured out 
that the major coffee CGA were all permeable, with the exception of 3,5-diCQA (4b). 
Furthermore, their work revealed a strong hint of decreasing permeability of 5-acyl 
CGA compounds within the CGA subgroup (5-FQA (3c), 5-CQA (1d)). The gastric 
permeability of diCQA (4a-c) was counting a multiple compared to other coffee 
polyphenols, especially 3,5-diCQA (4b) (Farrell et al., 2011). These observations may 
partially explain the data of one group which showed high amounts of CQA (1b-d) 
and even diCQA (4a-c) in plasma after coffee CGA consumption (Monteiro et al., 
2007; Farah et al., 2008).  
Individual absorption experiments with single compounds and physiological 
concentrations were performed in T84 colon cell line model (Bergmann et al., 2009). 
The structure-absorption relation showed a high absorption of the lipophilic cinnamic 
acid. In contrast, the more polar hydroxycinnamic acids showed a strongly decreased 
absorption in the following order: IFA (7g), FA (7a), CA (5a), p-CouA. These 
observations indicate a correlation of the physico-chemical properties of a compound 
and its permeability in the used T84 monolayer. Furthermore, different absorption 
rates of single CGA and HCA in vitro indicate limitations of comparing in vivo 
bioavailability studies with different CGA and HCA compositions. Thus, the ileal 
excretion of CGA after coffee consumption (Stalmach et al., 2010) or after apple juice 
consumption (Kahle et al., 2007) showed a limited comparability because coffee and 
apple juice showed a different CGA profile. 
 
Since the physico-chemical properties of a molecule can be an important factor in 
influencing its bioavailability, especially for a passive absorbed compound (see 
chapter 2.4.3), a structure-absorption relation (SAR) for the main coffee CGA is of 
interest. Concluding a SAR with the existing literature data on coffee CGA absorption 
is constricted because of the different concentrations used in these experiments and 
the limited number of investigated compounds (CGA and HCA) in the past. More 
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specifically, no individual experiments have been performed with single FQA (3a-c) 
and diCQA (4a-c) up to now.  
 
Table 2-8: Summary of in vitro (cell line) and ex vivo absorption studies with single 
chlorogenic acids, hydroxycinnamic acids and QA, modified according to 
(Deußer, 2010). c = incubation concentration; t = incubation time. 
 
c t Experimental Absorbed Reference 
Compound   (µM)   (min) design amount (%) 
     
Hydroxycinnamic acids     
CA (5a) 20 240 pig ileal 
mucosa* 
3.7 ± 0.1 (Deußer, 2010) 
 20 240 T 84 n.d. (Bergmann et al., 2009) 
 5,000 40 Caco-2 0.2 ± 0.0 (Konishi and Kobayashi, 
2004) 
FA (7a) 20 240 pig ileal 
mucosa* 
1.2 ± 1.1 (Deußer, 2010) 
 20 240 T 84 2.3 ± 0.2 (Bergmann et al., 2009) 
 5,000 40 Caco-2  3.4 ± 0.2 (Konishi and Shimizu, 2003) 
 30 60 Caco-2/HT29-
MTX 
9.4° (Poquet et al., 2008) 
p-CoA 20 240 pig ileal 
mucosa* 
3.3 ± 1.8 (Deußer, 2010) 
 20 240 T 84 n.d. (Bergmann et al., 2009) 
 1,000 40 Caco-2 1.6 ± 0.2 (Konishi et al., 2003) 
     
Caffeoylquinic acids     
1-CQA (1a) 10 240 pig ileal 
mucosa* 
n.d. (Deußer et al., 2013) 
 10 240 T 84 n.d. (Bergmann et al., 2009) 
3-CQA (1b) 50 240 pig ileal 
mucosa* 
1.5 ± 0.2 (Deußer et al., 2013) 
 50 240 T 84 n.d. (Deußer, 2010) 
4-CQA (1c) 10 240 pig ileal 
mucosa* 
n.d. (Deußer et al., 2013) 
 10 240 T 84 n.d. (Deußer, 2010) 
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c t Experimental Absorbed Reference 
Compound   (µM)   (min) design amount (%)  
      
5-CQA (1d) 50 240 pig ileal 
mucosa* 
1.9 ± 1.0 (Deußer et al., 2013) 
 50 240 T 84 n.d. (Bergmann et al., 2009) 
 5,000 40 Caco-2 0.1 ± 0.0 (Konishi and Kobayashi, 
2004) 
 5,000 60 Caco-2 0.1 ± 0.0 (Dupas et al., 2006) 
     
p-Coumaroylquinic acids     
4-p-CoQA 10 240 pig ileal 
mucosa* 
n.d. (Deußer et al., 2013) 
 10 240 T 84 n.d. (Deußer, 2010) 
5-p-CoQA 10 240 pig ileal 
mucosa* 
n.d. (Deußer et al., 2013) 
 10 240 T 84 n.d. (Deußer, 2010) 
      
D-(-)-Quinic acid 
(10a) 
80 240 pig ileal 
mucosa* 
0.5 ± 0.3 (Deußer et al., 2013) 
 80 240 T 84 0.5 ± 0.1 (Deußer, 2010) 
      
*ex vivo Ussing chamber experiments; ° calculated on the basis of permeation rate 
n.d. = not detected 
 
2.6.2.2.1 Site of CGA and HCA absorption 
The site of absorption is discussed controversially in literature. Several groups 
assume the colon as a major part of CGA absorption, but there is recent evidence for 
absorption taking place in the upper parts of the GIT such as the stomach and small 
intestine. 
The early occurrence of CGA and its metabolites after coffee consumption in the 
systemic circulation (Cmax and Tmax) (Stalmach et al., 2009; Renouf et al., 2010a) as 
well as in vitro (gastric cell line) (Farrell et al., 2011), ex vivo (pig ileal mucosa) 
(Deußer, 2010) and an animal study (ligated rat stomach) (Lafay et al., 2006) indicate 
a considerable contribution of the small intestine and stomach on CGA absorption. 
However, on the basis of several studies using the ileostomy model it is known that 
the absorption of CGA in the upper parts of the GIT varies (see Table 2-9). Following 
the absorption thesis of Olthof and coworkers in ileostomists (Olthof et al., 2001) 
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(CGACONSUMED – CGAILEAL-EXCRETION = CGAABSORBED) means an absorption in the 
upper GIT of 95% for caffeic acid (5a) and 22 - 74% for CQA (1b-d). Thus, high 
amounts can reach the colon (colonic availability) (see Table 2-9). Recent 
comparison of CGA absorption after coffee consumption in healthy volunteers (with 
colon) and ileostomy volunteers (without colon) revealed the importance of the colon 
with a three times higher absorption of CGA in the healthy volunteers (Rio et al., 
2010). The degradation products of CGA formed in the colon such as DHCA (6a), 
DHFA (8c) (Renouf et al., 2010a) or a potential liberation of CQA (1b-d) and CA (5a) 
from diCQA (4a-c) contribute to a higher total absorption in healthy volunteers.  
 
However, comparative considerations of the described ileostomy studies in Table 2-9 
are limited as some bioavailability factors that might influence the absorption are 
varying. Especially the different dosage forms such as apple beverage (Kahle et al., 
2007; Hagl et al., 2011), coffee (Stalmach et al., 2010) and pure compounds 
dissolved in hot water (Olthof et al., 2001), as well as different doses, consumed 
volumes from 200 mL to 1,000 mL have to be considered. Furthermore, the 
polyphenol composition of apple beverages is different to that of coffee with 
dihydrochalcone derivatives, flavan-3-ols and flavonols (Kahle et al., 2007; Hagl et 
al., 2011). Due to the lack of data on Tmax (ileal excretion), it is not possible to 
observe an influence of the GI transit time on absorption of CGA. Altogether, the high 
deviation in CQA ileal excretion might be caused by the different matrices (dosage 
forms), the different polyphenol compositions, the different consumed CGA doses 
and the different analytical methods used for CGA determination such as HPLC-DAD 
or LC-MS/MS measurement (with or without metabolite detection). Since several 
bioavailability factors are varying in these publications (see Table 2-9), the influence 
of one parameter such as dose cannot be determined. Therefore further studies are 
needed to answer the influence of individual parameters on bioavailability such as 
dose-response studies. 
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Table 2-9: Administered amount of chlorogenic acids (CGA) and corresponding ileal excretion in % (equivalent to colonic availability) 
observed in the ileostomy model. CQA = caffeoylquinic acid (1a-d); CA = caffeic acid (5a).  
Administered  Dosage form Age BMI Subjects Tmax Ileal Reference 
amount (µmol) Matrix   (a) (kg*m-2) (h) excretion (%)   
         2,800 5-CQA water (200mL) with light 
breakfast 
63 27 4 F 3 M n.d. 67* (Olthof et al., 2001) 
2,800 CA water (200mL) with light 
breakfast 
63 27 4 F 3 M n.d. 5* (Olthof et al., 2001) 
358 CQA cloudy apple juice        
(1,000 mL) 
fasted (light 
meal after 4h) 
40.8 n.d. 8 F 3 M ≈ 2 26* (Kahle et al., 2007) 
335 CQA apple smoothie (700 mL) not specified 52.9 25 5 F 5 M n.d. 78* (Hagl et al., 2011) 
385 CGA coffee (200mL) fasted (light 
meal after 3h) 
41-54 26 2 F 3 M n.d. 71 (Stalmach et al., 2010) 
         
*no metabolites were observed in these studies; tmax = time of maximum ileal excretion; n.d. not determined; F = female; M = male 
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2.6.2.2.2 Mechanisms of CGA and HCA absorption 
The way of CGA and HCA absorption is principally discussed either with a passive 
diffusion or an active transport process. As the active transport process can be 
limited by concentration (see Figure 2-9) the mechanism of absorption could be a 
decisive factor influencing the bioavailability. Due to the lack of in vivo dose-response 
studies a limitation of bioavailability by dose is not clarified up to now. However, 
several in vitro studies provide some hints for the absorption mechanism as well as a 
potential efflux transport which can also limit bioavailability. 
For instance several CGA, namely FA (7a), CA (5a) and 5-CQA (1d), were 
transported via the SLC transporter MCT through a monolayer (Caco-2) as a poor 
substrate (Konishi and Kobayashi, 2004). Contrary to this, the same group 
investigated non saturable transport of 5-CQA (1d) in a Caco-2 monolayer indicative 
for diffusion (Konishi and Kobayashi, 2004). This was confirmed by a hypothesized 
transcellular diffusion of FA (7a) through a co-cultured Caco-2 / HT29-MTX cell 
monolayer (Poquet et al., 2008) and a dose independent absorption of FA (Deußer, 
2010).  
The recent work of Farrell and coworkers (Farrell et al., 2011) indicated a much more 
complex situation and lead to the conclusion that absorption mechanisms have to be 
discussed for individual coffee CGA, respectively. In detail, for coffee solution mainly 
passive diffusion in a gastric cell layer was observed, but a potential carrier mediated 
transport for certain 4-acyl CGA subgroup (CQA (1c); FQA (3b)) was hypothesized. 
Beyond this a potential active efflux process (secretion) for diCQA (4a-c), decreasing 
its total absorption rate was discussed. Such efflux transport was observed via 
selective inhibition of MRP- and P-gp transporters in the secretion of ferulic acid 
glucuronide and dihydroferulic acid (Poquet et al., 2008). 
 
2.6.2.3 Distribution in the human body 
As the concentration of an ingested drug (such as CGA) cannot be detected readily 
at the direct site of drug action an equilibrium between its concentration in blood and 
concentration at the site of action is assumed (Chereson, 1996). 
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Therefore, no data of CGA distribution in the human body in different tissues exist 
despite quantitative data of plasma concentration summarized by (Williamson et al., 
2011) or urine concentration (see chapter 2.6.2.5). 
Pharmacokinetic data are only available from healthy volunteers after the ingestion of 
a single coffee dose (see Table 2-10). Comparing the plasma maximum CGA 
concentration (Cmax) per 50 mg CGA dose, the differences in the systemic availability 
of CGA are apparent, particularly for CA (5a) and CQA (1b-d).  
However, recent data showed that plasma AUC and Cmax of coffee metabolites 
appear proportionally to the ingested coffee dose in healthy volunteers (Renouf et al., 
2013). Furthermore, the studies summarized in Table 2-10 used all the same matrix 
(coffee) for CGA administration, other parameters than food matrix are influencing 
the bioavailability of CGA. The coffee consumed in the described studies (see Table 
2-10) had a volume from 190 to 400 mL and was normally consumed in a fasted 
state. Further factors might influence Cmax such as age, BMI, Tmax and different 
analytical measurements.  
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Table 2-10: Pharmacokinetic data of chlorogenic acids after the consumption of coffee beverage by healthy volunteers (dose calculated 
from total CGA content derived directly from the references indicated). Summarized by (Williamson et al., 2011). 
 
Dose Dosage form Age BMI Subjects Cmax Tmax AUC Cmax*50 mg-1 Reference 
Compound (mg) (mL)   (a) (kg*m-2) 
 
(nM) (h) (µmol*h-1*L-1) dose   
            CA (5a) 96 200 fasted n.d. n.d. 10 M 426 ~1 n.d. 222 (Nardini et al., 2002) 
 1,236 190 fasted (light 
meal after 
2 h) 
22-55 n.d. 4 F 2 M 1,560 1.4 2.8 63 (Monteiro et al., 2007) 
 145 200 fasted (lunch 
after 3 h) 
19-35 24 3 F 8 M 92 1 0.3 32 (Stalmach et al., 
2009) 
 335 400 not specified 34 24 5 F 4 M 81 1.6 n.d. 12 (Renouf et al., 2010a; 
Renouf et al., 2010b) 
            
FA (7a) 145 200 fasted (lunch 
after 3 h) 
19-35 24 3 F 8 M 76 0.6 0.5 26 (Stalmach et al., 
2009) 
 335 400 not specified 34 24 5 F 4 M 139 0.6 and 
6.0° 
n.d. 21 (Renouf et al., 2010a; 
Renouf et al., 2010b) 
            
IFA (7g) 335 400 not specified 34 24 5 F 4 M 98 1.8 n.d. 15 (Renouf et al., 2010a; 
Renouf et al., 2010b) 
            
DHCA (6a) 145 200 fasted (lunch 
after 3 h) 
19-35 24 3 F 8 M 346 5 2.8 119 (Stalmach et al., 
2009) 
 335 400 not specified 34 24 5 F 4 M 200 10 n.d. 30 (Renouf et al., 2010a) 
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Dose Dosage form Age BMI Subjects Cmax Tmax AUC Cmax*50 mg-1 Reference 
Compound (mg) (mL)   (a) (kg*m-2) 
 
(nM) (h) (µmol*h-1*L-1) dose   
            
CQA (1b-d) 96 200 fasted n.d. n.d. 10 M 0 n.d. n.d. 0 (Nardini et al., 2002) 
 1,236 190 fasted (light 
meal after 2 h) 
22-55 n.d. 4 F 2 M 4,890 2.3 11.5 198 (Monteiro et al., 2007) 
  145 200 fasted (lunch 
after 3 h) 
19-35 24 3 F 8 M 2 0.6 to 1 0.04 0.8 (Stalmach et al., 
2009) 
            
°Two peaks of FA were observed. n.d. = not determined; F = female; M = male
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2.6.2.4 Metabolization 
As the presystemic metabolism or first-pass metabolism in the small intestine and 
liver is able to reduce the systemic availability of an oral ingested drug, 
metabolization is a decisive bioavailability factor (Chereson and Banakar, 1996).  
The routes by which a drug (xenobiotic, such as CGA) might be metabolized are 
numerous and depend on the drug itself. Metabolization includes reactions such as 
oxidation, reduction, hydrolysis, hydration, conjugation and condensation reactions. 
Normally, xenobiotics metabolism is divided into two phases: phase I 
(functionalization reactions) and phase II (conjugative reactions). An overview of 
chemical reactions associated with phase I or II are given in Table 2-11. Phase I 
enzymes are thought to act as a preparation of a xenobiotic by formation of a 
chemically reactive functional group on which the phase II reactions can occur. 
Phase I enzymes are found in the liver, GIT, lung and kidney. They primarily consist 
of the cytochrome P 450 superfamily of microsomal enzymes (Gibson and Skett, 
2001). 
 
Table 2-11:  Reactions of xenobiotic metabolism classed as phase I or phase II 
metabolism according to (Gibson and Skett, 2001). 
Phase I Phase II 
  Oxidation Glucuronidation / glucosidation 
Reduction Sulfation 
Hydrolysis Methylation 
Hydration Acetylation 
Dethioacetylation Amino acid conjugation 
Isomerisation Glutathione conjugation 
 
Fatty acid conjugation 
 Condensation 
   
Conjugative reactions of phase II enzymes generally increase hydrophilicity and 
thereby enhance excretion in the bile or urine (Gibson and Skett, 2001). The phase II 
enzymes consist of many superfamilies such as sulfotransferase, glutathione S-
transferases and UDP-glucuronosyltransferases and can be found in several tissues 
such as liver, kidney and GIT (Xu et al., 2005). In Table 2-12 an overview of the 
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phase II enzymes is given with the corresponding conjugation reaction and 
corresponding functional group of xenobiotics. 
 
Table 2-12: Phase II conjugation reactions, corresponding enzyme and corresponding 
functional groups of xenobiotics, according to (Gibson and Skett, 2001) 
Phase II reaction Enzyme Functional group 
   Glucuronidation UDP-Glucuronosyltransferase -OH; -COOH; -NH2; -SH 
Glycosidation UDP-Glycosyltransferase -OH; -COOH; -SH 
Sulfation Sulfotransferase -NH2; -SO2NH2 
Methylation Methyltransferase -OH; -NH2 
Acetylation Acetyltransferase -NH2; -SO2NH2; -OH 
Amino acid conjugation 
 
-COOH 
Glutathione conjugation Glutathione-S-transferase Epoxide; Organic halide 
Fatty acid conjugation 
 
-OH 
Condensation  Various 
    
Once CGA are absorbed, an extensive biotransformation in the human body occurs 
(see Figure 2-14). Therefore, the bioavailability of CGA in its unconjugated form is 
limited due to metabolization. Phase II conjugation reactions are the major 
biotransformation steps in humans (Holst and Williamson, 2008). Furthermore, as 
CGA showed free hydroxyl groups (see Figure 2-1), the function of phase I reactions 
plays only a minor role in its metabolization (Wong et al., 2010). 
As reported by Rio et al. the typical metabolic actions observed for CGA in vivo are 
methylation, sulfation and glucuronidation (Rio et al., 2010). Additionally in vitro a 
glutathione conjugate formation by rat hepatocyte microsomes was observed for CA, 
DHCA and CGA (postulated for 5-CQA) (Moridani et al., 2001). Biotransformation 
probably already occurs in the stomach with hydrolyzation of CGA and subsequent 
methylation of HCA, observed in a gastric cell monolayer model (Farrell et al., 2011). 
Kahle et al. reported 5-CQA and CA to be stable whilst incubated with simulated 
gastric juice (Kahle et al., 2011), so the gastric cell monolayer itself reveals the 
metabolic activity. 
Esterases located in upper GIT are able to liberate HCA from CGA. Consequently, 
HCA are liberated and subsequently undergo further metabolic reactions: e.g. CA 
(5a) to its 3- and 4-O-sulfates (5e-d), FA (7a) to its 4-O-sulfate (7c), CA (5a) to form 
IFA (7g), its 3-O-suflate (7f) and glucuronide (7e) as observed in vivo (Rio et al., 
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2010) and in vitro using human intestinal and liver S9 homogenates (Wong et al., 
2010). The main HCA conjugates in urine are sulfates, with the exception of IFA 
which is mainly glucuronidated (Wong et al., 2010). Caffeoylquinde-, feruloylquinde-
sulfates, and feruloylquinde- glucuronides are the only CGA conjugates which have 
been identified up to now (Stalmach et al., 2009; Redeuil et al., 2011). Furthermore, 
influences of different ingested CGA doses on the routes by which CGA and liberated 
HCA are metabolized have not been clarified up to now. 
The colon is the major action site for liberation of HCA from CGA and conversion of it 
to dihydro compounds (as already described in chapter 2.6.2.1) (Rio et al., 2010). 
More specifically, once FA (7a) or benzoic acid (a microbial catabolite of CA (5a) or 
QA (10a)) are absorbed they will be conjugated to FA-glycine (7d) or to hippuric acid 
(Olthof et al., 2003; Rio et al., 2010). Furthermore a minor contribution of the hepatic 
NADPH-cytochrome P450 phase I metabolism in the formation of dihydrocinnamic 
acids (e.g. DHCA (6a), DHFA (8c)) was discussed by Stalmach 2009 and coworkers 
(Stalmach et al., 2009). 
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Figure 2-14: Metabolism pathway of CGA after acute ingestion of coffee in human volunteers: COMT = catechol methyltransferase; 
ST = sulfotransferase; EST = esterase; RA = reductase; GT = UDP-glucuronyltransferase; CoA = co-enzyme; Bold arrows indicate 
major pathways. According to (Stalmach et al., 2010). 
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2.6.2.5 Excretion 
Up to now, excretion of CGA after coffee consumption was observed by monitoring 
renal excretion, although an excretion via the enterohepatic circulation is theoretically 
possible as well.  
The overall renal excretion of an oral ingested drug such as CGA can be presumed 
to give evidence of its bioavailability as the concentration of a drug at the site of drug 
action cannot be directly measured readily (Chereson, 1996). A comparative 
consideration of data on renal excretion after CGA or HCA consumption is hindered, 
because factors which may influence the bioavailability differ in the considered 
studies (see Table 2-13). Different doses and dosage forms with partially different 
CGA and HCA compositions were administered and additionally different analytical 
methods were used for detection of compounds in urine.  
More specifically, Olthof and coworkers observed a different renal excretion after the 
consumption of CA or 5-CQA as pure compounds dissolved in hot water by 
ileostomists (Olthof et al., 2001). This finding provides evidence for a different 
absorption and excretion behavior according to the CGA or HCA composition of the 
consumed food. The consumed artichoke leaf extract (containing CGA and 
flavanoids) (Wittemer et al., 2005), the polyphenol rich extract (Ito et al., 2005) and 
the high bran cereal breakfast (Kern et al., 2003a) showed completely different 
polyphenol profiles to that of coffee, so the comparability of the described studies is 
less. Studies which determined the renal excretion of CGA after coffee consumption 
are different in administered dose and dosage forms, too. Farah and coworkers 
administered an encapsulated green coffee extract, which had to be disintegrated in 
the GIT before absorption (Farah et al., 2008), Rechner administered 6 cups of 
coffee within 8 hours (Rechner et al., 2001) and Stalmach administered a single dose 
of coffee to healthy (with colon) and ileostomists (without colon) (Stalmach et al., 
2009; Stalmach et al., 2010) see Table 2-13. 
Thus, it is not possible to draw a conclusion based on available literature data, 
whether the different doses and dosage forms are affecting the bioavailability. 
However, Wittemer et al. reported a renal excretion of about 4% of the ingested CGA 
after the consumption of two artichoke leaf extracts with two different CA equivalent 
amounts indicating a dose independent excretion (Wittemer et al., 2005). 
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Additionally, the analytical methodology influences the outcome, as shown by the 
group of Stalmach (Stalmach et al., 2009; Stalmach et al., 2010). They used an 
analytical method without enzyme hydrolysis of CGA metabolites and detected a 
multiple level of renal excretion compared to others (see Table 2-13). The 
metabolites were measured directly by Stalmach et al. with a high selective HPLC-
MS system in the multiple ion mode. Other groups reported significantly lower 
amounts excreted renally by using enzymatic hydrolysis of metabolites. These 
groups measured the aglyca by HPLC-DAD (Olthof et al., 2001; Rechner et al., 2001; 
Kern et al., 2003a; Farah et al., 2008), LC-MS/MS (Ito et al., 2005), or HPLC 
coulometric array detection (Wittemer et al., 2005). 
On the one hand an intervention study with different CGA doses in a single food 
matrix is required to investigate the influence of different doses on CGA 
bioavailability. On the other hand an individual dose and different matrices are 
required to answer the influence of different food matrices on bioavailability. 
Additionally, those studies have to be performed with a CGA source with a defined 
CGA and HCA composition and an analytical methodology for the excreted 
compounds without enzymatic hydrolysis. 
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Table 2-13: Summary of renal excretion after consumption of chlorogenic or hydroxycinnamic acids (within food matrix) in probands 
with colon (healthy volunteers). Renal excretion is given in % of ingested dose based on total cinnamates. Comparative 
consideration of renal excretion between the single studies is limited because of the different consumed doses, different dosage 
forms and different analytical methods used for measurement (with or without metabolite detection). FA = ferulic acid (7a). 
Dose Dosage form Age BMI Subjects Renal excretion Reference 
(mg) Matrix Consumption (a) (kg*m-2)  % of dose*  
Healthy subjects (with colon) 
107°° artichoke leaf 
extract  
with hydroxypropyl-methylcellulose 
gel 
not specified 25 22 7 F 7 M 4.7 Ɨ (Wittemer et al., 2005) 
148 coffee 200 mL fasted (lunch 
after 3 h) 
19 - 35 24 3 F 8 M 29 (Stalmach et al., 2009) 
154°° artichoke leaf 
extract 
with hydroxypropyl-methylcellulose 
gel 
not specified 25 22 7 F 7 M 4.0 Ɨ (Wittemer et al., 2005) 
259 polyphenol 
rich beverage 
4 g instant coffee; 0.3 g green tea 
extract; 10 g cocoa powder; 18 g 
grape skin extract; 200 mL 
not specified 25 22 5 F 4 M 3.8 Ɨ (Ito et al., 2005) 
259 FA in high 
bran cereal 
100 g commercial breakfast 
(containing 85% wheat bran) 
together with 
breakfast 
32 26 3 F 3 M 3.1 Ɨ (Kern et al., 2003a)  
170 green coffee 
extract 
encapsulated, 0.4 g fasted (light 
meal after 1 h) 
22 - 55  n.d. 5 F 5 M 5.5 Ɨ (Farah et al., 2008) 
898 coffee  6 cups within 8 hours not specified 31 25 5 M ≈ 5.9 Ɨ (Rechner et al., 2001) 
         
*as total cinnamates; °° CA equivalents; Ɨ after enzymatic hydrolysis (without metabolite identification); n.d. = not determined; F = female; M = male   
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Table 2-14: Summary of renal excretion after consumption of chlorogenic or hydroxycinnamic acids (as pure compound or within food 
matrix) in probands without a colon (ileostomy volunteers). Renal excretion is given in % of ingested dose based on total 
cinnamates. Comparative consideration of renal excretion between the single studies is limited because of the different consumed 
doses, different dosage forms and different analytical methodology used for measurement (with or without metabolite detection). 
CA = caffeic acid (5a), 5-CQA = 5-caffeoylquinic acid (1d). 
 
Dose Dosage form Age BMI Subjects Renal excretion Reference 
(mg) Matrix Consumption (a) (kg*m-2)  % of dose*  
 
Subjects without colon (ileostomists) 
139 coffee 200 mL   fasted (light 
meal after 3 h) 
41 – 54 26 2 F 3 M 8 (Stalmach et al., 2010) 
500 CA 200 mL hot water with light 
breakfast 
63 27 4 F 3 M 10.7 Ɨ (Olthof et al., 2001) 
1,000 5-CQA  200 mL hot water with light 
breakfast 
63 27 4 F 3 M 0.6 Ɨ (Olthof et al., 2001) 
         
* as total cinnamates; °° CA equivalents; Ɨ after enzymatic hydrolysis (without metabolite identification); n.d. = not determined; F = female; 
M = male 
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3 Aims 
Several previous studies on CGA oral bioavailability revealed contradictory data 
(Olthof et al., 2001; Kahle et al., 2007; Stalmach et al., 2010; Hagl et al., 2011; 
Williamson et al., 2011). Different factors can have an influence on the oral 
bioavailability of CGA, such as the dosage form, dose, proband’s physiology or the 
molecular properties of the drug (Chereson, 1996; Lipinski et al., 1997; Dietrich et al., 
2003; Williamson et al., 2011; El-Kattan and Varma, 2012). As different studies with 
healthy (see Table 2-10, State of knowledge) or ileostomy volunteers (see Table 2-9 
and Table 2-14, State of knowledge) showed methodological differences in their 
analytical strategies (sample preparation with or without enzymatic cleavage of CGA 
conjugates), dosage form (such as different CGA composition from different food 
matrix) or dose, the influence of a single parameter on bioavailability could not be 
observed.  
As coffee is the richest source of CGA in the western diet and a common coffee 
beverage (200 mL) serves between 70 and 350 mg CGA (Clifford, 1999; Farah and 
Donangelo, 2006) the main objective of this thesis was to monitor the effects of CGA 
and QA dose from coffee on their oral bioavailability. Especially an influence of 
ingested dose on the site where absorption occurs and metabolization was here in a 
closer focus. Therefore, ileostomy volunteers consumed three different doses of CGA 
and QA by coffee brew and the effect of dose was determined on: ileal excretion, 
plasma concentration, and renal excretion of QA, CGA and its metabolites. This 
dose-response study was performed in cooperation with the Department of Medicine 
II, Gastroenterology, University of Wuerzburg, Germany.  
 
Furthermore, the CGA composition of coffee beverages or other food matrices 
containing CGA vary (Farah and Donangelo, 2006; Neveu et al., 2010). As varying 
CGA compositions show different physico-chemical properties this could also have 
an influence on CGA bioavailability. However, this has not been sufficiently 
investigated for coffee CGA up until now. Especially, the effect of the 
physico-chemical properties of CGA from coffee on their individual absorption rates 
has not been investigated. Here, the objective was to determine effects of the 
physico-chemical properties on absorption of CGA and QA. This was performed ex 
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vivo using the Ussing chamber model, with pig jejunum and individual compounds in 
physiological concentrations. 
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4 Results 
In this work we investigated the bioavailability of coffee CGA and QA in the upper 
parts of the GIT. More specifically, we observed an influence of the consumption of 
different coffee doses on CGA and QA bioavailability in ileostomists and furthermore 
the influence of the chemical structure of CGA and QA on the bioavailability of those 
molecules in the pig jejunal mucosa model.  
 
Therefore, we established on the one hand an ex vivo absorption experiment with pig 
jejunal mucosa in the Ussing chamber using CGA and QA present in coffee to 
observe effects of the chemical structure on their bioavailability. For this, these 
molecules were applied in physiological concentrations (20 µM) and their total 
absorbed amounts were determined (luminal to serosal).  
Moreover, the mechanism of absorption was elucidated for 5-CQA, which is the 
dominating CGA in coffee. In order to differentiate between diffusion and active 
transport the absorption rates (flux) were measured at concentrations from 20 µM up 
to 3,500 µM (luminal to serosal). Secretion of CGA (serosal to luminal direction) were 
measured with 5-CQA at 20 µM with and without co-incubation of the metabolic 
inhibitor NaN3 (10mM). Furthermore, active efflux transporters were detected in the 
pig jejunal mucosa by Western blot analysis. 
 
In order to investigate the influence of different CGA doses on CGA bioavailability we 
performed a randomized, double-blinded and dose-response intervention study. On 
three separate days ileostomists consumed decaffeinated coffee with three different 
doses of CGA (HIGH 4,525 µmol; MEDIUM 2,219 µmol; LOW 1,053 µmol) and QA 
(HIGH 2,546 µmol, MEDIUM 1,373 µmol, LOW 695 µmol). The influence of the 
different consumed doses on total absorbed amounts (renal excretion), colonic 
availability (ileal excretion), metabolization and plasma concentrations was observed. 
Further, the stability of the mentioned coffee molecules in ileal fluid was investigated 
to observe any possible degradation during sample collection.  
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4.1 Stability of CGA in the small intestine (ileal fluid incubation) 
In order to simulate the ileal passage of CGA from coffee and to observe any 
possible CGA degradation and interesterification during sample collection in the 
dose-response intervention study (see chapter 4.3) we performed an ex vivo 
incubation experiment.  
This experiment was performed by incubating instant coffee with ileal fluid in an 
anaerobic chamber at physiological conditions (anaerobic, + 37°C) and 
concentrations (0.5 g instant coffee per L ileal fluid which corresponds to 132 µM 
CGA). Additionally, in order to determine the influence of ileal fluid on coffee CGA 
stability (e.g. ileal matrix, ileal micro flora), a further stability study was performed 
analog using only the incubation buffer (blank = without ileal fluid). 
The recovered amount of the CGA was lower than the applied amount. In the 0 h 
samples 22.8% of CGA were recovered with ileal fluids whereas 58.4% of CGA were 
found in the incubation experiment with buffer samples. Because of this the initial 
concentration detected at time point 0 h was set at 100% and the stability and 
degradation of CGA during incubation was calculated in % of initial concentration 
(see Figure 4-1). 
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Figure 4-1: Stability of coffee CGA subgroups during ex vivo incubations with ileal 
fluid simulating the passage of the small intestine (n = 5). Values are shown in 
% of the initial concentration at time point 0 h (incubation conditions see 
chapter 7.3.4). CQA = caffeoylquinic acid (1a-d); FQA = feruloylquinic acid 
(3a-c); CQL = caffeoylquinide (2a-b), diCQA = dicaffeoylquinic acid (4a-c).   
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It was shown that the CGA from coffee under study were stable during the incubation 
time of eight hours with ileal fluid, despite caffeoylquinides (2a-b) (Figure 4-1).  
The concentration of CQA (1a-d) and FQA (3a-c) slightly increased within the first 
4 hours of incubations and for diCQA (4a-c) within the first 6 hours of incubation. This 
effect was also observed in incubations without ileal fluid (buffer), indicating a non 
microbial influence. Approximately 85% of the initial detected concentration of CQA 
(1a-d), FQA (3a-c) and diCQA (4a-c) remained stable in ileal fluid until the end of 
incubation (8 h), whereas the stabilities in the buffer (without ileal fluid) were lower 
especially for diCQA (4a-c) (Figure 4-2) (see Table 10-2, Appendix). 
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Figure 4-2: Stability of CGA from coffee in: A = ileal fluid (inoculum) (n = 5) and 
B = buffer solutions (n = 2) at representative time points of 4 and 8 hours (given 
in % of initial amount). Incubation conditions see chapter 7.3.4. 
CQA = caffeoylquinic acid (1a-d); FQA = feruloylquinic acid (3a-c); 
CQL = caffeoylquinide (2a-b), diCQA = dicaffeoylquinic acid (4a-c). 
 
The incubation experiment using ileal fluid revealed that the CQL (2a-b) 
concentrations continuously decreased during the entire incubation time of 8 h and 
finally reached 48 ± 23% (mean value of 3- and 4-CQL) of the initial detected 
concentration at time point 0 h (see Figure 4-2 and Table 10-2, Appendix). 
Experiments using buffer media (without ileal fluid) showed that CQL remained more 
stable for the first 4 hours of incubation; followed by a strong decrease within the next 
4 hours. Overall, the investigated compounds in the incubation buffer solutions 
showed reduced stability in comparison to the observed stabilities in the incubation 
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experiment with ileal fluid (see Figure 4-2). Nevertheless, free CA (5a) or FA (7a) as 
proposed hydrolysis products were detected only in inoculum incubations. Here, the 
degradation of coffee CGA in inoculum was apparently linked to the formation of free 
CA (5a) and FA (7a) (see Figure 4-3). 
 
Additionally, we observed some interesterifications within the CGA subgroups, 
because the amount recovered at the end of incubations (8 hours) within a subgroup 
varied. For instance, about 94 ± 17% of the initial measured 3-CQA (1b) and 
107 ± 25% of the initial measured 3-FQA (3a) concentration was found when 
incubated with ileal fluid. Contrary to this, about 74 ± 18% of the initial measured 
5-CQA (1d) and 67 ± 14% of the initial measured 5-FQA (3c) concentration was 
found. This indicates a moderate interesterification within the CGA subgroups (see 
Table 10-2, Appendix).  
 
0 2 4 6 8
0
5
10
15
20
25
30
Co
nc
en
tra
tio
n 
[µ
M
]
time [h]
 CQA
 FQA
 CQL
 diCQA
 CA
 FA
 
Figure 4-3: Degradation of CGA from coffee and formation of free caffeic acid (CA) (5a) 
and ferulic acid (FA) (7a) during incubations with ileal fluids (n = 5). 
Experimental conditions see chapter 7.3.4 (used concentration: 0.5 g instant 
coffee per L ileal fluid which corresponds to 104.7 µM CQA; 12.0 µM FQA; 
6.3 µM CQL; 8.4 µM diCQA; 0.9 µM CA). CQA = caffeoylquinic acid (1a-d); 
FQA = feruloylquinic acid (3a-c); CQL = caffeoylquinide (2a-b), 
diCQA = dicaffeoylquinic acid (4a-c).  
Results  65 
 
 
4.2 Enzyme activities of ileal fluid 
Additionally to the ex vivo ileal fluid stability experiment with CGA from coffee, we 
determined in a semi-quantitative method the enzyme activities of ileal fluids. 
Different enzyme activities of ileal fluids from single volunteers could provide 
explanations for different CGA profiles and amounts excreted via ileal fluid in the 
dose-response study (see chapter 4.3). 
The enzyme activities were checked with an Api®-ZYM test kit (see Figure 4-4) which 
was incubated with ileal fluids. After an incubation time of 4 hours enzymatic activities 
were detected by color reactions in individual micro wells. In all ileal fluids under 
study we observed esterase activity (test kit No. 3 and 4 in Table 10-3, Appendix). 
Despite the ileal effluent of ileo 5, a β-glucuronidase activity in the ileal fluids of ileo 1 
to 4 was detected (micro well no. 15 in Table 10-3, Appendix).  
 
 
Figure 4-4: Representative Api®-ZYM test results after incubation with ileal fluid of 
ileostomist no. 3. The dark colored micro wells (1 to 20) indicate enzyme 
activities of ileal fluids, such as a β-glucuronidase activity in micro well no. 15. 
Coding of well no. (1 to 20) is given in Table 10-3, Appendix. Experimental 
conditions see chapter 7.3.4.6. 
 
4.3 Human dose dependent intervention study with instant coffee 
Until now the question of how the ingested doses of CGA and QA from coffee 
influence their absorption and metabolism remains unresolved. To assess absorption 
in the small intestine, we performed a dose-response study with a randomized, 
double-blinded, crossover design with five ileostomist subjects. After a two day 
polyphenol-free diet, in three separate occasions, the volunteers consumed, coffee 
with different total CGA contents (HIGH 4,525 µmol; MEDIUM 2,219 µmol; LOW 
1,053 µmol) and free QA contents (HIGH 2,546 µmol; MEDIUM 1,373 µmol; LOW 
695 µmol). CGA, QA and metabolite concentrations in plasma, ileal effluent and urine 
were subsequently identified and quantified by HPLC-DAD, -ESI-MS and -ESI-
MS/MS.  
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4.3.1 CGA and QA contents of instant coffee brews used for the dose-
response study 
The main CGA found in the coffee brews under study were CQA (1a-d) with 1-CQA 
(1a) as a minor component, and 3-CQA (1b), 4-CQA (1c) and 5-CQA (1d) as major 
ones. The CGA contents of the three different coffee brews (soluble coffee dissolved 
in hot water) are summarized in Table 10-5, Appendix. Free caffeic acid (5a) was 
only detectable in low amounts. Other CGA, such as FQA (3a-c), diCQA (4a-c) and 
CQL (2a-b), were also detected in lower amounts than the CQA (see Figure 4-5).  
 
 
Figure 4-5: Representative HPLC-DAD chromatogram (at 320 nm) of an instant coffee 
brew (used in the intervention study for trial LOW = 6.5 g instant coffee powder 
reconstituted in 650 mL water). (1a): 1-CQA, (1b): 3-CQA, (1c): 4-CQA, 
(1d): 5-CQA, (3a): 3-FQA, (5a): CA, (3b): 4-FQA, (3c): 5-FQA, (2a): 3-CQL, 
(2b): 4-CQL, (4a): 3,4-diCQA, (4b): 3,5-diCQA, (4c): 4,5-diCQA. Unmarked peaks 
were not identified, (HPLC conditions see chapter 7.2.1: HPLC system I 
conditions 1a). 
 
The total CGA contents in coffee brews consumed were 4,525 µmol (1,642 mg), 
2,218 µmol (805 mg) and 1,053 µmol (382 mg) for the HIGH-, MEDIUM- and 
LOW- doses, respectively. This corresponds to an ingestion of 59.7 ± 2.0, 29.1 ± 1.5 
and 13.8 ± 0.5 µmol*kg-1*BW-1. The average coffee volume was 381 ± 31 mL. The 
free D-(-)-quinic acid contents were 2,547, 1,373 and 695 µmol (HIGH; MEDIUM; 
LOW), respectively. This corresponds to an ingestion of 33.6 ± 3.6, 18.0 ± 1.7 and 
9.1 ± 0.8 µmol*kg-1*BW-1. Individual CGA and QA amounts consumed under study 
are given in Figure 4-6. 
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The different CGA and QA concentrations in the consumed dosages also affected 
the pH of coffee brews served: 5.4 (HIGH); 6.0 (MEDIUM); 6.8 (LOW). 
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Figure 4-6: Amounts of CGA and QA (in µmol) in the three different coffee brews 
(HIGH, MEDIUM, LOW) in the double blinded randomized trials (n = 5). 
CQA = caffeoylquinic acid (1a-d); FQA = feruloylquinic acid (3a-c); 
CQL = caffeoylquinide (2a-b), diCQA = dicaffeoylquinic acid (4a-c), CA = caffeic 
acid (5a), QA = quinic acid (10a). 
 
4.3.2 Ileal elimination of CGA, QA and metabolites after coffee consumption 
Ileostomy fluids were collected - 12 to 0, 0, 0.5, 1, 2, 3, 4, 6, 8 hours post coffee 
consumption, frozen and subsequently freeze dried. CGA and QA were extracted by 
solid-liquid extraction and identified and quantified by HPLC-DAD, -ESI-MS and -ESI-
MS/MS. 
 
4.3.2.1 Identification of CGA, QA and metabolites in ileal fluids  
Identification of CGA, QA and corresponding metabolites in ileal fluids was achieved 
by co-chromatography and matching MS2 spectra with available reference 
compounds (see chapter 7.1.2). CGA compounds without available references were 
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assigned using literature data (Clifford et al., 2003; Stalmach et al., 2009; Marmet et 
al., 2014) and similar MS2 spectra of corresponding precursor compounds. 
Glucuronides were additionally confirmed by neutral loss scan experiments (176 
amu). A total of 37 CGA and corresponding metabolites were identified in ileal fluids 
after coffee consumption. An overview is given in Table 4-1. 
 
Sulfates of CQA were detected with a precursor ion of m/z 433 and their 
characteristic product ions, especially the m/z 353 ion which indicates a loss of 80 
amu. The fragmentation pattern of 3-O-CQA-sulfate (1g) shows the m/z 135 and 
m/z 191 product ion ratio similar to 3-O-CQA (1b). The 4-O-CQA-sulfate (1h) gave a 
characteristic m/z 173 product ion similar to 4-O-CQA (1c) and 5-O-CQA-sulfate (1i) 
showed the dominating m/z 191 ion similar to 5-O-CQA (1d). Furthermore, we were 
able to identify all CQA-sulfates conjugated at position 3´ of the caffeic acid moiety by 
co-chromatography using reference compounds (provided by Denis Barron from 
NRC). Two CQA-glucuronides were detected in the product ion scan mode at 
m/z 529 via the product ion m/z 353 indicating the loss of a glucuronide unit (176 
amu). Identification was achieved according to similar MS2 spectra of corresponding 
precursor compounds. 3-O-CQA-glucuronide (1e) was identified by the product ion 
ratio m/z 135 and m/z 191 and 4-O-CQA-glucuronide (1f) by the characteristic 
m/z 173 product ion. However, it was not possible to determine the conjugation 
position at the caffeic acid moiety due to of lack of references. 
CQL-sulfates (2e-f) showed a [M-H]- of m/z 415. The product ion spectrum is 
dominated by m/z 161, typically for CQL, and m/z 335 is generated by a specific loss 
of 80 amu, according to the work of Stalmach and coworkers (Stalmach et al., 2009). 
CQL-glucuronides (2c-d) revealed a [M-H]- of m/z 511. The product ion spectrum 
was also dominated by m/z 161 and m/z 335 generated by a specific loss of 176 
amu. Due to lack of references it was not possible to identify the conjugation position 
of the caffeic acid moiety. 
Sulfates of FQA were detected by the precursor ion of m/z 447 and characteristic 
product ions of the FQA, especially the m/z 367 which indicates a loss of 80 amu. 
3-O-FQA-4´-O-sulfate (3g) has similar product ions (m/z 193 and m/z 134) to 
3-O-FQA (3a). 4-O-FQA-sulfate (3h) has the characteristic m/z 173 product ion 
similar to 4-O-FQA (3b). Confirmation was also achieved by co-chromatography and 
comparison of MS2 fragmentation patterns with a reference mix of FQA-sulfates 
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(Menozzi-Smarrito et al., 2011). Three FQA-glucuronides were detected with a [M-H]- 
of m/z 529. The neutral loss scan mode and the product ion m/z 367 indicate the loss 
of a glucuronide unit (176 amu). 3-O-FQA-4´-O-glucuronide (3d) was identified by the 
product ion m/z 193 similar to 3-FQA (3a), 4-O-FQA-4´-O-glucuronide (3e) by the 
characteristic product ion m/z 173 typical for 4-FQA (3b) and 
5-O-FQA-4´-O-glucuronide (3f) by the dominating m/z 191 product ion typical for 
5-FQA (3c). Confirmation of feruloylquinic acid glucuronide was also performed by 
co-chromatography and comparison of MS2 fragmentation patterns with a mix of 
feruloylquinic acid glucuronide references synthesized by Menozzi-Smarrito and 
coworkers (Menozzi-Smarrito et al., 2011).  
The identification of isoferuloylquinic acid-glucuronide (IFQA-GlucA) was assumed by 
the data obtained from FQA-GlucA. So we assumed the same product ion 
characteristics as feruloylquinic acid glucuronides. We identified 
3-O-IFQA-3´-O-glucuronide (3i) and 4-O-IFQA-3´-O-glucuronide (3j) corresponding 
to the MS2 fragmentation pattern. Feruloylglycine was identified by confirming the 
MS2 fragmentation pattern reported by Stalmach and coworkers. (Stalmach et al., 
2009).  
All CGA consumed via coffee brews by the volunteers were identified in the ileal 
fluids. We have observed an extensive metabolization in the upper parts of the GIT of 
ileostomists with 24 metabolites being formed (see Table 4-1). Among the group of 
CGA the dominating mechanisms were sulfation, glucuronidation and hydrolyzation. 
 
Table 4-1: Product ion scan of chlorogenic acids and metabolites detected in ileal fluid 
after coffee consumption (HPLC-MS2 conditions see chapter 7.2.2: HPLC 
system IV: conditions 1a). 
 tR  CE (m/z) 
Compound [min] eV [M-H]- product ion 
     
3-O-FQA-O-GlucA (3d) 18.7 - 40 543 367; 193; 113; 175; 149; 85 
3-O-CQA-3´-O-Sulf (1g) 19.0 - 40 433 353; 191; 179; 135 
3-O-CQA-O-GlucA (1e) 20.0 - 40 529 353; 179; 191; 135 
3-O-FQA-O-Sulf (3g) 20.1 - 40 447 367; 193; 191; 134; 173 
1-O-CQA (1a) 20.9 - 50 353 191; 85 
3-O-CQA (1b) 21.8 - 50 353 135; 191; 93 
5-O-FQA-O-GlucA (3f) 22.2 - 40 543 367; 191; 113; 85; 173 
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 tR  CE (m/z)  
Compound [min] eV [M-H]- product ion 
     
4-O-FQA-O-GlucA (3e) 23.0 - 40 543 367; 173; 193; 113; 85 
DHCA-3´-O-Sulf (6d) 23.6 - 50 261 59; 80; 121; 135; 181 
3-O-IFQA-O-GlucA (3i) 24.3 - 40 543 367; 193; 113; 173; 85  
4-O-CQA-O-GlucA (1f) 24.5 - 40 529 353; 173; 179.0; 191; 135 
4-O-CQA-3´-O-Sulf (1h) 24.5 - 40 433 353; 173; 179; 191; 135 
4-O-FQA-O-Sulf (3h) 25.2 - 40 447 367; 173; 191; 193; 134 
5-O-CQA-3´-O-Sulf (1i) 25.3 - 40 433 353; 191 
CA-4´-O-Sulf (5d) 25.7 - 50 259 135; 107; 80; 179; 97 
DHFA-4´-O-Sulf (8b) 25.7 - 40 275 59; 80; 135; 195 
CA-3´-O-Sulf (5e) 27.4 - 50 259 135;107; 80; 97; 179 
CA-3´-O-GlucA (5c) 27.7 - 40 355 135; 179; 85 
DHCA (6a) 28.5 - 50 181 59; 41; 109; 93; 121; 138 
4-O-CQA (1c) 29.0 - 50 353 135; 191; 93; 173 
4-O-IFQA-O-GlucA (3j) 29.0 - 40 543 367; 173; 113; 193  
FA-4´-O-Sulf (7c) 29.1 - 40 273 134; 178; 149; 193; 121; 97; 80 
5-O-CQA (1d) 29.8 - 50 353 191; 85; 93; 127 
3-O-FQA (3a) 30.0 - 50 367 134; 117; 193 
IFA-3´-O-Sulf (7f) 31.0 - 40 273 134; 178; 193; 137; 149; 80 
CQL-O-GlucA (2c-2d) 33.0 - 40 511 335; 161; 135; 179 
CA (5a) 33.1 - 50 179 134 
CQL-O-Sulf (2e-2f) 34.0 - 50 415 335; 161; 135; 173; 179 
FA-glycine (7d) 34.3 - 30 250 206; 191; 177; 149; 163; 134; 100 
4-O-FQA (3b) 34.6 - 50 367 134; 93; 173 
5-O-FQA (3c) 36.0 - 50 367 93; 191; 134 
3-O-CQL (2a) 36.7 - 50 335 161; 133 
4-O-CQL (2b) 37.8 - 50 335 161; 133 
FA (7a) 41.5 - 30 193 134; 178 
3,4-O-diCQA (4a) 55.3 - 50 515.5 173; 179; 135; 191 
3,5-O-diCQA (4b) 57.5 - 50 515.5 191; 179; 135 
4,5-O-diCQA (4c) 63.2 - 50 515.5 173; 179; 135; 191 
     
 
4.3.2.2 Quantification of CGA, QA and metabolites in ileal fluid 
Determination of CGA in ileal fluid samples was performed by HPLC-DAD (see 
chapter 7.3.1.6.2.2), QA was quantified by LC-MS/MS using stable isotope dilution 
analysis (see chapter 7.3.1.6.3). Quantification of metabolites in ileal fluids was 
performed semi-quantitative by HPLC-MS in the multiple ion mode (see chapter 
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7.3.1.6.2.3). In Figure 4-7 a typical HPLC-MS chromatogram of caffeoyl quinic acid 
metabolites in the multiple ion mode (molecular ion [M-H]-) is given. 
 
Figure 4-7: Typical HPLC-MS molecular ion [M-H]- chromatogram of caffeoylquinic 
acid glucuronides (m/z 529) and caffeoylquinic acid sulfates (m/z 433) detected 
in ileal fluid of ileo no. 2 two hours after coffee consumption (HIGH) in the 
multiple ion mode. Further chromatograms in the multiple ion mode (molecular 
ion [M-H]-) are given in Figure 10-1, Appendix. Experimental conditions see 
chapter 7.3.1.6.2.3. 1e* = 3-O-CQA-O-GlucA; 1f* = 4-O-CQA-O-GlucA; 
1g = 3-O-CQA-3´-O-Sulf; 1h = 4-O-CQA-3´-O-Sulf, 1i = 5-O-CQA-3´-O-Sulf. 
* = conjugation position was suspected at 3´. 
 
4.3.2.3 Dose-response effects of different ingested CGA and QA doses 
To assess dose-response effects on absorption in the upper GIT we determined the 
ileal excretion of CGA after the consumption of different CGA doses from coffee. All 
compounds identified in the coffee brews were recovered in the ileal fluids to a 
certain extent. In total, between 68.8 ± 9.0% (HIGH), 72.4 ± 4.7% (MEDIUM) and 
77.4 ± 4.3% (LOW) of the ingested amounts were excreted via the ileal fluids. The 
total ileal excretions are shown in Table 10-7, Appendix. 
Among the different polyphenol subgroups the ileal excretion rates showed minor 
variations (Table 10-6, Appendix). The ileal excretion rate of caffeoylquinides (2a-b) 
was considerably decreased (Table 10-6, Appendix).  
The recovery rates of QA (10a) showed high inter-individual variations and were 
86.5 ± 14.5% (HIGH); 81.9 ± 8.1% (MEDIUM) to 77.6 ± 17.5% (LOW) for subjects 
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1 to 4. For subject no. 5, QA ileal recovery was much lower: 38.1 ± 0.9% (HIGH); 
23.9 ± 1.0% (MEDIUM); 12.5 ± 0.3% (LOW).  
The dose-response effect of coffee CGA and QA consumption and excretion is 
shown in Figure 4-8. A higher consumption leads to a higher amount excreted ileally 
(Table 10-7, Appendix). 
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Figure 4-8: Dose-response relationships of CGA and QA (in µmol) excreted into ileal 
fluids of five probands after consumption of three different CGA doses from 
coffee (HIGH, MEDIUM, LOW) in double blinded randomized trials (n = 5). 
CQA = caffeoylquinic acids (1a-d); FQA = feruloylquinic acids (3a-c); 
CQL = caffeoylquinides (2a-b), diCQA = dicaffeoylquinic acids (4a-c), 
CA = caffeic acid (5a), QA = quinic acid (10a). 
 
4.3.2.4 Dose-response effects of different ingested CGA and QA doses (by 
instant coffee brew) with focus on its metabolization in the upper 
gastrointestinal tract 
Additionally to the observed amount of CGA excreted ileally, we determined the 
metabolization profile of CGA from coffee and the influence of the ingested doses on 
the metabolization profile.  
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About 6.7 ± 2.1% (HIGH), 7.7 ± 1.2% (MEDIUM) and 8.9 ± 1.3% (LOW) of the 
ingested CGA dose were metabolized or hydrolyzed during the passage of the GIT. 
Sulfation was the dominating conjugation, with a sulfation : glucuronidation ratio of 
8.2 : 1 (HIGH), 10.4 : 1 (MEDIUM) and 13.4 : 1 (LOW).  
Especially, CGA with a CA moiety were sulfated (Figure 4-9). Hereby the hydroxyl 
group at position 3´ of the CA molecule was important for conjugation reactions 
(Table 10-7, Appendix, Figure 2-1). Due to a lack of references, this could not be 
confirmed for CQA-GlucA. Further conjugation reactions observed were: methylation, 
verified by detected IFA compounds (7f, 3i, 3j), glycine conjugation monitored by 
feruloylglycine (7d) (Figure 4-10) and dehydrogenase reactions monitored by dihydro 
compounds (6a, 6d, 8b). Dimethylations (9a + 9b) were not observed in the ileal 
effluents.  
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Figure 4-9: Total amounts of excreted sulfated CGA metabolites (in µmol) in ileal fluids 
of five probands after consumption of three different CGA doses via coffee 
brew (HIGH, MEDIUM, LOW) in double blinded randomized trials (n = 5). 
CQA = caffeoylquinic acid; FQA = feruloylquinic acid; CQL = caffeoylquinide, 
CA = caffeic acid; DHCA = dihydrocaffeic acid; FA = ferulic acid; IFA = isoferulic 
acid; DHFA = dihydroferulic acid; Sulf = sulfate. 
 
Molecules esterified with QA (10a) at position 5 (5-CQA (1d), 5-FQA (3c)) dominate 
the polyphenol profile from coffee brews. Nevertheless, metabolization for these 
compounds was less (Figure 4-9 and Figure 4-10) as only small amounts of 
5-CQA-3´-Sulf (1i) were detectable.  
CA conjugates showed a relationship between the consumed CGA dose and the 
ileally excreted amount of CA conjugates. This characteristic was not as strong for 
the consumed FA (7a) and FA linked metabolites, especially FA-Sulf (7c) and 
IFA-Sulf (7f) (see Figure 4-9). 
Furthermore, we detected a moderate hydrolytic activity, indicated by the high 
content of free CA (5a) and the occurrence of DHCA (6a) and FA (7a) in the ileal 
fluids (Figure 4-9 and Figure 4-10).  
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Figure 4-10: Total amounts of excreted glucuronidated, hydrolyzed and glycine 
conjugated CGA metabolites (in µmol) in ileal fluids of five probands after 
consumption of three different CGA doses via coffee brew (HIGH, MEDIUM, 
LOW) in double blinded randomized trials (n = 5). CQA = caffeoylquinic acid; 
FQA = feruloylquinic acid; IFQA = isoferuloylquinic acid; CQL = caffeoylquinide, 
CA = caffeic acid; DHCA = dihydrocaffeic acid; FA = ferulic acid; 
GlucA = glucuronide; Gly = glycine. 
 
4.3.2.5 Physiological concentrations of CGA and QA in ileal fluids after coffee 
consumption 
By determining the weight of ileal fluid and the total amounts of CGA being excreted 
into the ileostomy effluents it was possible to calculate the physiological CGA 
concentrations. The calculations revealed that the concentrations of the intact esters 
(CQA (1a-d), FQA (3a-c), and diCQA (4a-c)) in the excreted ileal fluids were, at their 
maximum, at least twice as high as in the coffee consumed and that the 
concentrations of CA and QA in the ileal excretion reached a multiple of their 
respective concentrations in the coffee brews. But no dose-response effects were 
observable between the consumption of different coffee concentrations and the 
maximum of physiological CGA concentrations (Table 10-9, Appendix).  
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4.3.2.6 Gastrointestinal transit time (GI-TT) of CGA, QA and metabolites after 
coffee consumption 
As the gastrointestinal transit time (GI – TT) of a drug can have a major influence on 
its bioavailability we examined the ileal excretion Tmax of 5-CQA (1d), the major 
coffee CGA component as a parameter of GI - TT. The passage time of consumed 
coffee through the upper gastrointestinal tract varied between the five subjects. In 
particular, the GI - TT of one subject (no 5) differed significantly (Figure 4-11, 
p < 0.03) in comparison to other volunteers. Independently of the coffee dose, 
subject 5 revealed a shift in passage time of several hours by Tmax (5-CQA) as shown in 
Figure 4-11. This finding was confirmed by the separate GI - TT determinations using 
an anthocyanin-rich (colored) beverage. In this study all volunteers showed a GI - TT 
of 45 min, despite of ileo 5 with a GI - TT of up to 5 hours.  
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Figure 4-11: Representative kinetics of CGA and corresponding metabolites excreted 
via ileal fluid (% of ingested dose) (n = 5) after consumption of a MEDIUM 
coffee. 
 
The mean Tmax(5-CQA) of ileo 1 to 4 accelerated with increasing consumed coffee 
dose: 0.5 ± 0.0 h (HIGH); 0.8 ± 0.3 h (MEDIUM), 1.6 ± 1.0 h (LOW): This effect was 
not determined for Tmax(5-CQA) of ileo 5: 4.0 h (HIGH); 6.0 h (MEDIUM) and 4.0 h 
(LOW). Tmax of compounds originating in coffee were all in accordance to Tmax(5-CQA). 
Whereas the Tmax of metabolites were delayed for approximately 1 hour (see Table 
10-8, Appendix).   
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Only small amounts of CGA and metabolites were detectable in the ileal fluids 
(despite ileo no.5) eight hours after coffee consumption, indicating a completed 
GI - passage of compounds (see Figure 4-11). 
 
4.3.3 Renal excretion of CGA, QA and metabolites 
Urine samples were collected - 24 to 0, 0, 0.5, 1, 2, 3, 4, 6, 8, 8 to 24 and 
24 to 48 hours pre and post coffee consumption, rapidly acidified and frozen 
at  - 80 C°. QA was measured in urine by stable isotope dilution analysis without 
additional sample preparation. CGA and metabolites were isolated by solid-phase 
extraction (SPE). Identification and quantification were performed by HPLC-ESI-MS 
and -ESI-MS/MS. 
 
4.3.3.1 Identification and quantification of CGA, QA and metabolites in urine 
samples 
Identification of CGA, QA and corresponding metabolites in urine samples was 
performed by co-chromatography and matching MS2 spectra with available reference 
compounds (see chapter 7.1.2) as already described in chapter 4.3.2.1. Some 
compounds without available references were assigned using literature data (Clifford 
et al., 2003; Stalmach et al., 2009; Marmet et al., 2014) and similar MS2 spectra of 
corresponding precursor compounds. Glucuronides were confirmed additionally by 
neutral loss experiments (176 amu), as already described in chapter 4.3.2.1. 
We identified up to 38 CGA (metabolized or unmetabolized) in the urine samples of 
the ileostomists after coffee consumption (Table 4-2). Furthermore, neither 1-CQA 
(1a), diCQA (4a-c) nor dimethylated (9a + 9b) compounds were detectable in the 
urine samples under study. 
 
Quantification of CGA and corresponding metabolites in urine was performed as 
described in chapter 4.3.2.2 by HPLC-ESI-MS in the multiple ion mode (see chapter 
7.3.1.5.2.2 and Figure 10-1, Appendix); for QA by HPLC-ESI-MS/MS in the multiple 
reaction monitoring mode (see chapter 7.3.1.5.3). In order to determine the 
concentration of CGA, QA, and corresponding metabolites in urine independent of 
the excreted urine volume we additionally measured the creatinine amounts in all 
urine samples (see chapter 7.3.1.5.4).   
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Table 4-2: Product ion scan (HPLC-MS2) to identify chlorogenic acids and metabolites 
in urine samples after coffee consumption (HPLC-MS2 conditions see chapter 
7.2.2: HPLC system IV: conditions 1a). CQA = caffeoylquinic acid; 
FQA = feruloylquinic acid; IFQA = isoferuloylquinic acid, CQL = caffeoylquinide, 
diCQA = dicaffeoylquinic acid; CA = caffeic acid; DHCA = dihydrocaffeic acid; 
FA = ferulic acid; IFA = isoferulic acid; DHFA = dihydroferulic acid; 
GlucA = glucuronide; Sulf = sulfate. 
 tR  CE (m/z) 
Compound [min] eV [M-H]- product ion 
     
3-O-FQA-O-GlucA (3d) 18.7 - 40 543 367; 193; 113; 175; 149; 85 
3-O-CQA-3´-O-Sulf (1g) 19.0 - 40 433 353; 191; 179; 135 
3-O-CQA-O-GlucA (1e) 20.0 - 40 529 353; 179; 191; 135 
3-O-FQA-O-Sulf (3g) 20.1 - 40 447 367; 193; 191; 134; 173 
3-O-CQA (1b) 21.8 - 50 353 135; 191; 93 
5-O-FQA-O-GlucA (3f) 22.2 - 40 543 367; 191; 113; 85; 173 
DHCA-4´-O-Sulf (6c) 22.9 - 50 261 59; 88 
4-O-FQA-O-GlucA (3e) 23.0 - 40 543 367; 173; 193; 113; 85 
DHCA-3´-O-Sulf (6d) 23.6 - 50 261 59; 80; 121; 135; 181 
CA-4´-O-GlucA (5b) 24.0 - 40 355 135; 179 
3-O-IFQA-O-GlucA (3i) 24.3 - 40 543 367; 193; 113; 173; 85  
4-O-CQA-O-GlucA (1f) 24.5 - 40 529 353; 173; 179.0; 191; 135 
4-O-CQA-3´-O-Sulf (1h) 24.5 - 40 433 353; 173; 179; 191; 135 
4-O-FQA-O-Sulf (3h) 25.2 - 40 447 367; 173; 191; 193; 134 
CA-4´-O-Sulf (5d) 25.7 - 50 259 135; 107; 80; 179; 97 
DHFA-4´-O-Sulf (8b) 25.7 - 40 275 59; 80; 135; 195 
DHCA-3´-O-GlucA (6b) 26.0 - 40 357 181; 85; 113; 59; 138 
CA-3´-O-Sulf (5e) 27.4 - 50 259 135;107; 80; 97; 179 
DHFA-4´-O-GlucA (8a) 27.4 - 40 371 85; 59; 195 
CA-3´-O-GlucA (5c) 27.7 - 40 355 135; 179; 85 
FA-4´-O-GlucA (7b) 28.0 - 40 369 134; 178; 193; 85; 59; 149 
DHCA (6a) 28.5 - 50 181 59; 41; 109; 93; 121; 138 
4-O-CQA (1c) 29.0 - 50 353 135; 191; 93; 173 
4-O-IFQA-O-GlucA (3j) 29.0 - 40 543 367; 173; 113; 193  
FA-4´-O-Sulf (7c) 29.1 - 40 273 134; 178; 149; 193; 121; 97; 80 
5-O-CQA (1d) 29.8 - 50 353 191; 85; 93; 127 
3-O-FQA (3a) 30.0 - 50 367 134; 117; 193 
IFA-3´-O-Sulf (7f) 31.0 - 40 273 134; 178; 193; 137; 149; 80 
IFA-3´-O-GlucA (7e) 32.0 - 40 369 178; 193; 134; 85; 59 
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 tR  CE (m/z) 
Compound [min] eV [M-H]- product ion 
     
CQL-O-GlucA (2c-2d) 33.0 - 40 511 335; 161; 135; 179 
CA (5a) 33.1 - 50 179 134 
CQL-O-Sulf (2e-2f) 34.0 - 50 415 335; 161; 135; 173; 179 
FA-glycine (7d) 34.3 - 30 250 206; 191; 177; 149; 163; 134; 100 
4-O-FQA (3b) 34.6 - 50 367 134; 93; 173 
5-O-FQA (3c) 36.0 - 50 367 93; 191; 134 
3-O-CQL (2a) 36.7 - 50 335 161; 133 
4-O-CQL (2b) 37.8 - 50 335 161; 133 
FA (7a) 41.5 - 30 193 134; 178 
     
 
4.3.3.2 Dose-response effects of different ingested CGA and QA doses 
according to their total renal excretion and renally excreted metabolites 
In order to observe dose-response effects on CGA bioavailability we measured the 
amount of CGA and conjugates in urine samples after the ingestion of increasing 
CGA doses from coffee. The total renal excretion of CGA differed considerably 
among the ileostomists; in particular, subject no. 5 showed a longer and significantly 
higher renal excretion compared to the other ileostomists (p < 0.01; Figure 4-15).  
Between 8.0 ± 4.9% (HIGH), 12.1 ± 6.7% (MEDIUM) and 14.6 ± 6.8% (LOW) of the 
ingested CGA amounts and metabolites were detected in urine (Table 10-10, 
Appendix). Thus renal excretions of CGA and metabolites increased with decreasing 
coffee doses. We found 16.4 ± 6.0% (HIGH), 14.8 ± 1.5% (MEDIUM) and 
13.7 ± 2.7% (LOW) of the ingested QA in urine after coffee consumption. 
In contrast to the dominating 5-acyl compounds in the consumed coffees (5-CQA 
(1d), 5-FQA (3c), see Figure 4-6), in urine the unmetabolized 3-acyl compounds like 
3-FQA (3a) and 3-CQA (1b) were dominating independent of the administered doses 
(Figure 4-12). 
The maximum concentrations of CGA and metabolites in urine were calculated in 
nmol*g-1 creatinine (Cmax) after ingestion of the three different CGA doses from 
coffee. Cmax of CGA in urine was in relationship to the ingested dose for all CGA and 
QA (10a) (Table 10-12, Appendix).   
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Figure 4-12: Amounts of CGA and D-(-)-quinic acid (QA (10a)) (in µmol) renally 
excreted in five probands after consumption of three different CGA doses via 
coffee brew: (HIGH, MEDIUM, LOW) in double blinded, randomized trials (n = 5). 
CQA = caffeoylquinic acid; FQA = feruloylquinic acid; CQL = caffeoylquinide; 
CA = caffeic acid. 
 
In order to asses dose-response effects on the routes by which CGA are 
metabolized, we detected the renally excreted CGA conjugates. The rate of 
metabolized or hydrolyzed CGA was 67.0 ± 6.6% (HIGH), 69.2 ± 6.5% (MEDIUM) 
and 69.8 ± 3.4% (LOW) with a sulfation : glucuronidation ratio of 0.7 : 1 (HIGH), 1 : 1 
(MEDIUM) and 1.3 : 1 (LOW) (for details see, Table 10-10, Appendix). Similar to the 
metabolization profile in the ileal fluids, no metabolites of the 5-CQA (1d) or 5-FQA 
(3c) were detected in urine samples. Further, the 3´position of the caffeic acid moiety 
was preferred for sulfation.  
The influence of increasing CGA doses consumed with coffee on metabolization is 
shown in Figure 4-13 and Figure 4-14. 
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Figure 4-13: Summary of sulfated CGA metabolites (in µmol) renally excreted in five 
probands after consumption of three different CGA doses via coffee brews: 
(HIGH, MEDIUM, LOW) in double blinded, randomized trials (n = 5). 
CQA = caffeoylquinic acid; FQA = feruloylquinic acid; CQL = caffeoylquinide; 
CA = caffeic acid; DHCA = dihydrocaffeic acid; FA = ferulic acid; 
DHFA = dihydroferulic acid; Sulf = sulfate. 
 
After the consumption of the highest coffee dose (HIGH) no increase of the sulfated 
compounds: CQL-Sulf (2e + 2f), CA-3´-Sulf (5e), DHCA-3´-Sulf (6d), FA-Sulf (7c) 
and FA-Gly (7d) and DHFA-GlucA (8a) was observed.  
In addition, no sulfation of the hydroxycinnamic acid IFA (7g) took place during all 
three trials - only glucuronidation was observed (Figure 4-14).   
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Figure 4-14: Total amounts of excreted glucuronidated, hydrolyzed and glycine 
conjugated CGA metabolites renally excreted (in µmol) in five probands after 
consumption of three different CGA doses via coffee brews: (HIGH, MEDIUM, 
LOW) in double blinded, randomized trials (n = 5). CQA = caffeoylquinic acid; 
FQA = feruloylquinic acid; IFQA = Isoferuloylquinic acid; 
CQL = caffeoylquinide; CA = caffeic acid; DHCA = dihydrocaffeic acid; 
FA = ferulic acid; IFA = isoferulic acid; DHFA = dihydroferulic acid; 
GlucA = glucuronide; Gly = glycine. 
 
4.3.3.3 Kinetics of CGA, QA and corresponding metabolite being renally 
excreted after coffee consumption 
Kinetics of maximum concentration of CGA, QA and corresponding metabolites in 
urine samples after consumption of the different coffee doses were similar in the 
samples of all volunteers (Table 10-11, Appendix). The maximum concentrations of 
5-CQA (1d, Tmax(5-CQA)) in urine were observed at: 2.0 ± 0.0 h (HIGH); 2.0 ± 0.0 h 
(MEDIUM); 2.6 ± 1.2 h (LOW). Ileostomist 5 showed a prolonged renal excretion time 
(Figure 4-15) and thus, a significantly higher amount excreted (**p < 0.01). The time 
points of maximum renal QA (10a) excretions were also similar for all of the 
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volunteers and showed an extended Tmax(QA): 6.2 ± 2.5 h (HIGH), 5.6 ± 1.2 h 
(MEDIUM) and 7.4 ± 1.2 h (LOW). 
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Figure 4-15: Representative kinetics of the sum of chlorogenic acids and 
corresponding metabolites (in µmol*mg-1 creatinine) detected in urine samples 
of ileostomists (n = 5) after coffee consumption of a MEDIUM coffee dose. 
 
4.3.4 CGA and QA amounts in plasma 
Blood samples were collected at the following time points: 0, 0.5, 1, 2, 4, 6 and 8 
hours post coffee consumption, immediately centrifuged to generate plasma, 
subsequently stabilized and frozen at - 80°C (for details see chapter 7.3.1.7.1). At 
some study trials (LOW, MEDIUM, and HIGH dose consumption) data of one 
ileostomist was missing therefore, all plasma data was shown as the mean of 4 
ileostomists (n = 4) instead of five (for details see chapter 7.3.1.7.1 and 7.3.1.7.2.2). 
Due to the lack of references for quantification, the concentrations of CGA in plasma 
were measured after enzymatic hydrolysis of the sulfates and glucuronides by 
HPLC-MS/MS analysis in the selected reaction monitoring (SRM) mode (see chapter 
7.3.1.7.2.1). The quantification of QA was performed by stable isotope dilution 
analysis by HPLC-MS/MS in the MRM mode as described in chapter 7.3.1.7.3.  
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4.3.4.1 Dose-response effects of different ingested CGA and QA doses with 
focus on its plasma concentration 
We determined increasing CGA concentrations in plasma correlating with an 
increased consumption of CGA dose from the coffee beverages. The overall AUC of 
all CGA were 4,412 ± 751 nM*h0-8-1 (HIGH), 2,394 ± 637 nM*h0-8-1 (MEDIUM) 
1,782 ± 731 nM*h0-8-1 (LOW). AUC for plasma QA were 24.4 ± 5.6 µM*h0-8-1(HIGH), 
14.8 ± 5.0 µM*h0-8-1 (MEDIUM) and 8.0 ± 0.5 µM*h0-8-1 (LOW), respectively. 
No diCQA (4a-c) were detectable in plasma after consumption of the different coffee 
doses. All compounds, except for IFA (7g) and DiMeDHCA (9b), showed a dose-
dependent relationship in plasma AUC or Cmax (Figure 4-16; Table 10-13, Appendix).  
In contrast to the CGA profile in the consumed coffee, (5-acyl compounds are 
dominating, see Figure 4-6) the 4-acyl compounds of CQA (1c) and FQA (3b) were 
dominating in plasma (Table 10-13, Appendix) indicating a possible acyl migration. 
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Figure 4-16: Summary of area under the curves (AUC) of plasma samples (in nM*h0-8-1) 
of four probands after the consumption of HIGH, MEDIUM and LOW CGA doses 
by coffee (data expressed as mean values ± SD; n = 4). Plasma samples were 
enzymatically treated (glucuronidase and sulfatase), for details see chapter 
7.3.1.7.1. CQA = caffeoylquinic acid; FQA = feruloylquinic acid; CA = caffeic 
acid; DHCA = dihydrocaffeic acid; FA = ferulic acid; IFA = isoferulic acid; 
DHFA = dihydroferulic acid; DiMeCA = dimethoxycaffeic acid; 
DiMeDHCA = dimethoxydihydrocaffeic acid.  
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4.3.4.2 Kinetics of plasma CGA, QA and corresponding metabolite 
concentrations after coffee consumption 
After one hour nearly all CGA were almost at their maximal plasma concentration in 
each trial (see Table 10-13, Appendix). Volunteer 5 showed a slower elimination of 
CGA in comparison to the other volunteers (Figure 4-17) and thus, AUC was 
significantly increased (p < 0.05).  
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Figure 4-17: Representative kinetics of CGA and corresponding metabolites plasma 
concentrations (after enzyme hydrolysis) after consumption of a MEDIUM 
coffee dose by four ileostomist (ileo), (n = 4). Ileo 4 not shown (see chapter 
7.3.1.7.1). 
 
In all volunteers the plasma samples of the QA (10a) concentrations reached their 
maxima within about 4.5 hours after coffee consumption - much later than the max of 
CGA (see Figure 4-18 and Table 10-13, Appendix). Only a small decrease of QA was 
observed eight hours after coffee consumption (see Figure 4-18). Thus, elimination of 
QA from plasma was not complete eight hours after coffee consumption.  
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Figure 4-18: Plasma concentrations of free D-(-)-quinic acid (10a), after the 
consumption of three different CGA and QA doses from coffee (HIGH, MEDIUM 
and LOW) by four ileostomists (data expressed as mean values ± SD; n = 4). 
 
4.4 Individual coffee CGA and QA absorption (ex vivo in the pig jejunum 
Ussing model) 
The influences of CGA structural properties on bioavailability are not clearly 
observable as CGA underlie an extensive biotransformation. Furthermore, in vivo 
several physiological factors such as GI - TT may influence CGA absorption. 
Therefore, we performed an ex vivo transport experiment using pig jejunal mucosa in 
the Ussing chamber model (with standardized experimental conditions, see chapter 
7.3.2) to investigate the influence of the molecular properties / chemical structure 
(SAR) and doses (DAR) on absorption of CGA and QA in the upper GIT. In order to 
use relevant physiological concentrations we calculated the maximum concentrations 
in the upper GIT after coffee consumption (LOW) using data from the intervention 
study with five ileostomists, see chapter 4.3. It was possible to calculate CGA 
concentrations by the use of ileal fluid weight and the total amounts of CGA excreted 
after coffee consumption (LOW) into the ileal effluents (Table 10-9, Appendix).   
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4.4.1 Absorption (to serosal direction) 
Ussing chamber experiments conducted with physiologically relevant concentrations 
(20 µM, 4 h incubation) of 12 CGA and QA indicated a relationship between 
absorption and molecular properties (such as molecular structure (see chapter 8) and 
log D (Table 5-1, Discussion, calculated with MARVIN SKETCH 5.3.1). In increasing 
order, the amounts of initially applied compounds that passed through the jejunal 
mucosa from the mucosal (pH 6.0) to the serosal side (pH 7.4) were (approximately) 
1% for CQA (1a-d), 1.5% for CA (5a), 2% for FQA (3a-c), and 4% for QA (10a) 
(Table 10-14, Appendix); only trace amounts of diCQA (4a-c) were detected on the 
serosal side. No significant differences were detectable within the CQA (1a-d) and 
FQA (3a-c) subgroups (Figure 4-19). 
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Figure 4-19: Percentages (% of initial amounts) CGA and D-(−)-quinic acid (20 µM) 
recovered at the serosal side of pig mucosa after 4 h incubation (pH 6 at 
luminal side, pH 7.4 at serosal side) (mean ± SD; n = 4). Experimental design 
see chapter 7.3.2.3. CQA = caffeoylquinic acids (1a-d); FQA = feruloylquinic 
acids (3a-c); diCQA = dicaffeoylquinic acids (4a-c), CA = caffeic acid (5a), 
QA = quinic acid (10a). 
 
The kinetics of transport to the serosal side revealed an increase in absorption 
through the jejunal tissue during the entire incubation time. In short, the transport was 
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directly proportional to the serosal concentration for all investigated compounds 
(Figure 4-20, Table 10-15, Appendix). 
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Figure 4-20: Transport kinetics (in nmol*cm-2) to the serosal side for 5-caffeoylquinic 
acid (5-CQA (1d)), 5-feruloylquinic acid (5-FQA (3c)), quinic acid (QA (10a)) and 
caffeic acid (CA (5a)) for 4 h at 20 µM. Experimental details see chapter 7.3.2.3. 
 
4.4.2 CGA and QA amounts associated with the pig jejunal mucosa 
The analytical method used for CGA extraction (see chapter 7.3.2.6, material and 
methods section) did not distinguish between cytosolic or tissue associated CGA. 
Therefore, CGA were detected on or in the tissue samples (tissue associated) in 
amounts of 1 to 1.5% of the initially applied amount (see Figure 4-21), except for 
diCQA (4a-c) detected in lower amounts. Approx. 0.2% were detected for 3,4-diCQA 
(4a) and 3,5-diCQA (4b) and trace amounts for 4,5-diCQA (4c). 
When 5-CQA (1d) (20 µM) was incubated at the serosal compartment 0.5 ± 0.3% 
and when co-incubated with the metabolic inhibitor NaN3 0.8 ± 0.3% of the amount 
applied initially was recovered. 
In the DAR experiment with increasing 5-CQA (1d) concentrations (0.02 to 3.5 mM) 
0.6 ± 0.1% (at 0.5 mM) up to 1.9 ± 0.6% (at 3.5mM) were associated with the tissue 
(see Table 10-14, Appendix).  
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Figure 4-21: Percentages (% of initial amounts) of CGA associated with pig jejunal 
mucosa after 4 h of incubation at 20 µM (pH 6 at luminal side, pH 7.4 at serosal 
side, mean ± SD; n = 4). CQA = caffeoylquinic acid; FQA = feruloylquinic acid; 
CA = caffeic acid; diCQA = dicaffeoylquinic acid; QA = D-(-)-quinic acid. 
Experimental details see chapter 7.3.2.3. 
 
All data is provided in detail in Table 10-14, Appendix. 
 
4.4.3 Secretion of 5-caffeoylquinic acid (5-CQA) (to luminal direction) 
In the CGA secretion experiment (sample applied at serosal side and transfer to 
luminal direction was monitored) 5-CQA (1d) (20 µM) was applied at the serosal side 
(pH 7.4) and the amount transferred to the mucosal compartment (pH 6.0) was 
measured. Secretion occurred at a significantly higher rate (2.3 ± 0.6%) than 
absorption (0.9 ± 0.2%; p < 0.001). When the metabolic inhibitor NaN3 was used a 
significant decrease in secretion was observed (1.3 ± 0.5%; p < 0.05; see Table 
10-14, Appendix, Figure 4-22). This provides evidence for an active-transport 
inhibition.   
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Figure 4-22: Total absorption and secretion of 5–CQA (% of initial amounts) through 
the pig jejunal mucosa after 4 h incubation at 20 µM (***p < 0.001). 5-CQA was 
applied on either the mucosal side (absorption) or the serosal side (secretion) 
and coincubation of NaN3 (10 mM) with 5-CQA on the serosal side (*p < 0.05), 
(pH 6 at luminal side, pH 7.4 at serosal side) (charted data are mean ± SD; 
n = 4.) 
 
4.4.4 Identification of ABC-transporters in the pig jejunal mucosa 
As the experiments with the metabolic inhibitor NaN3 (see chapter 4.4.3) indicated an 
active CGA secretion, we performed Western blot experiments with pig jejunal 
mucosa to identify active efflux transporters. The ABC efflux transporters MRP 2 and 
the P-gp transporter MDR 1 were identified in pig jejunal mucosa for the first time 
(see Figure 4-23) with the support of Johanna Hauser (diploma thesis), (see chapter 
7.3.3 for experimental conditions).  
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Figure 4-23: Western blot analysis of the ABC-transporters MDR 1 (MW = 150 kD) and 
MRP 2 (MW = 180 kD) in the pig jejunal mucosa. Analytical conditions see 
chapter 7.3.3 (Western blot analysis was performed by Johanna Hauser). 
 
4.4.5 Dose-dependent transfer rates of 5-CQA (to serosal direction) 
In the dose-absorption experiment using pig mucosa and 5-CQA (applied at doses of 
0.02 to 3.5 mM), the total amount transported to the serosal side was approximately 
1% independent of the applied dose (Table 10-14, Appendix). Saturation of 
absorption was not observed up to the highest concentration of 3.5 mM. 
However, after 2 h of incubation the flux (dose–transport rate in nmol*h-1*cm-2) 
relationship was linear (Figure 4-24) indicating a passive diffusion of 5-CQA (1d) (cf. 
Figure 2-9, see State of knowledge).  
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Figure 4-24: Flux rates for 5-CQA [nmol*h-1*cm-2] (concentration: 0.02 to 3.5 mM) from 
mucosal to serosal side at 2 h of incubation with pig jejunal mucosa in the 
Ussing chamber (mean ± SD; n = 4). R2 = 0.99. 
 
4.4.6 Mass balance of individual coffee compounds in the Ussing chamber 
experiments 
Some interesterifications of CGA were observed in the mucosal compartment. CQA 
(1a-d) and FQA (3a-c) interesterified into their corresponding isomers, with QA esters 
linked at position 4 being the most unstable (see Table 4-3). The measured CGA 
composition in the mucosal compartment after 4 h incubation with 5-CQA (1d) is 
shown in Figure 4-25 with 3- (1b) and 4-CQA (1c) as interesterification products and 
CA (5a) as a product of hydrolysis.  
On the serosal side, only the FQA subgroup formed interesterification artefacts (see 
Table 4-3). The interesterification rates of 5-CQA (1d) did not change with increasing 
concentrations (up to 3.5 mM). In the secretion experiments (serosal application) with 
5-CQA at pH 7.4, interesterification in the serosal compartment occurred at a higher 
rate (17.8% on initial amount) than in all other absorption experiments (see Table 
4-3).  
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Figure 4-25: Composition of mucosal compartment (% of initial amount) after 4 h 
incubation in Hank’s balanced salt solution (HBSS) (pH 6) at + 37°C in the 
Ussing chamber with 5-CQA (20 µM) (pH 7.4 at serosal side, mean ± SD; n = 6). 
 
Interesterification of diCQA (4a-c) was only observed for 3,5-diCQA (4b) in low 
amounts. Some diCQA (4a-c) showed less stability with a liberation of free CA (5a) 
up to 6.2% of the initial concentration. The hydrolytic reaction products, CA of CQA, 
were observed only on the mucosal side (see Table 4-3).  
As an indication of some hydrolytic reactions the free hydroxycinnamic acids, namely 
CA (5a) and FA (7a), were detectable after incubations with CQA (1a-d) (from 0.1 up 
to 0.4% CA), and 5-FQA (3c) (0.8% FA), respectively (see Table 4-3).  
 
The stability of a compound (mass balance) after 4 h of incubation was calculated as 
the sum of recovered amount of incubated molecule, its interesterification and 
hydrolytic products in the individual Ussing chamber compartments (serosal, 
mucosal, tissue). We recovered mass balances after 4 hours from 69.8 up to 121.1% 
of the initial amounts applied (shown in Table 4-3). 
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Table 4-3: Summary of data for interesterification, hydrolysis and mass balance (sum 
of mucosal, serosal and tissue located amounts) 4 h after incubation of CGA 
(20 µM) in the Ussing chamber model using pig jejunal tissue. Details see 
chapter 7.3.2.3 (n.d. = not detected; < LOQ = below LOQ), (mean ± SD as a 
percentage of the initial concentration; n = 4). 
 
Interesterification  Hydrolysis Mass balance 
Application (20 µM) Mucosal Serosal Mucosal Entire distribution 
  
  
  
Mucosal (pH 6.0)       
 
     
1-CQA (1a) < LOQ n.d. 0.4 ± 0.2 100.3 ± 10.0 
3-CQA (1b) 3.7 ± 0.4 n.d. 0.4 ± 0.1 104.9 ± 7.6 
4-CQA (1c) 6.1 ± 1.4 n.d. 0.4 ± 0.2 103.6 ± 12.1 
5-CQA (1d) 1.6 ± 0.6 n.d. 0.1 ± 0.0 99.3 ± 8.4 
  
  
  
3-FQA (3a) 1.1 ± 0.6 0.6 ± 0.2 n.d. 106.6 ± 17.6 
4-FQA (3b) 15.7 ± 3.2 0.8 ± 0.2 n.d. 103.4 ± 8.1 
5-FQA (3c) 2.0 ± 0.2 0.3 ± 0.1 0.8 ± 0.1 106.0 ± 4.2 
  
  
  
3,5-diCQA (4b) 1.7 ± 0.4 n.d. 6.2 ± 1.1 69.8 ± 21.5 
3,4-diCQA (4a) n.d. n.d. n.d. 84.6 ± 4.2 
4,5-diCQA (4c) n.d. n.d. 4.0 ± 1.1 99.2 ± 11.1 
  
  
  
CA (5a) 
   
100.4 ± 7.8 
D-(-)-QA (10a) 
   
108.4 ± 13.4 
     
Serosal (pH 7.4)       
 
5-CQA (1d) 0.2 ± 0.1 17.8 ± 1.8 n.d. 121.5 ± 16.8 
      
4.4.7 Metabolic actions of pig jejunal tissue on 5-CQA 
At the highest concentration of 5-CQA (3.5 mM) applied, a metabolite was identified 
in the serosal compartment of the Ussing chamber. A CQA-glucuronide was 
identified in the product-ion scan mode at m/z 529 via its product ions at m/z 191 (QA 
(10a)) and m/z 162 (CA (5a) minus H2O), indicating the loss of a glucuronic acid unit 
(176 amu). The loss of 176 amu was confirmed by a HPLC-MS/MS neutral-loss 
experiment. Furthermore, the product ion at m/z 191 gives a hint for 5-CQA (1d) 
fragmentation. 
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5 Discussion 
5.1 Liberation of HCA and degradation of CGA from coffee in ileal fluid 
(ex vivo stability experiments) 
By performing ex vivo experiments we have simulated the ileal passage of CGA from 
coffee to monitor any possible CGA degradation during ileal transit in vivo and, or 
sample collection (ileal bags) in our dose-response intervention study (see chapter 
4.3). For this we have performed an ex vivo incubation experiment with CGA and ileal 
effluent at physiological ileal conditions (see chapter 4.1). 
The instant coffee concentrations in the inoculum (0.5 g*L-1) were significantly 
smaller than the instant coffee concentrations consumed during the LOW dose 
treatment (10 g*L-1) in the coffee intervention study (see chapter 4.3.1). As a 
recovery rate of 70% of the consumed CGA in ileal effluent is known (see Figure 5-1) 
an incubation concentration of 0.5 g instant coffee per L ileal effluent corresponds to 
a physiological concentration that can be easily reached after the consumption of 
coffee.  
However, the overall recovery of CGA used in the study was low which was 
presumably the effect of the high organic solvent concentration in the used extraction 
solution (99% EtOH). Other extraction methods achieved higher recovery rates 
(Olthof et al., 2001; Kahle et al., 2011) using considerably lower organic solvent 
concentrations as well as used for ileal fluids extraction after coffee consumption (in 
vivo study) in this work (see chapter 7.3.1.6.1).  
Because of the low recovery of CGA, the initial measured concentration at time point 
0 h was set at 100%. Therefore, stability and degradation of CGA compounds were 
shown in % of the initial measured concentration and the achieved results can be 
only considered as a hint of the actual behaviour of CGA during ileal passage. 
Nevertheless, in literature comparable investigations were performed for 5-CQA (1d) 
and CA (5a) with ileal fluid confirming our observations (Olthof et al., 2001; Kahle et 
al., 2011) of a negligible influence of ileal conditions on coffee CGA degradation, 
except for CQL (2a-b) degradation. 
The observed changes in CGA concentration during the ex vivo simulations using 
ileal fluids are shown in Figure 4-1, Results. Specifically concentrations of CQL 
(2a-b) were continuously decreasing during the eight hours of the experiment 
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whereas concentrations of CQA (1a-d), FQA (3a-c) and diCQA (4a-c) were less 
affected. Moreover, CQA (1a-d), FQA (3a-c) and diCQA (4a-c) concentrations 
increased during the incubation time before its decrease during the last two hours of 
the experiment as shown in Figure 4-1, Results. Here, we presume a release of 
these compounds from polymeric compounds such as melanoidins, where CGA can 
be bond covalently or non covalently during roasting (Nunes and Coimbra, 2010). 
Simultaneously, a degradation of all other CGA was observed during incubations of 
instant coffee with ileal fluids following the formation of the free hydroxycinnamic 
acids (CA (5a), FA (7a)) as shown in Figure 4-3, Results. 
Phenolic compounds from coffee with an intramolecular ester bridge such as the 
lactones (CQL (2a-b)) showed the highest degradation within 8 hours of incubation 
(48% of the initial measured concentration was recovered), whereas the QA esters 
(CQA, FQA, diCQA) remained much more stable (at least 84% of the initial measured 
concentration was recovered) after 8 hours (Table 10-2, Appendix). The recovery 
rates of CGA in ileal effluent after coffee consumption revealed a similar outcome 
with a decreased recovery of CQL in comparison to CQA, FQA or diCQA (Table 
10-6, Appendix).  
Several mechanisms such as chemical, microbial or enzymatic reactions could affect 
the outcomes of our observations. Therefore, additional experiments were performed 
without ileal fluid, using only buffer solutions (Figure 4-2, Result section) indicating 
that ileal conditions without ileal fluid and ileal microbiota such as chemical processes 
might cause the observed effects. 
Hence, the enzymatic esterase in the ileal effluents detected via Api®-ZYM test kit 
(see Figure 4-4, Results) was not cleaving the ester bond between HCA and QA. 
Furthermore, the microbiota content deviations of ileal effluents (Table 10-4, 
Appendix) (Fallingborg, 1999) might not have influenced the stability of CGA and 
HCA. Here, we observed ex vivo moderate interesterifications within the CQA (1b-d) 
subgroup and significant interesterifications for the FQA (3a-c) (*p < 0.05) subgroup. 
The 5-acyl compounds decreased (1d, 3c) and the 3-acyl increased (1b, 3a) (Table 
10-2, Appendix), respectively. This means that after 8 hours of incubation the CQA 
and FQA profiles were closer to the equilibrium than the CQA and FQA profiles of the 
incubated instant coffee. Previously, these findings were observed for CQA in ileal 
effluents after consumption of apple beverages (Kahle et al., 2007; Hagl et al., 2011) 
or coffee (Stalmach et al., 2010). 
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In the diCQA (4a-c) and the CQL (2a-b) subgroup interesterification seemed to be 
sterically hindered. Nevertheless, in the diCQA (4a-c) subgroup, 3,5-diCQA (4b) 
showed a decreased stability during the ex vivo incubations with ileal fluid (Table 
10-2, Appendix). These findings are in agreement with the recovery of 3,5-diCQA in 
the ileal effluent after consumption of different coffee doses (Table 10-6, Appendix) or 
by (Stalmach et al., 2010). These changes upon the coffee CGA profile at ileal 
conditions were corroborated by the Ussing chamber experiments with individual 
CGA (see chapter 4.4.6). Due to these individual incubations we know now that 
interesterification from 5-acyl into 3-acyl occurs via the 4-acyl compound as an 
intermediate product (Figure 5-7).  
In conclusion, the CGA under study were stable within the first six hours of ileal fluid 
incubations. Thus, CGA consumed from coffee were stable during the ileal passage 
and sampling in the ileal bags in the dose-response intervention study performed 
(see chapter 4.3). This confirms that the ileostomy model is a suitable tool in CGA 
bioavailability research. However, the CQL showed a decreased stability and might 
be partially degraded during ileal passage or sampling in the ileal bags. This has to 
be taken into account by interpreting data from human intervention studies collecting 
ileostomy bags after coffee consumption. 
 
5.2 Human dose-response intervention study with coffee polyphenols 
and QA 
As existing bioavailability data of chlorogenic acids in literature after single dose 
consumption used different study designs such as different doses or different dosage 
forms with different polyphenol compositions and different analytical strategies (with 
or without metabolite detection), a comparative consideration of the somewhat 
controversial bioavailability data was not possible. Thus, the influence of the above 
mentioned study factors on bioavailability cannot be observed. 
Due to this, we performed a dose-response study with different CGA doses (HIGH, 
MEDIUM, LOW), coffee as dosage form and one analytical strategy. Here, the effect 
of the dose on the bioavailability in the upper GIT and on the sites within the GIT 
where absorption occurs (e.g. colonic availability) was observed as this was the only 
factor differing during the study trials. Therefore, ileostomists consumed different 
coffee doses in mg*kg-1*BW-1, in a randomized, double blinded, crossover trial and 
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the observed effects on coffee polyphenol and free QA (10a) absorption, ileal 
excretion and metabolism were documented.  
 
5.2.1 CGA and QA amount in instant coffee 
The main CGA subclass found in the administered instant decaffeinated coffees 
under study was CQA (1a-d) with 5-CQA (1d) as major ones (Table 10-5, Appendix). 
Other CGA, such as FQA (3a-c), diCQA (4a-c) and CQL (2a-b) were also detected in 
lower amounts than the CQA (see Figure 4-5, Results). CGA profile in g % dry matter 
basis of the instant coffee powder under study was: 7.0% CQA, 1.0% FQA, 1.0% 
diCQA, and 1.4% CQL. This profile was confirmed by previous investigations on the 
coffee CGA profile in g % dry matter basis (cf. Table 2-6, State of knowledge 
(Clifford, 1999; Farah and Donangelo, 2006)). Moreover, the 5-acyl compounds 
(5-CQA (1d) and 5-FQA (3c)) were dominating their subgroup and the major quinide 
was the 3-CQL (2a) (Farah et al., 2005b). Free acids such as CA (5a) and QA (10a) 
were observed as reported previously (Hucke and Maier, 1985; Badoud and Pratz, 
1986; Farah and Donangelo, 2006; Farah, 2012).  
The total CGA amount in g % dry matter basis of instant coffee powder was 10% 
CGA which is close to the instant coffee used by the group of (Renouf et al., 2013)(cf. 
Table 2-6, State of knowledge) (Farah and Donangelo, 2006), and a CGA amount 
which is comparable to CGA amounts of green unroasted coffee beans (cf. Table 
2-5, State of knowledge) (Farah and Donangelo, 2006).  
A common coffee serves ~ 400 µmol CGA per 200 mL cup (Clifford, 1999). The total 
CGA contents consumed via coffee brew in our intervention study were 4,525 µmol 
(1,642 mg), 2,218 µmol (805 mg) and 1,053 µmol (382 mg) for the HIGH-, MEDIUM- 
and LOW- doses, respectively (Table 10-5, Appendix). This means a 2.5 to 10 times 
higher dose than normally ingested (Clifford, 1999). This enabled us to observe 
possible dose-response effects on bioavailability in the upper GIT by acute ingestion. 
 
5.2.2 Ileal elimination of CGA, QA and metabolites after coffee consumption 
Because of the colon resection in ileostomists it is possible to detect the colonic 
availability of orally ingested nutritional compounds such as CGA from coffee by 
analyzing the ileal effluents. Furthermore, bioavailability and metabolization in the 
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upper GIT could be observed without the intensive colonic microbial degradation of 
nutritional compounds as occurring in healthy volunteers with a colon.  
 
5.2.2.1 Effects on ileal excretion by an increasing consumption of CGA and QA 
from coffee 
After coffee consumption by ileostomy volunteers, we recovered about ⅔ of the CGA 
metabolites in ileal fluids (see Table 10-7, Appendix), indicating that about ⅓ of them 
were absorbed in the small intestine, comparable to a previous single-dose study on 
a different group of ileostomist volunteers (Stalmach et al., 2010). Other studies using 
single doses detected a similar colonic availability of CGA (Olthof et al., 2001; Hagl et 
al., 2011) in spite of the group of Kahle et al. (Kahle et al., 2007) that found a 
considerable smaller colonic availability (see Figure 5-1). Comparative considerations 
to our data are limited due to the missing metabolite detections in these studies (see 
Table 2-9, State of knowledge) and different consumed CGA compositions. 
Nevertheless, the CGA recoveries in the bioavailability studies (Olthof et al., 2001; 
Hagl et al., 2011) (without metabolite detection) are assumed to be close to our 
observations (see Figure 5-1), because less than 10% of consumed CGA were 
metabolized or hydrolyzed when passing the upper GIT, as observed in our dose-
response study after coffee consumption (see chapter 4.3.2.4, Results). 
For the determination of CGA and potential metabolites the groups of (Olthof et al., 
2001; Hagl et al., 2011) and (Kahle et al., 2007) used an HPLC-DAD system. In 
contrast, the group of Stalmach and our current study used an HPLC-MS system in 
the multiple ion mode (see chapter 7.3.1.6.2). The HPLC-MS as well as the 
HPLC-DAD analytical system showed a similar sensitivity for CGA (LOD 5-CQA absolute: 
HPLC-DAD = 0.2 ng; HPLC-MS (multiple ion mode) = 0.5 ng). The high number of 
CGA and CGA metabolites in ileal effluent and a similar absorption wavelength (λmax) 
of CGA compounds complicated a chromatographic separation of all compounds. 
Such a chromatographic separation is necessary for HPLC-DAD detection but not for 
HPLC-MS detection. The HPLC-MS system in the multiple ion mode showed a high 
selectivity by detection of the mass to charge ratio. Thus, we conclude CGA 
metabolites detection by HPLC-DAD might be incomplete due to low selectivity. 
Hence, the technical limitations of the HPLC-DAD method are not suitable for CGA 
metabolite detection in contrast to the HPLC-MS system.  
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Therefore, identification of CGA, QA and corresponding metabolites was conducted 
with the HPLC-MS system (see chapter 7.3.1.6.2.1). More specific, Co-
chromatography, matching MS2 spectra of available reference compounds (see 
chapter 7.1.2) and literature data (Clifford et al., 2003; Stalmach et al., 2009) were 
used for identification. CGA compounds without available references such as FA-Gly 
(7d) were identified using literature data (Clifford et al., 2003; Stalmach et al., 2009) 
and similar MS2 spectra of corresponding precursor compounds.  
As no reference compounds of isoferuloylquinic acid-glucuronide (IFQA-GlucA 
(3i, 3j)) or its precursor compound isoferuloylquinic acid (IFQA) were available 
identification was assumed by the data obtained from FQA-GlucA. Comparative 
consideration of recently published IFQA product ion characterization was limited as 
the reference FQA compounds were already showing different retention times and 
product ions presented in that reference, in contrast to our observations (Kuhnert et 
al., 2010). Nevertheless, a later retention time of IFQA-GlucA was confirmed 
(Kuhnert et al., 2010).   
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Figure 5-1: Amounts (%) of chlorogenic acids (CGA) excreted into ileostomy effluents 
and corresponding amounts of CGA consumed, published in literature (grey 
bars) compared to our findings (LOW, MEDIUM and HIGH). Different CGA 
matrices and amounts were used in single dose studies published, such as AS 
= apple smoothie with 120 mg CGA (Hagl et al., 2011); CAJ = cloudy apple juice 
with 127 mg CGA (Kahle et al., 2007); COFF = coffee with 139 mg CGA 
(Stalmach et al., 2010) and PURE = 1,000 mg 5-CQA in water (Olthof et al., 2001). 
In our dose-response study three different coffees LOW, MEDIUM, HIGH with 
382, 805 and 1,642 mg CGA were consumed. * = without identification of CGA 
metabolites.  
 
The consumption of different doses of CGA via coffee did not greatly affect 
absorption in the small intestine, see Figure 5-1.  
Thus, the existing contradictory data in literature on ileal excretion of CGA (Kahle et 
al., 2007) must have been influenced by other bioavailability factors such as food 
matrix or dosage forms. 
Furthermore, we determined no relationship of consumed coffee dose versus the 
maximal physiological CGA concentrations (Cmax) in the ileal effluents, Cmax 5-CQA: 
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4.1 (HIGH), 6.0 (MEDIUM), 2.3 (LOW) µmol per g ileal fluid, (see Table 10-9, 
Appendix). Water consumption was allowed ad libitum during the remaining study 
trial once the ileostomist had drunk the coffee. We assume that potentially different 
amounts of water being consumed within the three trials affected the Cmax values 
more than different amounts of coffee CGA doses consumed. Moreover, maximal 
physiological CGA concentrations in the excreted ileal fluids were higher as in the 
consumed coffees. As the upper GIT of ileostomists is adapted to water absorption 
(see chapter 2.4.2, State of knowledge) (Ladas et al., 1986; Fallingborg, 1999), a 
concentration process of CGA in the upper GIT due to water absorption is 
conceivable. 
 
The observed interesterification of CGA in the ex vivo ileal fluid experiments (see 
chapter 4.1 and Table 10-2, Appendix) could also be observed in vivo in the 
dose-response study with ileostomists independent of the doses after coffee 
consumption (see Table 10-6, Appendix). More specifically, recovery rates of 3-acyl 
compounds of CQA (3-CQA, 1b) and FQA (3-FQA, 3a) were higher than their 
corresponding 5-acyl compounds. Furthermore, 3,5-diCQA (4b) showed the lowest 
recovery rate of the diCQA (4a-c) subgroup (Table 10-6, Appendix). This effect is 
much more distinctive in the ex vivo ileal fluid incubation experiments compared to 
the in vivo dose-response experiment with ileostomists because of the much longer 
CGA residence time used in the ex vivo experiments (8 hours) in comparison to the 
residence time of consumed coffee CGA in the ileum (see Figure 4-11, Results).  
These observations indicate a small interesterification as discussed in detail in 
chapter 5.3.4 and are in agreement with a previous coffee intervention study with 
ileostomists (Stalmach et al., 2010). 
We calculated a considerably lower recovery rate for CQL (2a-b) in relation to the 
other CGA from coffee investigated; see Table 10-2 and Table 10-6, Appendix. We 
conclude that the lower ileal recovery of consumed CQL (2a-b) in the in vivo dose-
response study resulted in a higher absorption rate and/or in a partial degradation 
during passage of the ileum. This thesis is corroborated by the high content of CQL 
metabolites detected either in ileal fluid or urine in the current in vivo study or by 
others (Stalmach et al., 2010) and an observed degradation of CQL ex vivo at ileal 
conditions (see chapter 4.1).  
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The high inter-individual differences in Tmax 5-CQA did not relate to the total amounts of 
CGA reaching the ileal effluents. Especially ileo 5 showed a significant decelerated 
excretion compared to ileo 1-4 (p < 0.03) (see Figure 4-11, Results) but a similar total 
amount of ileal excreted CGA.  
However, the excreted QA content showed significant inter-individual differences, 
especially in subject no. 5 who had a very long transit time (ileo 5 compared to ileo 1-
4, p < 0.01). On the one hand these inter-individual differences were confirmed by an 
additional study observing the GI – TT after consumption of an anthocyanin rich test 
beverage, and on the other hand high inter-individual differences have already been 
observed in transit time by others (6.2 – 12.8 hours) (Fallingborg et al., 1990).  
Additionally, we could show that ingestion of a higher coffee dose lead to a faster 
transit time (Tmax 5-CQA (ileo 1-4) in hours: HIGH 0:5 ± 0:0; MEDIUM 0.8 ± 0.3; LOW 
1.6 ± 1.0) (p < 0.09). Considering that these factors might influence the gastric 
emptying time, playing a key role in upper GI - TT (chapter 2.4.1.2), a relationship 
between the different coffee doses / concentrations seems probable.  
 
5.2.2.2 Effects on CGA metabolite amounts by increasing coffee doses 
consumed 
Once absorbed into the enterocyte CGA undergo phase II reactions such as 
sulfation, glucuronidation, methylation or hydrolysis (Kern et al., 2003b; Wong et al., 
2010). Subsequently, the formed metabolites can reach the circulatory system or 
they secrete back into the gut lumen and could be excreted via ileal fluid. The 
bioavailability of CGA from coffee is limited by metabolization. Up until now it is not 
clear if consumption of different doses influences the metabolic pathways of CGA 
from coffee.  
In our dose-response study the amounts being metabolized or hydrolyzed after the 
ingestion of different CGA doses indicate an extensive metabolic activation occurring 
during the passage of the upper GIT. Moreover, the determined metabolites showed 
a clear delay in ileal excretion in comparison to the unmetabolized CQA (e.g.: Tmax at 
the HIGH trial: CQA (1a-d) ≈ 1.2 vs. CQA-Sulf (1g-i) ≈ 2.2 h or CQA-GlucA (1e-f) 
≈ 2.2 h; Table 10-8, Appendix). 
A proportionally lower amount (in %) of CGA was metabolized or hydrolyzed with 
consumption of increasing CGA doses which could conceivably be due to enzyme 
saturation, limitation of substrates, limited transport capacities at the enterocyte 
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(influx and efflux) or an influence of the GI - TT. In an similar study ileostomy 
probands consuming one dose of coffee, Stalmach et al. (Stalmach et al., 2010) 
observed that 22% was metabolized or hydrolyzed with a low dose of CGA ingestion 
(2.7 times smaller than our LOW dose) with a sulfation : glucuronidation ratio of 
10.5 : 1. In agreement with Stalmach et al., we also identified sulfation as the major 
phase II conjugation reaction in the upper GIT, but we additionally observed an 
increase in proportion of glucuronidation with increasing CGA dose.  
We detected no inter-individual differences in the sulfation : glucuronidation ratios of 
ileal effluents after coffee consumption. This indicates that the inter-individual 
differences of ß-glucuronidase activity measured in the ileal effluents (ileo 1-4) (see 
Table 10-3, Appendix) had no detectable influence on the glucuronide amounts in 
ileal effluents. 
The selectivity preference for sulfation and glucuronidation on the 3´-hydroxyl of CA 
(5a) and DHCA (6a) as also observed by others (Wong et al., 2010) was consistent 
over the three applied doses in both the ileal effluents as well as in the urine 
samples. Moreover phase II conjugations of 5-acyl compounds such as 5-FQA (3c) 
or 5-CQA (1d) were sterically hindered. We detected only small amounts of 
5-CQA-3´-Sulf (see Figure 4-9, Results) similar to a previous study on one dose 
(Stalmach et al., 2010). 
The group of Wong (Wong et al., 2010) and Stalmach (Stalmach et al., 2009; 
Stalmach et al., 2010) showed an extensive metabolism of CGA during the passage 
through the body. We confirm an extensive metabolism of CGA (Stalmach et al., 
2009; Stalmach et al., 2010; Wong et al., 2010) and additionally novel metabolites in 
urine. Furthermore, we observed that FA-Gly, DHCA and DHFA can be formed in 
probands without a colon after coffee consumption. 
 
Small amounts of the free HCA (CA (5a), FA (7a)) as well as free DHCA (6a) indicate 
some esterase activity in the upper GIT (Table 10-7, Appendix). Despite the potential 
esterase activity along the upper GIT (Andreasen et al., 2001; Lafay et al., 2006; 
Farrell et al., 2011) the chemical hydrolytic activity in the ileal fluids as already 
discussed in chapter 5.1 may also contribute to the free acid content.  
 
Passive diffusion into the enterocyte should be limited for molecules which are high in 
molecular weight and having an adverse log D. The latter (log D) describes the 
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distribution of an ionizable molecule (such as CGA) between an octanol and water 
phase at a certain pH and is therefore a suitable descriptor for the lipophilicity of a 
molecule. 
We postulate an active efflux mechanism at the enterocyte for sulfated or 
glucuronidated metabolites, especially for the intact esters high in molecular weight 
with an adverse log D (e.g.: CQA-Sulf (1g-i) or -GlucA (1e-f), FQA-Sulf (3g-h) or –
GlucA (3d-f)) as previously reported with FA (7a) metabolites in vitro (Poquet et al., 
2008).  
 
5.2.3 Renal excretion of CGA and QA after coffee consumption  
Based on the premise of a concentration equilibrium of CGA and QA between the 
systemic circulation and urine (Chereson, 1996) we determined the influence of 
increasing CGA and QA doses on renal excretion. Due to a lack of references (such 
as CGA sulfates and glucuronides) we achieved semi-quantitative data (see chapter 
7.3.1.5.2.1). 
 
5.2.3.1 Effect of an increasing amount of CGA and QA consumed by coffee on 
renal excretion 
Renal excretions correlated negatively with increasing CGA doses ingested and high 
inter-individual variations (Table 10-10; Appendix). We presume a relationship 
between GI - TT and CGA bioavailability. More specifically, one volunteer showed a 
much longer GI - TT (Ileo 5) and therefore the renal excretion was twice as high as 
for the other subjects. The relationship between GI – TT and renal excretion of each 
volunteer shown in Figure 5-2 gives a hint that a decelerated passage of CGA in the 
gastrointestinal tract leads to a higher absorption rate.  
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Figure 5-2: Relationship of total renal excretion of consumed CGA in %, with maximum 
of ileal excretion (Tmax CQA) in hours of each ileostomist given for all doses 
(HIGH; MEDIUM; LOW). Linear fit: R2 = 0.64; y = 2.8x + 6.2. 
 
Due to the extensive biotransformation that CGA undergo in the human body it is not 
possible to calculate recovery rates of individual CGA. Therefore, total renal excretion 
of CGA is reported here. It was determined between 8.0 ± 4.9% for the high dose and 
14.6 ± 6.8% for the low dose. Other research groups detected similar renal amounts 
being renally excreted in ileostomists of 8% after ingestion of 385 µmol CGA from 
coffee (with a comparable semi-quantitative analytical method as used in our study) 
(Stalmach et al., 2010) and 11% after administration of 2,800 µmol pure CA (5a) 
(Olthof et al., 2001) (enzyme treatment was used as analytical method) (see Table 
2-14, State of knowledge). In healthy volunteers the total renal recovery of CGA after 
coffee consumption was reported to be about 3 times higher in contrast to 
ileostomists. This was reported by Stalmach et al., 2009 and Rio et al., 2010 who 
used a comparable analytical method to our study (Stalmach et al., 2009; Rio et al., 
2010). 
In previous bioavailability studies healthy probands consumed CGA and considerable 
lower total excretions of CGA were observed (see Table 2-13, State of knowledge). 
However, these groups used different analytical methods (mostly with enzymatic 
cleavage of CGA metabolites), different CGA dosage forms such as encapsulated 
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green coffee and different CGA compositions in ingested food such as artichoke leaf 
extract (see Table 2-13, State of knowledge). Due to this, the reported total renal 
CGA excretions determined in these studies (Rechner et al., 2001; Ito et al., 2005; 
Wittemer et al., 2005; Farah et al., 2008) are not further discussed. 
As previously reported, we found unmetabolized CGA in urine (Olthof et al., 2001; 
Stalmach et al., 2009; Stalmach et al., 2010; Kahle et al., 2011). Hereby, especially 
3-FQA (3a) and 3-CQA (1b) of these two CGA subgroups were predominant in urine, 
independent of the administered dose (Table 10-10, Appendix, Figure 5-3), whereas 
in plasma the 4-acyl compounds were predominant after enzyme hydrolysis (Figure 
5-3, Table 10-13, Appendix). The 5-acyl compounds (5-FQA (3c), 5-CQA (1d)) were 
detected in both compartments only in minor amounts. The group of Renouf et al. 
determined after coffee consumption and enzymatic hydrolysis of plasma in terms of 
apparent plasma appearance the following order: 3-FQA > 5-FQA > 4-CQA > 4-FQA 
> 5-CQA > 3-CQA (Renouf et al., 2013). The differences to our observations (see 
Figure 5-3) might be caused due to the fact that healthy volunteers (with colon) 
consumed the coffee in this study. 
Interesterification reactions at the physiological plasma pH could be a reason for this. 
Such interesterification reactions were also observed in the ex vivo incubation 
experiments with CGA and ileal effluents, see Table 10-2, Appendix. Especially, the 
3-acyl compounds (3-FQA (3a), 3-CQA (1b)) showed high recoveries in these ex vivo 
experiments as well as in urine and plasma after coffee consumption (see Figure 
5-3).  
Furthermore, the elimination of CGA and metabolites via urine could be affected by 
the various phase II conjugation reactions. The SULT enzyme family seems to prefer 
the 3- and 4-acyl CQA and FQA, similar to the UGT enzyme family, which 
additionally showed a high affinity for 4-CQA and 4-IFQA (see Figure 5-3, Table 
10-10, Appendix). Both enzyme families showed an inhibition for 5-CQA (1d) or 
5-FQA (3c) conjugation. 
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Figure 5-3: Representive kinetics of caffeoylquinic acids (CQA), feruloylquinic acids (FQA), isoferuloylquinic acids (IFQA) and 
metabolites in urine (µmol*mg-1 creatinine) and plasma (after enzyme hydrolysis, in nM) of ileostomist no. 2 after the consumption 
of coffee (HIGH CGA dose, 4,525 µmol). Sulf = sulfate, GlucA = glucuronide. 
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Despite unmetabolized CGA, we were not able to identify any diCQA (4a-c) in 
plasma or in urine. Caffeoylquinides (CQL) (2a-b) were highly absorbed; particularly 
its sulfated metabolites (CQL-Sulf) were detectable in urine (Table 10-10, Appendix). 
In comparison to CGA the QA (10a) moiety of CQL (2a-b) have an intra-molecular 
ester bridge which decreases the polarity. Specifically, the calculated log D(pH6.0) for 
CQL was + 0.4 which is more suitable for passive absorption than the log D(pH 6.0) for 
CQA of – 2.9 (calculated with MARVIN SKETCH 5.3.1). 
 
As early as 1964 one study reported QA (10a) in urine (Halpern, 1964), whereas 
previous bioavailability studies described its colonic metabolites in urine at its most, 
e.g. hippuric acid (Rechner et al., 2001; Olthof et al., 2003; Kahle, 2008).  
In 1970 Adamson and coworkers orally administered 12 g [14C] QA to Rhesus 
monkeys. This group detected QA being aromatized by the gut flora to hippuric acid 
and found 32% of the radioactivity as hippuric acid in urine (Adamson et al., 1970). 
But, in 2011 Pero and Lund observed millimolar concentrations of QA in urine after 
consumption of a nutritional supplement (AIO + AC-11®) (Pero and Lund, 2011).  
However, the renal dose dependent recovery of QA was determined here for the first 
time. Recovery rates were nearly similar in all trials with about 15%. Hence, the 
recovery of QA in urine was not affected by the consumed dose or GI-TT. But a 
potential hydrolysis of CGA into QA and HCA was indicated by measurable free HCA 
in our studies; and in previous work (Kahle et al., 2007). Taking the potential 
hydrolysis of CGA into account the actual recovery rates of free QA consumed with 
the coffee brews under study was estimated to be less than 15%. 
 
5.2.3.2 Effect of increasing CGA dose consumption on CGA metabolite 
formation 
The total percentage of CGA metabolites (conjugates or hydrolytic products) in urine 
were not affected by the doses consumed, whereas the ratios of 
sulfation : glucuronidation (sulf : glucA) in urine showed a dose-dependency similar to 
the formation of metabolites excreted via ileal effluents. The sulf : glucA ratio 
changed from 0.7 : 1 (HIGH), 1 : 1 (MEDIUM), up to 1.3 : 1 (LOW). In a previous 
study with ileostomy volunteers (Stalmach et al., 2010), the urinary sulf : glucA ratio 
was 5.6 : 1. In this study CGA consumption via coffee compared to our lowest coffee 
dose (LOW) was 2.7 times lower. This could explain the higher amount of sulfation in 
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this study (Stalmach et al., 2010). We conclude that sulfation is limited by increasing 
dose conceivably due to enzymatic saturation, limitation of substrates, limited 
transport capacities of the enterocyte (influx and efflux) or an influence of the GI - TT. 
Our findings of a regioselectivity preferences of conjugating enzymes at the hydroxyl 
position 3´ (Figure 2-1, Sate of knowledge) confirmed the findings of recently 
published studies (Stalmach et al., 2010; Wong et al., 2010). 
Thereupon, the conjugation enzymes being involved in renal and ileal excretions are 
regulated by the substitutes at the aromatic ring of the hydroxycinnamic acid 
moieties, dose unaffected. For instance, we determined a sulfation preference for CA 
(5a) and DHCA (6a) both molecules have two hydroxyl groups at position 3´ and 4´ 
(see Figure 4-13, Results). Furthermore, a strong glucuronidation affinity for IFA (7g) 
and IFQA (3i, 3j), both molecules with a methoxy group at position 4´ was observed 
(Figure 4-14, Results).  
 
Moreover, for the first time we described metabolites of the intact CGA and 
corresponding metabolic profile in urine (such as CQA-Sulf and CQA-GlucA), in spite 
of sulfated CQL (2e-f) which were already reported by (Stalmach et al., 2009; 
Stalmach et al., 2010). We were able to show that conjugating enzymes involved in 
renal excretion are also regulated by the hydroxycinnamic acid moiety. For instance, 
whereas the CQL (2a-b), a CA with quinide moiety, showed a strong affinity for 
sulfation (Figure 4-13, Results), the CQA (1a-d) a CA with quinic acid moiety seemed 
to hinder the preferred sulfation with the consequence of higher affinity to the UGT 
enzyme family (Figure 4-14, Results).  
 
5.2.4 Influence of coffee dose on plasma CGA and QA occurrence 
In order to determine the effect of different consumed CGA and QA doses on oral 
bioavailability in ileostomists we measured their plasma concentrations and 
metabolites after consumption of increasing doses of coffee. Since a lack of 
references for quantification, the concentrations of CGA in plasma were measured 
after enzymatic hydrolysis of the sulfates and glucuronides (see chapter 7.3.1.7.2.1). 
Furthermore, plasma data is available for four probands per study trial only as two 
volunteers withdrew their permission for blood collection (Ileo 3 at the HIGH trial and 
Ileo 4 at the MEDIUM trial) and the individual calibration curve of ileo 5 at the study 
trial LOW could not be used for quantification. Additionally, the needle of Ileo 1 was 
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blocked after five hours at the MEDIUM trial. Here data for time points six and eight 
are missing (see chapter 7.3.1.7). 
 
Within the first 30 min after consumption plasma concentrations of CGA showed a 
strong ascent and Tmax was reached dose independently within the first hour of 
consumption (Table 10-13, Appendix, Figure 4-17, Results) for all CGA, as confirmed 
by other published data (Nardini et al., 2002; Renouf et al., 2010a; Renouf et al., 
2010b; Renouf et al., 2013). Hereby, methylation was shown to be a fast phase II 
conjugation reaction, indicated by the early Tmax and the high AUC level of 
methylated hydroxycinnamic acids, e.g. for IFA (7g) (see Table 10-13, Appendix, 
Figure 4-16, Results). Considering a possible gastric residence time from 0.2 up to 
3.8 hours (Fallingborg et al., 1990) a CGA uptake and methylation in the stomach 
would be conceivable. An animal study with rats published by (Lafay et al., 2006) and 
the recently performed work on permeation of CGA through cultured gastric cells 
(Farrell et al., 2011) confirmed this thesis. Furthermore, the low gastric pH influences 
the log D of CGA (see Figure 2-2, State of knowledge) so these molecules are more 
lipophilic which might facilitate diffusion into the blood stream. Plasma appearance 
was linearly correlated to most compounds within the different ingested doses (see 
Figure 4-16, Results, Table 10-13, Appendix). A non linear plasma appearance of 
some compounds might be result from inter-individual difference in the probands 
physiology. 
 
It is known from ileal excretions of CGA after coffee consumption that about ⅓ of 
consumed CGA are potentially absorbed dose unaffected (Figure 5-1). Nevertheless, 
most bioavailability studies on CGA from coffee show an early Tmax and Cmax (Table 
2-10, State of knowledge) indicating a major influence of the upper GIT on 
absorption. Thus, the contribution of the large intestine (in healthy volunteers) to 
plasma Tmax and Cmax of CGA and their metabolites is low, except for metabolites 
formed by colonic microflora. Due to this, Tmax and Cmax from CGA bioavailability 
studies with ileostomy volunteers (without colon) are comparable with data from 
studies with healthy volunteers (with a colon). Up until now there is no literature data 
for CGA plasma concentrations in ileostomists after coffee consumption available. 
We calculated the maximum plasma concentration (Cmax level) at a theoretically 
consumed dose of 50 mg CGA from coffee and compared the data from studies with 
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healthy volunteers with data of the current study shown in Figure 5-4 (according to 
Table 2-10, State of knowledge (Williamson et al., 2011)). 
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Figure 5-4: Maximum plasma concentrations (Cmax) (in nM) per 50 mg consumed CGA 
dose by coffee reported in literature (healthy, with colon) (grey bars) compared 
to our findings after consumption of different coffee doses (LOW, MEDIUM, 
HIGH) by four ileostomists (without colon). Different CGA amounts via coffee 
were consumed in single dose studies published, with 96 mg = (Nardini et al., 
2002); 145 mg = (Stalmach et al., 2009); 335 mg = (Renouf et al., 2010a; Renouf 
et al., 2010b); 1,236 mg = (Monteiro et al., 2007), see Table 2-10, State of 
knowledge.   
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CA (5a) concentrations in plasma after coffee consumption have been investigated 
for more than ten years. Previous studies reported a high Cmax of CA (Nardini et al., 
2002; Monteiro et al., 2007) compared to our findings. We observed a dose 
independent plasma concentration of CA. This was confirmed by the observations of 
the group of Renouf et al. who performed a dose-response study with healthy 
volunteers consuming coffee in a dose range from 176 to 704 mg CGA (Renouf et 
al., 2013). The detected plasma CA concentrations are in agreement with recently 
published data (Stalmach et al., 2009; Renouf et al., 2010a; Renouf et al., 2010b); 
see Figure 5-4. The latter research groups have also determined a similar FA (7a) 
and the COMT metabolite IFA (7g) Cmax per 50 mg CGA coffee dose (see Figure 
5-4). In the above mentioned dose-response study with healthy volunteers similar 
Cmax per 50 mg CGA coffee dose were detected for CA (5a), FA (7a) and IFA (7g) 
(Renouf et al., 2013)2. This indicates the key position of the upper GIT after CGA 
consumption in absorption and the maximum plasma levels. 
In 2002 for the first time Nardini and coworkers reported a very high Cmax level of CA 
in humans with a pioneering methodology, so the reported values have to be 
considered in an qualitative point of view and not quantitatively (Nardini et al., 2002; 
Williamson et al., 2011). The relevance of the reported data on CA of Monteiro et al. 
2007 is also doubtful because of the high standard deviation (see Figure 5-4). 
In our study the maximum plasma concentration of the dimethylated compound 
DiMeCA was quantified for the first time. Moreover, a plasma ratio of FA 
(7a) : DiMeCA (9a) of about 1 : 2 60 min after coffee consumption was described 
recently (Nagy et al., 2011) contrary to our data (FA : DiMeCA ≈ 2 : 1). However, the 
administered coffee dose in this study remains unknown and plasma was treated with 
chlorogenic acid esterase prior to analysis so compounds such as FQA (3a-c) were 
cleaved (Nagy et al., 2011).  
 
In contrast to others, for the first time (Nardini et al., 2002; Stalmach et al., 2009; 
Redeuil et al., 2011) both, CQA (1a-d) and FQA (3a-c) were detected in plasma as 
intact compounds in significant amounts (Figure 4-16, Results). Cmax and AUC in 
plasma correlated with the different ingested doses (see Table 10-13, Appendix, 
                                            
2 Plasma Cmax is shown only in figures in that publication. Therefore an exact calculation of Cmax*50 mg 
dose-1 was not possible. 
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Figure 4-16, Results). AUC as well as the renal excretions seemed to be affected by 
the different GI – TT, see chapter 5.2.3.1. 
The CQA and FQA plasma profiles were not similar to the ones determined in the 
original beverage (cf. Figure 5-3 and Figure 4-6, Results). The 5-acyl compounds 5-
CQA (1d) and 5-FQA (3c) were dominating the CGA profile in the beverage. 
However, only small amounts of these compounds are present in plasma after coffee 
consumption. This difference was also observed by others (Stalmach et al., 2009; 
Renouf et al., 2013).  
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Figure 5-5: Maximum plasma concentrations (Cmax) of caffeoylquinic and feruloylquinic 
acids (in nM) per 50 mg consumed CGA dose by coffee reported in literature 
(healthy, with colon) (grey bars) compared to our findings after consumption of 
different CGA doses from coffee (LOW, MEDIUM, HIGH) by four ileostomists 
(without colon). Different CGA amounts were consumed in reported single dose 
studies, with 96 mg = (Nardini et al., 2002); 145 mg =  (Stalmach et al., 2009); 
1,236 mg = (Monteiro et al., 2007), see Table 2-10, State of knowledge.  
 
The dominance of the 4-acyl compounds in plasma could be explained by a possible 
facilitated transport for 4-CQA (1c) and 4-FQA (3b) as observed by (Farrell et al., 
2011) or potential isomerization within the CGA subgroups. Other research groups 
(Monteiro et al., 2007; Farah et al., 2008) detected the 5-CQA as the major plasma 
CQA and moreover high amounts of diCQA in plasma after coffee consumption. 
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Our data and the findings of other groups (Renouf et al., 2013), (summarized by 
Williamson et al., 2011) were not in agreement with this high amounts of diCQA in 
plasma after coffee consumption. A possible explanation for this difference might be 
the different pharmacokinetic data. The time point of maximum plasma concentration 
(Tmax) for CQA in two studies (Monteiro et al., 2007; Farah et al., 2008) were 
considerably late (3.3 h for 5-CQA (1d) (Farah et al., 2008) and maximum plasma 
concentration (Cmax) for CQA showed multiple levels (Farah et al., 2008) in 
comparison to our study or the data of the group of (Stalmach et al., 2009; Renouf et 
al., 2013) (Figure 5-5). Furthermore, the dosage form was completely different in the 
study reported by Farah since volunteers consumed 451 µmol encapsulated CGA 
from a green coffee extract. Nevertheless, we detected a dose independent 
bioavailability of the CQA subgroup after consumption of different CGA doses from 
coffee by ileostomists (see Figure 5-5). 
The subgroup of FQA (3a-c) was quantified in plasma of healthy volunteers after 
coffee consumption by the groups of (Stalmach et al., 2009) and (Renouf et al., 
2013). The data agrees (in Cmax*50 mg dose-1) with our data and corroborates a dose 
independent bioavailability (see Figure 5-5). These findings are not consistent with 
other data published (Nardini et al., 2002; Monteiro et al., 2007). In 2002, Nardini et 
al. did not determine any FQA in human plasma with a pioneering methodology and 
in 2007 Monteiro et al. noted that FQA were also absent in plasma, despite a very 
high plasma CQA amount after coffee consumption (see Figure 5-5) (Williamson et 
al., 2011). 
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Figure 5-6: Maximum plasma concentrations (Cmax) (in nM) per 50 mg consumed CGA 
dose by coffee reported in literature (healthy, with colon) (grey bars) compared 
to our findings after consumption of different doses (LOW, MEDIUM, HIGH) by 
four ileostomists (without colon). Different coffee CGA amounts were 
consumed in published single dose studies, with 145 mg = (Stalmach et al., 
2009); 335 mg = (Renouf et al., 2010a; Renouf et al., 2010b), see Table 2-10, 
State of knowledge. * =  SD was not determined in that publication. 
 
The colonic microflora is thought to be the key metabolic site for reduction of 
hydroxycinnamic acids into dihydro compounds (DHCA (6a), DHFA (8c)) (Stalmach 
et al., 2009; Renouf et al., 2010a; Renouf et al., 2013). Other studies with 
ileostomists confirmed these findings (Stalmach et al., 2010). In our study the plasma 
concentrations and Tmax (≤ 0.9 h) of DHFA (8c), DHCA (6a) and DiMeDHCA (9b) 
indicated also a small contribution of reduction processes (e.g. by hepatic 
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NADPH-cytochrome P450 phase I metabolism or in the enterocyte) in the upper parts 
of the GIT, see Figure 5-6 (Table 10-13, Appendix).  
 
In general, the plasma Cmax data in our dose-response study correlates well with 
recently published data achieved with healthy volunteers (with colon) consuming 
coffee (Stalmach et al., 2009; Renouf et al., 2010a; Renouf et al., 2010b; Renouf et 
al., 2013), indicating a major influence of the upper GIT on maximum CGA plasma 
concentrations (e.g. CA (5a), FA (7a), IFA (7g), CQA (1a-d), FQA (3a-c)). 
Nevertheless, comparative considerations between ileostomists and healthy 
volunteers are not possible without restrictions, since overall ileal bacterial count, ileal 
microbiota composition and GI – TT are different in ileostomy volunteers (Fallingborg, 
1999).  
 
A comparative consideration of the coffee CGA uptake into the circulatory system 
(plasma AUC) with existing literature (with healthy volunteers) was not possible. ⅔ of 
ingested CGA were recovered in the ileostomy bags and would be available in the 
colon of healthy persons. For instance, a study using a ≈ 2.7 times smaller dose than 
our lowest dose (LOW) reported a higher plasma AUC level which was probably due 
to the esterase activity of the colonic microflora. The AUC was ten times higher for 
the liberation products CA (5a) and FA (7a) (Stalmach et al., 2009) and compounds 
which do not undergo microbial liberation such as FQA (3a-c) were found to have an 
AUC nearly three times higher in this study (Stalmach et al., 2009). So it can be 
concluded that amounts of CGA that reach the colon were absorbed in its intact form 
(such as FQA) and after microbial biotransformation (such as CA and FA).  
The sum of plasma AUC for CGA and metabolites showed no linear dose-response 
to the ingested dose (AUC: 4,412 ± 751 nM*h0-8-1 (HIGH), 2,394 ± 637 nM*h0-8-1 
(MEDIUM) and 1,782 ± 731 nM*h0-8-1 (LOW)). This was most likely due to the high 
interindividual variability in absorption which was already observed in total renal 
excretion and the low number of 4 volunteers. The group of Renouf et al. observed 
also a strong interindividual variability in plasma appearance but a linear dose-
response between the sum of AUC and the ingested CGA dose in ten healthy 
volunteers (Renouf et al., 2013).  
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Previous research on QA (10a) bioavailability predominantly focused measuring urine 
levels of QA and its colonic metabolite hippuric acid. Nevertheless, more than 50 
years ago QA was once observed in serum of humans (Halpern, 1964). Moreover, 
recent data revealed free QA in plasma after oral ingestion of 6 g QA (Pero et al., 
2009). 
In our study the plasma concentrations of QA (10a) showed a dose independent 
absorption. However, the elimination of QA from the circulatory system (Figure 4-18, 
Results) was not complete (Tmax ≈ 5 h) even eight hours after coffee consumption. 
Pero and coworkers observed a Tmax of 10.5 h for QA in the plasma of a single 
healthy man (with colon) and discussed a possible accumulation of QA here (Pero et 
al., 2009). A possible hydrolysis of absorbed coffee CGA in the circulatory system 
and a slow elimination could impact this. Maximum plasma concentrations of QA 
were linear dose-dependent. Because of this, it is imaginable that a habitual coffee 
drinker (3 to 5 cups during the day) might accumulate QA in the circulating system. 
 
5.2.5 Conclusive considerations 
Due to the somewhat controversial and inconsistent bioavailability data for 
chlorogenic acids in literature, we performed a dose-response study with different 
CGA doses. Therefore, ileostomists consumed increasing coffee doses in a 
randomized, double blinded, crossover trial and the dose effects on coffee 
polyphenol and free D-(-)-quinic acid absorption in the upper GIT, ileal excretion 
(equivalent to colonic availability in healthy volunteers) and metabolism were 
observed. 
 
Our results show, that after coffee consumption with different CGA and QA doses the 
oral bioavailability of CGA in ileostomists was slightly decreased by increasing doses 
(total renal excretion in %: 14.6 ± 6.8 (LOW), 12.1 ± 6.7 (MEDIUM) and 8.0 ± 4.9 
(HIGH)).  
As both CGA bioavailability and GI - TT of CGA slightly decreased by consumption of 
increasing doses, we conclude a dose independent absorption of CGA from coffee. 
Therefore, the dose-response study revealed that the absorption in the upper GIT 
after CGA consumption is not influenced by different doses. Thus, other factors such 
as the dosage form (e.g. food matrices), different polyphenol compositions of 
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ingested foods (e.g. CGA composition in artichoke), differences in analytical 
methodology (e.g. with or without enzymatic cleavage of CGA conjugates) or different 
GI - TT have to be taken into account and investigated further. More specifically, 
considering the fact that different CGA doses from coffee may influence the GIT - TT, 
it is conceivable that previous studies on CGA bioavailability with different 
administered dosage forms and food matrices revealed different bioavailability data 
(Olthof et al., 2001; Kahle et al., 2007; Stalmach et al., 2010; Hagl et al., 2011).  
The inter-individual differences in GI - TT in our study were in agreement with the 
inter-individual differences of CGA and metabolites plasma curves, ileal and renal 
excretions, especially for volunteer 5. For instance, the decelerated GI - TT of this 
volunteer (no. 5), resulted in delayed plasma elimination and prolonged renal 
excretion (cf. Figure 4-11, Figure 4-15, Figure 4-17, Results).  
A relationship of coffee dose versus the maximum physiological CGA concentrations 
in the ileal fluids was not observed probably due to the different amounts of water 
being consumed during the study by the volunteers (see Table 10-9, Appendix). 
Nevertheless, the maximal physiological CGA concentrations in the ileostomy 
effluents were at least twice as high as in the coffee being consumed. The reasons 
for these relatively high CGA concentrations in ileal fluids may result from a 
concentration process in the upper GIT – tract due to the absorption of water over 
time. 
 
Approximately 15% of the QA were available for systemic circulation and about 70% 
of CGA would be available in the colon independently of the consumed doses. 
Furthermore, due to the high amounts of free QA in coffee, its high plasma Cmax and 
the small amounts being renally eliminated, QA is surely an underestimated 
compound in coffee. 
 
We observed an extensive metabolism for CGA and HCA via passage through the 
body in ileostomists with new routes of metabolization determined by HPLC-MS in 
the multiple ion mode, in contrast to the literature (Kahle et al., 2007; Stalmach et al., 
2010). The bioavailability of CGA and intensive metabolization was independent of 
the ingested dose (rates of renally excreted metabolites in % of total renal excretion: 
67.0 ± 6.6% (HIGH), 69.2 ± 6.5% (MEDIUM) and 69.8 ± 3.4% (LOW)). However, the 
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routes of metabolization shifted for CGA and HCA from sulfation to glucuronidation 
with increasing CGA doses. 
Furthermore, we did not identify any diCQA in urine nor in plasma. The higher 
molecular weight of diCQA (516.5 g*mol-1) might hinder passage across the 
GI - barrier. Nevertheless, a lack of diCQA in ileal recovery was observed and may 
be due to hydrolysis in the GIT liberating CQA (1a-1d), CA (5a) and QA (10a) as 
already discussed in chapter 5.1.  
The plasma appearance of CGA and metabolites after coffee consumption showed 
that plasma Cmax of ileostomists is comparable to plasma Cmax of healthy volunteers, 
except of colonic metabolites (Stalmach et al., 2009; Renouf et al., 2013). This 
indicates the key position of the upper GIT in CGA absorption. Dimethoxy derivatives 
of CA (5a) and DHCA (6a) (DiMeDHCA (9b) and DiMeCA (9a)) were observed in 
plasma by others, too (Nagy et al., 2011; Redeuil et al., 2011). Elimination profiles of 
dimethoxy derivatives in plasma were similar to all other compounds observed, 
although we did not identify any of these molecules in urine nor in ileal fluids. Thus, 
we conclude that the body might not be able to eliminate the high lipophilic molecules 
via renal or bilary excretion (enterohepatic circulation). We presume a demethylation 
followed by a subsequent conjugation reaction by SULT or UGT enzymes.   
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5.3 Absorption of individual CGA and QA from coffee in the Ussing chamber 
with pig jejunal mucosa (ex vivo) 
Owing to the dearth of data on CGA absorption in the jejunum, we chose pig jejunal 
mucosa to be used in the Ussing chamber model as it is the best non-primate 
human-nutrition model (Patterson et al., 2008). Furthermore, for CGA and QA we 
investigated the influence of physico-chemical properties (structure-absorption 
relation, (SAR)) and dose (dose-absorption relation, (DAR)) on their absorption in the 
jejunum.  
On the basis of our data provided by the coffee dose-response study with 
ileostomists (see chapter 4.3.2), we applied the physiological concentrations of CGA 
in ileal effluents after coffee consumption in the Ussing chamber model (Table 10-9, 
Appendix). Thus, we used a concentration of at least 20 µM which should be easily 
reached in the upper GIT after the consumption of a single cup of coffee or other 
food containing CGA (Neveu et al., 2010), see Table 2-4, State of knowledge. 
 
5.3.1 Individual structure-absorption relation (SAR) of CGA and QA from 
coffee in pig jejunal mucosa (to serosal direction) 
Our results showed that the investigated CGA crossed the pig jejunal epithelium (see 
Figure 4-19, Results, Table 10-14, Appendix) toward a proton gradient 
(pH 6.0 mucosal / pH 7.4 serosal). Only trace amounts of diCQA passed the mucosa and 
were observable on the serosal side. These findings are in agreement with our 
observations in the dose-response study with ileostomists (see chapter 4.3). Here 
diCQA were absent in urine and plasma after coffee consumption. Mostly all other 
data, available from bioavailability studies (Williamson et al., 2011), confirmed this as 
well; except for the observation of Farrell et al., 2011 observing a moderate diCQA 
uptake in gastric and Caco-2 monolayers (Farrell et al., 2011). In this study the low 
pH (pH 3) of the gastric monolayer might have influenced the log D of CGA (see 
Figure 2-2, State of knowledge) and particularly the use of a monolayer in contrast to 
a “poly-layer” (jejuna epithelium) used in our study could explain these different 
observations.  
For the subgroups of CGA the following qualitative SAR were determined: 
CQA (≈ 1%) < CA (≈ 1.5%) < FQA (≈ 2%) < QA (≈ 4%). This is in accordance with 
the existing literature for CQA and CA absorption in other parts of the GIT (Konishi 
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and Kobayashi, 2004; Deußer et al., 2013). In the pig ileal mucosa Deußer and co-
workers observed CQA (1a-d) absorption only for 3-CQA (1.5 ± 0.2%) and 5-CQA 
(1.9 ± 1.0%) in contrast to 1-CQA and 4-CQA. This is presumably the consequence 
of the different concentrations used in their study: 50 µM for 3- and 5-CQA in contrast 
to 10 µM for 1- and 4-CQA. The above mentioned order of the CGA subgroups can 
be explained in part by the different physico-chemical properties of the subgroups 
(see Table 5-1).  
Table 5-1: Absorption rates (to serosal direction) of individual coffee polyphenols in % 
(at 20 µM each) in the Ussing chamber with its corresponding physico-chemical 
properties: molecular weight and distribution coefficient in octanol/water 
(log D, calculated with MARVIN SKETCH 5.3.1). 
Compound Absorption (%) MW (g*mol-1) log D (pH 6) 
    1-O-Caffeoylquinic acid (1a) 1.4 ± 0.7 354.3 - 2.99 
3-O-Caffeoylquinic acid (1b) 1.0 ± 0.3 354.3 - 2.88 
4-O-Caffeoylquinic acid (1c) 1.0 ± 0.3 354.3 - 2.83 
5-O-Caffeoylquinic acid (1d) 0.9 ± 0.2 354.3 - 2.88 
    Caffeic acid (5a) 1.4 ± 0.8 180.2 - 0.8 
    3-O-Feruloylquinic acid (3a) 2.6 ± 1.4 368.3 - 2.74 
4-O-Feruloylquinic acid (3b) 2.0 ± 0.3 368.3 - 2.68 
5-O-Feruloylquinic acid (3c) 2.6 ± 0.5 368.3 - 2.74 
    3,4-O-diCaffeoylquinic acid (4a) < LOQ 516.5 - 0.47 
3,5-O-diCaffeoylquinic acid (4b) < LOQ 516.5 - 0.5 
4,5-O-diCaffeoylquinic acid (4c) < LOD 516.5 - 0.47 
    D-(-)-Quinic acid (10a) 3.9 ± 1.3 192.2 - 5.19 
     
Firstly, the molecule size seems to affect the absorption from the mucosal to the 
serosal side. This is clearly the case when comparing data for diCQA 
(MW = 516.5 g mol−1) (see Table 5-1) with CA and QA (180.2 and 192.2 g mol−1). In 
both the Ussing chamber SAR experiment and in the human intervention study 
(dose-response coffee consumption) an absorption of diCQA was not detected, 
whereas CA (5a) and QA (10a) were systemically available in the jejunal SAR and 
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human dose-response study (see chapter 4.3.4). A lower molecule size seems to 
benefit the absorption, whereas the stretchable and elastic atom bonds of QA might 
also matter. Here QA showed the highest absorption rate (3.9%), despite its 
hydrophilic log D (see Table 5-1 and Figure 4-19, Results). Deußer reported about 
0.5% of QA passing the ileal pig mucosa and a T84 colon carcinoma cell monolayer 
(Deußer et al., 2013). Both experimental designs simulated different parts of the GIT 
in contrast to our study. Furthermore, the concentrations used for the incubations 
were four times higher than the ones used in our study. 
In our investigations the FQA were absorbed to a higher extent than the CQA. The 
differences in chemical structures between CQA and FQA are one methoxy group at 
the hydroxycinnamic acid moiety. Although this additional group increases the 
molecular size of FQA its lipophilicity is increasing as well. Thus, we conclude that 
the influence of log D on absorption is higher than that of the molecule size for 
monoCGA (one QA moiety). The influence of molecule lipophilicity (log D) was 
already reported recently on HCA permeation through a T84 cell monolayer 
(Bergmann et al., 2009).  
In our dose-response human intervention study both CGA subgroups, CQA and FQA, 
were also detected in plasma after coffee consumption (see chapter 4.3). Because of 
the extensive metabolism CGA undergo during the passage of the upper GIT, a 
comparison of the Ussing chamber data discussed here with data from other human 
bioavailability studies is not possible (Stalmach et al., 2010). Nevertheless, we are 
able to conclude that absorption in the pig jejunum observed in our study or in a 
gastric epithelial monolayer (Farrell et al., 2011) contributes to the early appearance 
of CGA in plasma after coffee consumption.  
Another factor that contributes to absorption, apart from the physico-chemical 
properties, could be active transport. For instance, Konishi and Kobayashi 2004 
identified an active transport for certain hydroxycinnamic acids (Konishi and 
Kobayashi, 2004). FA (5a) and CA (7a) may in part be actively transported by a 
monocarboxylic acid transporter (MCT) across the monolayer (Konishi and 
Kobayashi, 2004; Poquet et al., 2008). Moreover, an active transport is imaginable 
for QA (10a) which shows strong structural similarities to D-glucose. An active 
transport of this compound similar to that of glucose uptake via SGLT is conceivable 
but not supported by our data, especially since high concentrations of QA have been 
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detected in the human plasma and urine after coffee consumption in our dose-
response study (see Table 5-1 and chapter 4.3). 
The differences in absorption within the CQA, FQA, and diCQA subgroups were 
rather small. The position of esterification at the QA moiety did not affect the 
absorption in the pig jejunum at the concentration of 20 µM. Previous intestinal 
absorption models have considered other parts of the GIT and used different CGA 
concentrations (Deußer, 2010; Farrell et al., 2011). Nevertheless, the results of 
Farrell and co-workers gave a hint for a higher absorption of 3,5-diCQA (4b) in 
contrast to other diCQA (Farrell et al., 2011). 
Moreover, the Ussing chamber experiments revealed that the incubation time used 
and the serosal concentrations were in relation. This implies that a longer residence 
time of coffee CGA at the luminal side corresponds to a higher absorbed CGA 
amount (see Figure 4-20, Results). 
 
5.3.2 Amounts of CGA and QA located at the jejunal pig mucosa 
Except for the diCQA, 1 to 1.5% of the CGA and the QA were associated (inside or 
membrane bound) with the tissue (Figure 4-21, Results). The low levels of diCQA 
associated with tissue are in accordance with their limited absorption rates. In an 
Ussing chamber study using T84 cell monolayers, CA (5a) and 5-CQA (1d) were 
identified mainly in the cytosol of the cells (Deußer, 2010). This in agreement with the 
previously hypothesized transcellular diffusion of hydroxycinnamic acids through a 
co-cultured Caco-2 / HT29-MTX cell monolayer (Poquet et al., 2008).  
The significant differences (*p < 0.05) in tissue associated 5-CQA (1d) after a 
mucosal application (1.4 ± 0.8%) vs. serosal application (0.5 ± 0.3%) (see Table 
10-14, Appendix), could be explained by the unstirred water layer at the mucosal 
side, where 5-CQA might be associated as well. 
 
5.3.3 Secretion of 5-CQA (to mucosal direction) 
The amount of 5-CQA (1d) secreted from the serosal to mucosal side was 
significantly higher than the amount absorbed (p < 0.001). Coincubations with the 
metabolic inhibitor NaN3 (p < 0.05) reduced the secretion (Figure 4-22, Results), 
indicating the involvement of an active efflux process. Farrell and co-workers have 
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already discussed the effects of increased CGA secretion in contrast to absorption; 
the presence of an active efflux transport was postulated (Farrell et al., 2011). 
Selective inhibition showed an influence on MRP- and P-gp transporters in the 
secretion of the CGA, FA glucuronide (7b) and DHFA (8c) reported by Poquet 
(Poquet et al., 2008). In our study, we were able to identify MRP 2 and the P-gp 
transporter MDR 1 in pig jejunal mucosa by Western blot analysis (see Figure 4-23, 
Results). Up until now no such transporters have been reported for pig jejunum. In 
the human jejunum, these two ABC efflux transporters are located on the mucosal 
side (Taipalensuu et al., 2001; Seithel et al., 2006). A potentially similar organization 
of transporters in the pig jejunum might contribute to the significantly higher secretion 
than absorption and hence reduction of 5-CQA bioavailability. 
 
5.3.4 Stability and interesterification of individual coffee compounds in the 
ex vivo experiment 
Interesterification reactions and hydrolytic activities were observed in the mucosal 
compartment (see Table 4-3, Results); being in agreement with other studies (Kahle 
et al., 2007; Hagl et al., 2011) and with the incubation experiments with CGA and 
ileal effluents as already discussed in chapter 5.1. Furthermore, the observed 
moderate hydrolytic activity was in agreement with other in vivo studies (Stalmach et 
al., 2010). In Figure 4-25, Results, levels of the identified interesterification (CQA) 
and hydrolytic (caffeic acid, 5a) products of 5-CQA (1d) at pH 6 on the mucosal side 
are given.  
The highest rates of interesterification were observed for 4-acyl CQA (1c) and 
FQA (3b) because this para-position is sterically benefited (see Figure 5-7). 3- and 
especially 5-acyl CQA (1b, 1d) and FQA (3a, 3c) exhibited lower rates of 
interesterification and 1-CQA (1a) exhibited none (see Table 4-3, Results). Due to the 
steric preference of position 4, the 3- and 5-acyl mono CGA migrated nearly 
exclusively to this position. Additionally, 4-acyl mono CGA migrated dominantly into 
the 3-acyl one (see Figure 5-7). The migration strongly depends on the pH in the 
medium, as shown when 5-CQA (1d) was applied at the serosal side with the higher 
pH of 7.4 (interesterification of approximately 18%) (see Table 4-3, Results) and by 
previous results (Farah et al., 2006). Whereas previously no interesterification of 5-
CQA (1d) was reported after an incubation with T84 cells in HBSS medium (pH 7.4; 
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4 hours) in the Ussing chamber (Bergmann et al., 2009). However, Bergman and 
coworkers did not increase the buffer capacity of the HBSS medium with NaHCO3 
which is necessary to stabilize pH at 7.4 when gassed with CO2. We observed a 
decrease of pH in HBSS without additional NaHCO3 from 7.4 to 6.9, because of the 
formation of H2CO3 in the HBSS buffer when gassed with CO2. Hence, pH might have 
changed during the experiment of Bergman et al. and therefore, no interesterification, 
of 5-CQA (1d) was observed. 
 
Figure 5-7: Structure of D-(-)-quinic acid (10a). Schematic acyl migration 
(interesterification) pathways of monoCGA (FQA (3a-c), CQA (1a-d)) during 
incubation of individual monoCGA in the Ussing chamber experiments (pH 6). 
Experimental conditions see chapter 7.3.2. R = H, CA (5a) or FA (7a). Bold 
arrows are major acyl migration pathways. Acyl migration at position 1 (e.g. 
1-CQA) is sterically inhibited and at the para position 4 sterically benefited. 
 
Lower interesterification levels were observed for the diCQA (4a-c), but 
simultaneously exhibited an increased hydrolysis. Due to the steric benefit of position 
3 and especially the para position 4 at the QA molecule (Figure 5-7), 3,4-diCQA (4a) 
showed neither hydrolysis nor acyl migration (see Table 4-3, Results). The molecule 
4,5-diCQA (4c) was less stable and showed some hydrolysis (4%) but no acyl 
migration as the benefited position 4 is already substituted. However, we observed 
some hydrolysis (6%) and interesterification (1.7%) of 3,5-diCQA (4b) into the more 
stable 3,4-diCQA (4a). 
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These findings are in agreement with our observations of 3,5-diCQA (4b) being less 
stable in contrast to 3,4-diCQA (4a) in the incubation experiments with CGA in ileal 
fluids (see chapter 5.1 and Table 10-2, Appendix). Additionally, in the dose-response 
study (chapter 4.3 and Table 10-6, Appendix)) 3,5-diCQA showed the lowest 
recovery rates of diCQA subgroup in ileal effluents after coffee consumption being in 
agreement to another coffee consumption study with one single coffee dose 
(Stalmach et al., 2010). 
 
5.3.5 Metabolic actions of pig jejunal tissue on 5-CQA 
As a consequence of the low dose of CGA used in the SAR experiments (20 µM) 
metabolites were not detectable. At higher concentrations (≥ 100 µM), applied to the 
pig ileal mucosa, conjugation reactions of FA (7a) have been reported previously 
(Deußer, 2010). In our dose-response study (see chapter 4.3) and in a recently 
published study a significant proportion of CGA metabolism occurred in the human 
upper GIT, except for 5-CQA (Stalmach et al., 2010), metabolites including free and 
sulfated caffeic and ferulic acids and others occurring. In those studies no 
glucuronidation of CQA was observed in the upper GIT. Here, ex vivo trace amounts 
of a 5-CQA glucuronide were detected on the serosal side of the pig mucosa when 5-
CQA was applied at high concentration (3.5 mM). Glucuronidation as the major 
phase II metabolism in pigs was reported before (Wu et al., 2005; Espín et al., 2007). 
 
5.3.6 Pig jejunal absorption mechanism of the main polyphenol (5-CQA) from 
coffee 
The DAR experiment was performed with the most abundant CGA, 5-CQA (1d). In 
our in vivo dose-response study with ileostomists (see chapter 4.3) we discovered an 
influence of the GI – TT on CGA bioavailability. Such effects could be excluded in the 
ex vivo Ussing chamber absorption experiments. The concentrations used here were 
0.02 up to 3.5 mM, covering the physiological range in the GIT after the consumption 
of a cup of the coffee (LOW) (see Table 10-9, Appendix). Dose-response studies 
indicated a non-saturable, dose-independent absorption of 5-CQA in pig jejunum as 
the flux (nmol*h-1*cm-2) was linear over the concentration range (Figure 4-24, 
Results). Thus, we conclude a passive diffusion being the major absorption 
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mechanism in the pig jejunal mucosa (cf. Figure 2-9, State of knowledge). 
Furthermore, the dependency of CGA absorption on its molecular weight and 
lipophilicity (log D) as shown in chapter 5.3.1 gives evidence for diffusion processes 
as well. 
This is in agreement with previous studies using gastric and Caco-2 cell monolayers 
(Konishi and Kobayashi, 2004; Farrell et al., 2011). In these studies, a linear 
relationship and a non saturable absorption were reported indicating a diffusion 
process. In the dose-response study with ileostomists we discovered evidence of a 
dose-independent absorption of CGA in the upper GIT (see chapter 4.3). 
Nevertheless, 5-CQA has been shown to be a poor substrate for MCT in a Caco-2 
cell model (Konishi and Kobayashi, 2004) and a non-linear transport has been 
observed in a gastric cell model for some CGA by others (Farrell et al., 2011). 
 
5.3.7 Conclusive Considerations 
As the absorption of CGA in vivo is influenced by various bioavailability factors such 
as extensive biotransformation or differences in proband’s physiology (e.g. GI – TT) 
investigations on individual CGA absorption are limited (see chapter 4.3.2) (Stalmach 
et al., 2010). Therefore, the influence of the physico-chemical properties on 
absorption of individual CGA (SAR) and the mechanism of CGA absorption (DAR) 
were investigated using the Ussing chamber model (with its standardized 
experimental conditions). Furthermore, owing to the dearth of data on CGA 
absorption in the jejunum, we chose pig jejunal mucosa for the Ussing chamber 
model.  
 
It was shown that an absorption in the upper GIT contributes to the early plasma 
appearance of CGA after coffee consumption (Table 10-13, Appendix) (Renouf et al., 
2010a). Additionally, the absorption of CGA from coffee in the jejunum strongly 
depends on their physico-chemical properties (absorption rate: 
CQA (≈ 1%) < CA (≈ 1.5%) < FQA (≈ 2%) < QA (≈ 4%)) and the absorption rate of 
the main CGA from coffee (5-CQA (1d)) was not saturable by increasing doses, 
indicating a passive diffusion as the absorption mechanism. 
Furthermore, we conclude the following relationship: the longer the incubation time of 
CGA with pig jejunal mucosa in the Ussing chamber, the higher the absorbed CGA 
amounts. Therefore, incubation time and absorbed CGA amount were in a direct 
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proportion (Figure 4-20, Results). This outcome confirmed our thesis of a relation 
between the total GI – TT of CGA after coffee consumption and the total absorbed 
CGA amount in humans. More specifically, in vivo an increased total renal CGA 
excretion is associated with an increased GI – TT of CGA (see Figure 5-2). Thus, the 
GI – TT becomes a decisive parameter for CGA uptake. 
In spite of this, the detected active efflux transport of 5-CQA (1d) is limiting its 
bioavailability. Nevertheless, it can be enhanced ex vivo by the metabolic inhibitor 
NaN3. This observation confirms our postulated thesis of an active efflux transport of 
CGA and especially CGA-metabolites at the enterocyte.  
Enhancing bioavailability of CGA might also be possible via competitive inhibition of 
efflux transporters by other polyphenols as already discussed by others (Williamson 
et al., 2007; Walter et al., 2010). Such interactions have not been sufficiently 
investigated, but the flavanol quercetin seems to show hereupon an influence. Its 
metabolites have shown an interaction with MRP2 and its aglyca led to an increased 
absorption of the polyphenol hesperitin in a Caco-2 cell model (Williamson et al., 
2007; Brand et al., 2010). Thus, quercetin glycosides which also occur in apple juice 
besides CGA (Kahle et al., 2005) can be released by ileal microbiota (Knaup et al., 
2007) or by lactase-phlorizin hydrolase (Day et al., 2003) and may increase the 
absorption of other polyphenols. Such possible synergistic effects make the 
bioavailability of polyphenols more sophisticated and may partially explain the 
differences in ileal recovery of CGA after apple juice consumption (Kahle et al., 2007) 
in comparison to coffee consumption (see Figure 5-1). 
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6 General discussion 
The lifelong daily exposure of CGA and their potentially beneficial effects on human 
health generates a growing interest in them. A precise knowledge of CGA bioavailability 
is important for the understanding of health effects related to CGA consumption since 
bioavailability describes the amount of CGA and metabolites becoming available at the 
site of action.  
However, several factors have an influence on the oral bioavailability of a drug such as 
CGA. The dosage form (e.g. matrix), dose, proband’s physiology or the molecular 
properties of the drug can affect its bioavailability (Chereson, 1996; Lipinski et al., 1997; 
Dietrich et al., 2003; Williamson et al., 2011; El-Kattan and Varma, 2012). In the diet, 
daily intake of CGA (dose) varies from 25 up to 1000 mg a day (Clifford, 1999). As CGA 
show a wide distribution among edible plants (Neveu et al., 2010) the dosages (matrix) 
varies, as well. Furthermore, the CGA composition in food (e.g. apple juice, artichoke 
leaf extract, coffee) can be different (Farah and Donangelo, 2006; Neveu et al., 2010) 
resulting in different physico-chemical properties of the CGA compositions.  
Up to now studies on oral bioavailability of CGA with different study designs (e.g. dose 
or dosage form) might be the reason for the inconsistent and contradictory data (Olthof 
et al., 2001; Nardini et al., 2002; Kahle et al., 2007; Monteiro et al., 2007; Stalmach et 
al., 2009; Renouf et al., 2010a; Renouf et al., 2010b; Stalmach et al., 2010; Hagl et al., 
2011; Williamson et al., 2011; Renouf et al., 2013). Hence, we addressed the question: 
can different administered doses of CGA (dose-absorption relation) or different CGA 
compositions (structure-absorption relation) influence their bioavailability in the upper 
GIT? 
 
As coffee is one of the richest dietary sources of CGA (Clifford, 1999; Farah and 
Donangelo, 2006) we used decaffeinated instant coffee in our study to observe 
dose-response effects on oral bioavailability in the upper GIT, on metabolization and on 
the sites where absorption occurs within the GIT. Therefore, ileostomy volunteers 
consumed three different doses (HIGH, MEDIUM, LOW) of CGA and QA by instant 
coffee on separate occasions. The consumed doses were 2.5 to 10 times higher than 
amounts normally ingested by a single cup of coffee. A possible effect of dose on 
bioavailability by acute ingestion was determined by ileal effluents (equivalent to colonic 
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availability in healthy subjects), plasma, and renal concentrations of QA, CGA and 
metabolites.  
Furthermore, the influence of the physico-chemical properties of CGA and QA from 
coffee on its bioavailability was monitored since structure-absorption relation (SAR) 
bioavailability data of the individual coffee CGA and QA was inconsistent. This was 
performed ex vivo with the so called Ussing chamber model using pig jejunum mucosa 
applying individual polyphenol compounds from coffee (1-, 3-, 4-, 5-CQA (1a-d), 3-, 4-, 
5-FQA (3a-c), CA (5a), 3,4-, 3,5-, 4,5-diCQA (4a-c), QA (10a)) in physiological 
concentrations. Additionally, we performed a dose-response experiment in the Ussing 
chamber to clarify the mechanism of CGA absorption as the data of CGA absorption 
mechanism is controversial as well (Konishi and Kobayashi, 2004; Deußer, 2010; 
Farrell et al., 2011).  
 
Our results show that after coffee consumption of different doses of CGA and QA by 
ileostomy subjects, bioavailability was affected by the GI – TT. An accelerated ileal 
excretion reduced the systemic bioavailability of nearly all CGA when increasing doses 
of CGA from soluble coffee were ingested (total renal excretion in %: 14.6 ± 6.8 (LOW), 
12.1 ± 6.7 (MEDIUM) 8.0 ± 4.9 (HIGH)). As both CGA bioavailability and GI - TT slightly 
decreased by consumption of increasing doses, we conclude a dose independent 
absorption. The total bioavailability of QA is observed independent of dose as well. 
These observations were confirmed by Ussing chamber experiments with pig jejunum 
mucosa where on one hand a dependency of total absorption and residence time was 
observed and on the other hand a dose independent absorption of 5-CQA (1d). 
Hence, the GI – TT is a decisive bioavailability parameter for CGA uptake in the upper 
GIT. Consequently, considering differing gastric residence times after consumption of 
different meals (Zimmermann and Leitold, 1992) this means an influence of GI – TT by 
the chemical composition of ingested food (see chapter 2.4.1.2, State of knowledge) 
might influence the CGA absorption in a much more complex way than different CGA 
amounts itself. Due to this, the GI – TT has to be taken into account in bioavailability 
studies in the future. 
 
For the first time, a high availability of QA in the upper GIT (approx. 15% renally 
excreted) and the dose independent colonic availability of CGA (about 70%) was 
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observed in vivo. So the sites where CGA absorption occurs within the GIT was 
regardless of the dose.  
 
We detected a much more extensive metabolism during the passage of CGA through 
the body in ileostomists than expected from literature (Stalmach et al., 2010). 
Nevertheless, for the first time significant amounts of unmetabolized CGA (3-, 4-, 5-
CQA (1b-d), 3-, 4-, 5-FQA (3a-c), 3-, 4-CQL (2a-b)) from coffee were detected in urine 
supporting their systemic availability. Whereas in the coffee beverage the 5-acyl 
compounds 5-CQA (1d) and 5-FQA (3c) were dominant within a CGA subgroup, the 4-
acyl compounds, 4-CQA (1c) and 4-FQA, (3b) were predominant at the site of action. 
This has to be taken into account for future in vitro studies. The routes of CGA 
metabolization were influenced by the dose since a shift from sulfation to 
glucuronidation occurred with increasing doses.  
The major mechanism of CGA absorption is governed by their physico-chemical 
properties (especially log D and molecular weight) in the upper part of the GIT, but 
differences of CGA subgroups in absorption were less (absorption rate: 
CQA (≈ 1%) < CA (≈ 1.5%) < FQA (≈ 2%) < QA (≈ 4%)) as we were able to show by our 
Ussing chamber experiments using ileal pig mucosa.  
We conclude that after coffee consumption at high CGA and QA doses the 
bioavailability of CGA was not limited and that different CGA profiles can have a minor 
influence on bioavailability in the upper GIT. The variations observed on CGA 
bioavailability in the current in vivo study were based on differences in volunteers 
physiology (GI - TT) and could not explain the differences in literature data reported 
(Monteiro et al., 2007; Williamson et al., 2011). According to the contradictory data from 
literature on CGA bioavailability it is possible that the different consumed dosage forms 
(matrices) influence the absorption behaviour of CGA. Additionally, differences in 
analytical methodologies used (e.g. with or without enzyme cleavage of CGA 
conjugates) might have influenced the outcomes as well. On the basis of those 
considerations a bioavailability study with a consumption of CGA in different matrices 
with one analytical method is suggested. 
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7 Materials and methods 
7.1 Materials 
7.1.1 Register of chemicals 
3,4,5-trimethoxyphenylacetic acid Fluka, Steinheim (Germany) 
Acetic acid     Merck, Darmstadt (Germany) 
Acetonitrile     J.T.Baker, Deventer (Netherland) 
Acrylamide     Roth, Karlsruhe (Germany) 
ALIGAL  80% N2 20% CO2, Drumm, Kaisersalutern 
(Germany) 
Ammonia     Sigma Aldrich, Steinheim (Germany) 
Ammonium persuflate (APS)  Roth, Karlsruhe (Germany) 
CaCl2 x 2 H2O    Sigma Aldrich, Steinheim (Germany) 
Carbogen gas    AirLiquide, Düsseldorf (Germany) 
CoCl2 x 6 H2O    Merck, Darmstadt (Germany) 
Creatinine      Sigma Aldrich, Steinheim (Germany) 
CuSO4 x 5 H2O     Merck, Darmstadt (Germany) 
Cysteinehydrochloride x H2O  Sigma Aldrich, Steinheim (Germany) 
Dimethylsulfoxid    Merck, Darmstadt (Germany) 
EDTA      Merck, Darmstadt (Germany) 
EtOH p.a.     Roth, Karlsruhe (Germany) 
FeSO4 x 7 H2O    Merck, Darmstadt (Germany) 
Formic acid     Chemsolute, Renningen (Germany) 
Goat anti-mouse IgG-HRP  Santa Cruz Biotechnology, Heidelberg 
(Germany) 
H2O bidist.     Büchi, Essen (Germany) 
H3PO4     Sigma Aldrich, Steinheim (Germany) 
Hanks´ balanced salt solution  Sigma Aldrich, Steinheim (Germany) 
Hydrochloric acid    J.T.Baker, Deventer (Netherland) 
K2CO3     Sigma Aldrich, Steinheim (Germany) 
KCl p.a.     Sigma Aldrich, Steinheim (Germany) 
L-ascorbic acid    Sigma Aldrich, Steinheim (Germany) 
MAb C219 (P-gp)    Abcam, Cambridge (UK) 
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MAb M2 III-6 (MRP 2)   Abcam, Cambridge (UK) 
MeOH     J.T.Baker, Deventer (Netherland) 
MgCl2 x 6 H2O    Sigma Aldrich, Steinheim (Germany) 
Milk powder     Roth, Karlsruhe (Germany) 
MnSO4 x 1 H2O    Merck, Darmstadt (Germany) 
Mo7(NH4)6O24 x 4 H2O   Merck, Darmstadt (Germany) 
Mouse mAb (beta-actin)   Cell Signaling, Frankfurt am Main (Germany) 
Na2SO4, waterfree    Sigma Aldrich, Steinheim (Germany) 
NaCl      Merck, Darmstadt (Germany) 
NaH2PO4     Sigma Aldrich, Steinheim (Germany) 
NaHCO3     Merck, Darmstadt (Germany) 
NaOH      Merck, Darmstadt (Germany) 
Natriumazid     Sigma Aldrich, Steinheim (Germany) 
NiCl2      Sigma Aldrich, Steinheim (Germany) 
o-Coumaric acid    Sigma Aldrich, Steinheim (Germany) 
Perchloric acid 70-72% GR for analysis Merck, Darmstadt (Germany) 
Picric acid      Sigma Aldrich, Steinheim (Germany) 
Resazurin     Sigma Aldrich, Steinheim (Germany) 
See Blue Plus 2    Invitrogen, Darmstadt (Germany) 
Sodium acetate    Merck, Darmstadt (Germany) 
Sodium dodecylsulfate (SDS)  Roth, Karlsruhe (Germany) 
Solution I     EtOH / H2O / formic acid (30/69.9/0.1, v/v/v) 
Solution II (Homogenize buffer) Tris (6.057 g) + EDTA (146.12 mg) diluted in 
500 mL H2O and adjusted to pH 7.6 
Sulfatase (Cat No S-9754)  Sigma Aldrich, Steinheim (Germany) 
Tetramethylethylenediamine  Sigma Aldrich, Steinheim (Germany) 
Tris      Roth, Karlsruhe (Germany) 
Urea      Merck, Darmstadt (Germany) 
ZnSO4 x 7 H2O    Merck, Darmstadt (Germany) 
β-glucuronidase (Cat No G-7396) Sigma Aldrich, Steinheim (Germany) 
 
7.1.2 Register of used CGA, QA and metabolites 
1-O-Caffeoylquinic acid  Provided by Hannah Deuser (Bergmann et al., 
2009) 
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5-O-Caffeoylquinic acid   Sigma Aldrich, Steinheim (Germany) 
3-O-Feruloylquinic acid   Provided by Denis Barron (NRC) 
4-O-Feruloylquinic acid   Provided by Denis Barron (NRC) 
5-O-Feruloylquinic acid   Provided by Denis Barron (NRC) 
Caffeic acid     Sigma Aldrich, Steinheim (Germany) 
Ferulic acid     Sigma Aldrich, Steinheim (Germany) 
Dihydrocaffeic acid    Fluka, Steinheim (Germany) 
D-(-)-Quinic acid    Sigma Aldrich, Steinheim (Germany) 
U-13C-D-(-)-Quinic acid   Isolife, Wageningen (Netherland) 
Isoferulic acid    Extrasynthèse, Lyon (France) 
Dihydroferulic acid    Fluka, Steinheim (Germany) 
Dimethoxycaffeic acid   Sigma Aldrich, Steinheim (Germany) 
Dimethoxydihydro caffeic acid  Sigma Aldrich, Steinheim (Germany) 
d13C2-Caffeic acid  Orphachem S.A., Clermont Ferrand (France) 
3-O-Caffeoylquinic acid   Synthesis and isolation (see chapter 7.3.5.1) 
4-O-Caffeoylquinic acid   Synthesis and isolation (see chapter 7.3.5.1) 
3-O-Caffeoylquinide  Synthesis and isolation (see chapter 7.3.5.2) 
4-O-Caffeoylquinide   Synthesis and isolation (see chapter 7.3.5.2) 
1,3-O-diCaffeoylquinic acid  Biopurify Phytochemicals Ltd., Chengdu 
Sichuan (China) 
1,5-O-diCaffeoylquinic acid  Biopurify Phytochemicals Ltd., Chengdu 
Sichuan (China) 
3,4-O-diCaffeoylquinic acid  Synthesis and isolation by Eric Heinen 
3,5-O-diCaffeoylquinic acid  Alexis Biochemicals, Lörrach (Germany) 
4,5-O-diCaffeoylquinic acid  Biopurify Phytochemicals Ltd., Chengdu 
Sichuan (China) 
 
The following CGA metabolites were all kindly provided by Denis Barron from the 
Nestle´ research centre in Lausanne (NRC). 
Ferulic acid 4´-O-glucuronide 
Isoferulic acid 3´-O-glucuronide 
Caffeic acid 4´-O-glucuronide 
Caffeic acid 3´-O-glucuronide 
Dihydroferulic acid 4´-O-glucuronide 
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Dihydrocaffeic acid 4´-O-glucuronide 
Dihydrocaffeic acid 3´-O-glucuronide 
Dihydro caffeic acid 4´-O-sulfate 
Dihydro caffeic acid 3´-O-sulfate 
Dihydro ferulic acid 4´-O-sulfate 
Caffeic acid 4´-O-sulfate 
Caffeic acid 3´-O-sulfate 
Ferulic acid 4´-O-sulfate 
Isoferulic acid 3´-O-sulfate 
 
Mix of FQA-4´-O-sulfates, containing: 
3-O-FQA-4´-O-sulfate; 4-O-FQA-4´-O-sulfate; 5-O-FQA-4´-O-sulfate 
Mix of FQA-4´-O-glucuronides, containing: 
3-O-FQA-4´-O-glucuronide; 4-O-FQA-4´-O-glucuronide; 5-O-FQA-4´-O-glucuronide 
Mix of CQA-3´-O-sulfates, containing: 
3-O-CQA-3´-O-sulfates; 4-O-CQA-3´-O-sulfates; 5-O-CQA-3´-O-sulfates 
Mix of CQA-4´-O-sulfates, containing: 
3-O-CQA-4´-O-sulfates; 4-O-CQA-4´-O-sulfates; 5-O-CQA-4´-O-sulfates 
 
7.1.3 Consumable material 
AnaeroGen™    Oxoid Ltd., Basingstoke, Hamphire (UK) 
Api® ZYM      BioMeriéux, Marcy-l`Etoile (France) 
Bicinchoninic acid assay, Kit Uptima KMF Laborchemie, Darmstadt (Germany) 
Cryo tubes 1 mL    Greiner Bio-one, Frickenhausen (Germany) 
Falcons 15 and 50 mL   Greiner Bio-one, Frickenhausen (Germany) 
HPLC-vial     Buddeberg, Mannheim (Germany) 
HPLC-vial-inserts    Wagner & Munz, München (Germany) 
Incubation vessels 15 mL   Sarstedt, Nümbrecht (Germany) 
Monovette tubes 9 mL  Potassium EDTA-gel, Sarstedt, Nümbrecht 
(Germany) 
Pipette tips     Greiner Bio-one, Frickenhausen (Germany) 
PVDF-filter    13 mm, 0.45 µm, Pall Corporation, Port, 
Washington, Michigan (USA) 
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SPE-column Bond-elut PH 500 mg, 3 mL, Varian, Agilent 
Technologies, Böblingen (Germany) 
Syringe 1 mL    Terumo, Somerset, New Jersey (USA) 
Tubes 1.5 mL and 2 mL   Greiner Bio-one, Frickenhausen (Germany) 
Urine collection flask   2.5 L, Sarstedt, Nümbrecht (Germany) 
 
7.2 Equipment 
7.2.1 High performance liquid chromatography – diode array-detection (HPLC-
DAD) 
HPLC system I: HPLC-DAD (Agilent HPLC System) 
Degasser    G1379B, Agilent, Waldbronn (Germany) 
Binary HPLC-pump   G1312A, Agilent, Waldbronn (Germany) 
Autosampler  + 4°C, G1329A with G1320B, Agilent, Waldbronn 
(Germany) 
Column oven + 30°C, G1316A, Agilent, Waldbronn (Germany) 
DAD-detector G1315D, Agilent, Waldbronn (Germany) 
Detection wavelengths  254 nm, 270 nm, 320 nm 
Software Chemstation Revision B.02.01. SR2, Agilent, 
Waldbronn (Germany) 
 
Conditions 1a 
Eluate A H2O (0.1% formic acid) 
Eluate B ACN 
Gradient ascending: time (min)  ACN (%) 
0 5 
21 17.5 
27 24 
30 28 
60 28 
Flow  0.5 mL*min-1 
Injection volume 20 µL 
Column Synergy polar-RP, 80 Å, 250 x 4.6 mm, 4 µm, 
Phenomenex, Aschaffenburg (Germany) 
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Conditions 1b 
Eluate A H2O (0.1% formic acid) 
Eluate B ACN 
Gradient ascending: time (min)  ACN (%) 
0 7 
80  27 
Flow  1.1 mL*min-1 
Injection volume 20 µL 
Column Atlantis T3, 3 µm, 4.6 x 150 mm, Waters, Eschborn 
(Germany) 
 
Conditions 1c 
Eluate A H2O (0.1% formic acid) 
Eluate B ACN 
Gradient isocratic, 12% eluate B in 40 min 
Flow  0.8 mL*min-1 
Injection volume 20 µL 
Column Atlantis T3, 3 µm, 4.6 x 150 mm, Waters, Eschborn 
(Germany) 
 
HPLC system II: HPLC-DAD (Agilent HPLC System) 
Degasser    G1379B, Agilent, Waldbronn (Germany) 
Binary HPLC-pump   G1312B, Agilent, Waldbronn (Germany) 
Autosampler  + 4°C, G1367C with G1330B, Agilent, Waldbronn 
(Germany) 
Column oven + 40°C, G1316B, Agilent, Waldbronn (Germany) 
DAD-detector   G1315C, Agilent, Waldbronn (Germany) 
Detection wavelengths  254 nm, 270 nm, 320 nm 
Software Chemstation Revision B.04.01.- SP1 [647], Agilent, 
Waldbronn (Germany)  
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Conditions 1a 
Eluate A H2O (0.1% formic acid) 
Eluate B ACN 
Gradient ascending: time (min)  ACN (%) 
0 1 
10 8 
20 18 
Flow  0.8 mL*min-1 
Injection volume 40 µL 
Column Eclipse plus C18, 2.1 x 50 mm, 1.8 µm, Agilent, 
Waldbronn (Germany) 
 
Conditions 1b 
Eluate A H2O (0.1% formic acid) 
Eluate B ACN 
Gradient isocratic, 12% eluate B in 40 min 
Flow  0.8 mL*min-1 
Injection volume 20 µL 
Column Atlantis T3, 3 µm, 4.6 x 150 mm, Waters, Eschborn 
(Germany) 
 
HPLC system III: HPLC-DAD (Hewlett Packard 1090 series, compact system) 
Degasser    Helium-online-degassing 
Binary HPLC-pump   Hewlett Packard 1090 series, photodiode array 
Autosampler    Hewlett Packard 1090 series, photodiode array 
Column oven + 40°C, Hewlett Packard 1090 series, photodiode 
array  
DAD-detector   Hewlett Packard 1090 series, photodiode array  
Detection wavelengths  254 nm, 280 nm, 320 nm, 360 nm 
Software HP Chemstation for LC 
 
Conditions 1a 
Eluate A H2O (0.1% formic acid) 
Eluate B ACN 
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Gradient isocratic, 9% eluate B 
Flow  1.0 mL*min-1 
Injection volume 20 µL 
Column Waters symmetry C18, 4.6 x 250 mm, 5 µm, Waters, 
Eschborn (Germany) 
 
Conditions 1b 
Eluate A H2O (0.1% formic acid) 
Eluate B ACN 
Gradient isocratic, 12% eluate B in 40 min 
Flow  0.8 mL*min-1 
Injection volume 20 µL 
Column Atlantis T3, 3 µm, 4.6 x 150 mm, Waters, Eschborn 
(Germany) 
 
 
7.2.2 High performance liquid chromatography – mass-spectrometry (HPLC-MS) 
HPLC system IV: HPLC-MS 
Degasser DG-2080-53 3-Line-Degasser, Jasco, Groß-Umstadt 
(Germany) 
System control   LC-Net II/ADC, Jasco, Groß-Umstadt (Germany) 
Binäry HPLC-pump PU-2080 plus intelligent HPLC pump, Jasco, Groß-
Umstadt (Germany) 
Thermostat controlled  AS-2057 plus intelligent sampler, + 4°C, Jasco, Groß-
autosampler     Umstadt (Germany) 
Mass spectrometer API 3200 triple quadrupole LC-MS/MS mass 
spectrometer with valcovalve, Applied Biosystems, 
Darmstadt (Germany) 
Software    Analyst 1.4.2, Jasco, Groß-Umstadt (Germany) 
 
Conditions 1a 
Eluate A H2O (0.1% formic acid) 
Eluate B ACN  
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Gradient ascending: time (min)  ACN % 
1 5 
21 17.5 
27 24 
30 28 
48 28 
Flow  0.5 mL*min-1 
Injection volume 80 µL 
Column Synergy polar-RP, 80 Å, 250 x 4.6 mm, 4 µm, 
Phenomenex, Aschaffenburg (Germany) 
Ionization electrospray ionization (ESI-neg.), - 4.5 kV 
Operating mode product ion (MS2) 
Resolution Q1: unit 
Resolution Q3: unit 
 
Curtain gas nitrogen, 30 psi at + 370°C 
Gas 1 70 psi 
Gas 2 40 psi 
CAD 3.0 units 
Electron multiplier voltage 2.0 kV 
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7-1: Product ion scan (MS2) conditions for CGA and metabolites. 
Compounds Q1 m/z DP (V) EP (V) CEP (V) CE (V) CXP (V) 
       Caffeoylquinic acids 353 - 25.0 - 2.5 - 32.4 - 50.0 - 2.0 
Caffeoylquinic acid-O-GlucA 529 - 35.0 - 4.5 - 37.2 - 40.0 - 2.0 
Caffeoylquinic acid-O-Sulf 433 - 25.0 - 2.5 - 34.6 - 40.0 - 2.0 
Caffeoylquinides 335 - 25.0 - 2.5 - 31.9 - 50.0 - 2.0 
Caffeolyquinide-O-GlucA 511 - 40.0 - 4.5 - 36.7 - 40.0 - 2.0 
Caffeoylquinide-O-Sulf 415 - 25.0 - 2.5 - 34.1 - 50.0 - 2.0 
Feruloylquinic acids 367 - 25.0 - 2.5 - 32.8 - 50.0 - 2.0 
Iso/-feruloylquinic acid-O-GlucA 543 - 30.0 - 9.0 - 37.5 - 40.0 - 2.0 
Feruloylquinic acid-O-Sulf 447 - 25.0 - 3.5 - 35.0 - 40.0 - 2.0 
Caffeic acid 179 - 25.0 - 2.5 - 27.7 - 50.0 - 2.0 
Caffeic acid-O-GlucA 355 - 35.0 - 4.5 - 32.5 - 40.0 - 2.0 
Caffeic acid-O-Sulf 259 - 25.0 - 2.5 - 50.0 - 50.0 - 2.0 
Dihydrocaffeic acid 181 - 25.0 - 2.5 - 27.8 - 50.0 - 2.0 
Dihydrocaffeic acid-O-GlucA 357 - 35.0 - 4.5 - 32.5 - 40.0 - 2.0 
Dihydrocaffeic acid-O-Sulf 261 - 25.0 - 2.5 - 29.9 - 50.0 - 2.0 
Ferulic acid 193 - 35.0 - 3.0 - 28.1 - 30.0 - 2.0 
Iso-/ferulic acid-O-GlucA 369 - 30.0 - 9.0 - 32.8 - 40.0 - 2.0 
Iso-/ferulic acid-O-Sulf 273 - 25.0 - 3.5 - 30.3 - 40.0 - 2.0 
Feruloylglycine 250 - 35.0 - 3.0 - 29.6 - 30.0 - 2.0 
Dihydroferulic acid -4´-O-GlucA 371 - 30.0 - 9.0 - 32.9 - 40.0 - 2.0 
Dihydroferulic acid-4´-O-Sulf 275 - 25.0 - 3.5 - 30.3 - 40.0 - 2.0 
diCaffeoylquinic acids 515.5 - 25.0 - 2.5 - 36.8 - 50.0 - 2.0 
        
Conditions Ib 
Eluate A H2O (0.1 % formic acid) 
Eluate B ACN 
Gradient ascending: time (min)  ACN % 
0 5 
21 17.5 
27 24 
30 28 
48 28 
Flow  0.5 mL*min-1 
Injection volume 40 µL 
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Column Synergy polar-RP, 80 Å, 250 x 4.6 mm, 4 µm, 
Phenomenex, Aschaffenburg (Germany) 
Ionization electrospray ionization (ESI-neg.), - 4.5 kV 
Operating mode Q1 mi (multiple ions) 
Curtain gas nitrogen, 30 psi at + 370°C 
Gas 1 70 psi 
Gas 2 40 psi 
Electron multiplier voltage 2.1 kV 
Dwell time 70 msec 
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7-2: Multiple ion scan conditions for CGA and metabolites. 
Compounds Q1 m/z DP (V) EP (V) CEP (V) 
     Caffeoylquinic acids 353 - 25.0 - 2.5 - 32.4 
Caffeoylquinic acid-O-GlucA 529 - 30.0 - 3.5 - 37.2 
Caffeoylquinic acid-O-Sulf 433 - 27.0 - 3.5 - 34.6 
Caffeoylquinides 335 - 25.0 - 2.5 - 31.9 
Caffeolyquinide-O-GlucA 511 - 40.0 - 4.5 - 36.7 
Caffeoylquinide-O-Sulf 415 - 40.0 - 4.5 - 34.1 
Feruloylquinic acids 367 - 25.0 - 2.5 - 32.8 
Iso/-feruloylquinic acid-O-GlucA 543 - 27.0 - 5.0 - 37.5 
Feruloylquinic acid-O-Sulf 447 - 25.0 - 3.0 - 35.0 
Caffeic acid 179 - 25.0 - 2.5 - 27.7 
Caffeic acid-O-GlucA 355 - 35.0 - 4.5 - 22.0 
Caffeic acid-O-Sulf 259 - 30.0 - 5.0 - 16.0 
Dihydrocaffeic acid 181 - 25.0 - 2.5 - 27.8 
Dihydrocaffeic acid-O-GlucA 357 - 35.0 - 4.5 - 32.5 
Dihydrocaffeic acid-O-Sulf 261 - 25.0 - 2.5 - 29.9 
Ferulic acid 193 - 35.0 - 3.0 - 28.1 
Iso-/ferulic acid-O-GlucA 369 - 30.0 - 9.0 - 18.0 
Iso-/ferulic acid-O-Sulf 273 - 25.0 - 3.5 - 16.0 
Feruloylglycine 250 - 35.0 - 3.0 - 29.6 
Dihydroferulic acid -4´-O-GlucA 371 - 30.0 - 9.0 - 32.9 
Dihydroferulic acid-4´-O-Sulf 275 - 25.0 - 3.5 - 30.3 
o-Coumaric acid 163 - 25.0 - 5.0 - 12.0 
      
Conditions Ic 
Eluate H2O (0.1% formic acid) - ACN; (99/1 ,(v/v)) 
Flow  0.5 mL*min-1 
Injection volume 20 µL 
Column Atlantis RP 18 4.6 x 150 mm, 3 µm, Waters, Eschborn 
(Germany) 
Ionization electrospray ionization (ESI-neg.), - 4.5 kV 
Operating mode MRM (multiple reaction monitoring) 
Curtain gas nitrogen, 25 psi at + 450°C  
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Gas 1 60 psi 
Gas 2 50 psi 
Declustering potential - 55 V 
Entrance potential - 10.5 V 
Cell entrances potential - 28 V 
Collison gas nitrogen, 6 units 
Collision energy - 30 V 
Cell exit potential 0 V 
Electron multiplier voltage 2.2 kV 
Dwell time 2 msec 
 
Conditions Id 
Eluate H2O (0.1% formic acid) - ACN; (99/1 ,(v/v)) 
Flow  0.5 mL*min-1 
Injection volume 70 µL 
Column Atlantis RP 18 4.6 x 150 mm, 3 µm, Waters, Eschborn 
(Germany) 
Ionization electrospray ionization (ESI-neg.), - 4.5 kV 
Operating mode MRM (multiple reaction monitoring) 
Curtain gas nitrogen, 25 psi at + 370°C 
Gas 1 60 psi 
Gas 2 50 psi 
Declustering potential - 50 V 
Entrance potential - 11 V 
Cell entrances potential - 30 V 
Collison gas nitrogen, 4 units 
Collision energy - 30 V 
Cell exit potential - 2 V 
Electron multiplier voltage 2.3 kV 
Dwell time 150 msec 
 
HPLC system V: HPLC-MS 
HPLC Transcend system Thermo Scientific, Dreieich (Germany)  
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Mass spectrometer TSQ Vantage Mass Spectrometer, Thermo Scientific, 
Dreieich (Germany) 
PAL System    Thermo Scientific, Dreieich (Germany) 
 
Conditions 1a 
Eluate A H2O (1% acetic acid) 
Eluate B ACN (1% acetic acid) 
Gradient ascending: time (min)  Eluate B% 
0 3 
1 3 
16 20 
26 30 
Flow  0.2 mL*min-1 
Injection volume 50 µL 
Column UPLC Acquity BEH C18, 1.8 µm, 2.1x150 mm, 
Waters, Eschborn (Germany) at + 35°C 
Ionization electrospray ionization (ESI-neg.), - 2.5 kV 
Operating mode SRM 
Collision Gas Pressure 1.5 mTorr 
Cycle time 1 sec 
DCV 2 V 
Capillary temp. + 270°C 
Vaporizer temp. + 350°C 
Sheath gas pressure 40 units 
Ion sweep gas pressure 0 units 
Aux valve flow 20 
Discharge current - 4.0 
 
Table 7-3: Selective Reaction Monitoring scan (SRM) conditions for CGA. 
Compound Parent mass (m/z) Product 1 (m/z) CE [V] S-Lens 
     
CA 179.06 135.10 17 56 
FA 193.07 134.10 18 57 
IFA 193.07 178.10 14 57 
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Compound Parent mass (m/z) Product 1 (m/z) CE [V] S-Lens 
DHCA 181.00 137.10 13 60 
DHFA 195.08 136.10 17 52 
3-CQA 353.09 191.20 21 68 
4-CQA 353.10 173.10 17 74 
5-CQA 353.10 191.10 18 69 
3-FQA 367.11 193.10 19 70 
4-FQA 367.11 173.10 15 70 
5-FQA 367.11 191.10 22 70 
1,3-diCQA 515.12 353.20 19 100 
1,5-diCQA 515.12 191.10 31 100 
3,4-diCQA 515.12 179.10 29 100 
3,5-diCQA 515.12 191.10 31 100 
4,5-diCQA 515.12 173.10 29 100 
DiMeCA 207.10 103.20 16 62 
DiMeDHCA 209.10 150.20 15 75 
d13C2-caffeic acid 182.10 137.10 16 52 
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7.2.3 Ussing Chamber  
 
 
Figure 7-1: Design of the Ussing type chamber: (A) gassing (95% O2, 5% CO2); (B) pig 
jejunal mucosa; (C) tissue conductance (Gt); (D) short-circuit current. Hanks‘ 
balanced salt solution at + 37°C was used as medium. Modified according to 
(Deußer, 2010). 
 
Ussing chamber  K. Mußler, Software Clamp 2.14, 2001 Aachen 
(Germany) 
Area (Figure 7-1, B)   0.785 cm2 
Operating mode:    open circuit 
Action replay    1 min, mean value of 2 
Pulse duration   1 sec 
Pulse distance   1 sec  
Number of pulse   1 
Gt-parameter: 
  Unit    mS*cm-2 
  Amplitude   100 µA 
  Pulse duration  200 msec (bipolar)  
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7.2.4 Other equipment 
Anaerobic chamber Arylic glas chamber, self constructed 
Biofreezer     Sanyo, München (Germany) 
Blot apparatus, Hoefer TE 77 Amersham Biosciences; München (Germany) 
Bioimpedance     BF-906, Maltron, Gauting (Germany) 
Centrifuge I     5804R, Eppendorf, Hamburg (Germany) 
Centrifuge II     5417R, Eppendorf, Hamburg (Germany) 
Drying oven     Binder, Tuttlingen (Germany) 
Freezer (- 24°C)    Liebherr Premium, Ochsenhausen (Germany) 
Lumi-Imager     Roche, Mannheim (Germany) 
Lyophilization machine   Christ, Osterode am Harz (Germany) 
MS1 Minishaker    IKA, Staufen, (Germany) 
NMR, AMX-400    Bruker, Rheinstetten (Germany) 
pH meter  Hanna Instruments, Ann Arbor, Michigan (US) 
Pipettes     Research, Eppendorf, Hamburg (Germany) 
Potter      Schuett, Göttingen (Germany) 
UV-VIS Spectrophotometer  SHIMADZU, Duisburg (Germany) 
(UVmini 1240) 
Thermomixer    5436, Eppendorf, Hamburg (Germany) 
Ultrasonic bath  Sonorex Super RK 102 P, Bandelin, Berlin 
(Germany) 
Vacuum centrifuge   Unicryo MC2L, UniEqup, Martinsried 
(Germany) 
Vacuum manifold    Supelco, Bellefonte (US) 
Vacuum-pump  Rotary vane vacuum pump RZ 5, Vacubrand, 
Wertheim (Germany) 
Vortexer     Genius 3, IKA, Staufen (Germany) 
Water bath     Julabo, Seelbach (Germany) 
Weighing machine    CP64-0CE, Sartorius, Göttingen (Germany) 
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7.3 Methods 
7.3.1 Human intervention study 
This study was performed in the Division of Gastroenterology, Department of 
Medicine II, University of Wuerzburg. 
 
7.3.1.1 Ethical approval 
The study protocol was approved by the Ethics Committee of the Medical Faculty, 
University of Wuerzburg (No. 124/04 and 32/10). 
 
7.3.1.2 Volunteers 
Five female subjects who have undergone colectomy with a terminal stoma of the ileum 
(but otherwise healthy) have participated in this randomized, double-blinded and 
3-period-crossover intervention study. They consumed a single dose of decaffeinated 
coffee with different amounts of CGA and QA (HIGH, MEDIUM and LOW) on three 
separate days. All treatments were ingested at one occasion with a minimum on one 
week washout in between. Ileostomy bags, blood samples and urine samples were 
collected at selected time points. 
 
7.3.1.2.1 Inclusion and exclusion criteria 
Volunteers had to comply with the following inclusion criteria:  
• Having undergone colectomy with terminal ileostomy, but otherwise 
healthy. 
• Age > 18 years. 
 
Volunteers which represented one or more of the following criteria were excluded from 
participation in the study: 
• Previous occupational exposure to green coffee beans. 
• Having a regular consumption of medication. 
• Currently participating or having participated in another clinical trial during 
the last three weeks prior to the beginning of this study.  
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7.3.1.2.2 Anthropometry 
Anthropometric data of volunteers: average age of 41 ± 3.6 years; BMI of 
27.4 ± 2.1 kg/m2, body fat content of 33.9 ± 2.6% and a basic metabolism rate of 
1403.6 ± 58.3 kcal. The reason for colectomy were a Morbus Crohn`s disease or 
Ulcerative colitis, volunteers underwent surgery 10.6 ± 6.1 years ago. Anthropometric 
data of volunteers were measured with Maltron Body Fat-Instrument BF-906 from 
Juwell medical (for detailed data see Table 10-1, Appendix). 
 
7.3.1.3 Study design 
Subjects consumed a single dose of decaffeinated instant coffee with different amounts 
of CGA and QA (HIGH, MEDIUM and LOW see Table 10-5, Appendix) on three 
separate days in randomized order. Two days before the start and during study period, 
volunteers consumed a CGA-free diet and arrived at the study day in a fasted state at 
8:00 am. At the beginning of each study day the body weight of each volunteer was 
measured (see Table 10-1, Appendix) and the total coffee volume to be administrated 
was calculated (mg*kg-1*BW-1). Instant coffees were reconstituted with boiling water 
prior to consumption and consumed at a temperature of + 55 – 60°C in less than 
10 min. The administered coffee volume was without sugar or milk and served in 
mg*kg-1*BW-1. A breakfast was served consisting of one white bread and artificial honey 
(invertase treated sugar product). Volunteers remained fasted for 5 h after breakfast 
and then consumed a light meal (white bun with ham and cheese) without CGA. Water 
consumption was allowed ad libitum.  
Biological fluids were collected at the following time points: Ileostomy fluid - 12 to 0, 0, 
0.5, 1, 2, 3, 4, 6, 8 hours, urine - 24 to 0, 0, 0.5, 1, 2, 3, 4, 6, 8, 8 to 24 and 24 to 48 
hours, blood samples 0, 0.5, 1, 2, 4, 6 and 8 hours post consumption. Sample storage 
and preparation is described in the following chapters, respectively: ileostomy fluids see 
chapter 7.3.1.6, urine samples see chapter 7.3.1.5 and blood samples see chapter 
7.3.1.7. 
After the last blood and ileal fluid sample collection, the volunteers took home a 
standardized dinner (pasta with cream-cheese sauce and plain yoghurt) and remained 
on a CGA-free diet until the last urine collection 48 hours after coffee consumption. In 
Figure 7-2 an overview of the collection intervals of blood, urine and ileostomy bags is 
given.  
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Figure 7-2: Scheme of blood, urine and ileal fluid collection before and after coffee 
consumption in the ileostomy intervention study. Volunteers consumed a single 
dose of decaffeinated coffee with different amounts of chlorogenic acid and quinic 
acid (HIGH, MEDIUM and LOW) on three separate days in randomized order. 
 
Accordingly, on a separate day, volunteers consumed, 2 hours after breakfast, an 
anthocyanin-rich blueberry beverage to determine the GI - TT by observing the color 
change of ileal excretion. 
 
7.3.1.4 Instant coffee 
On each study day three aliquots of 15 mL of coffee beverage were taken as retain 
sample and stored at - 80°C. For analysis coffee samples were thawed quickly, 
centrifuged (5 min, 5,000 x g), membrane filtered (0.45 µm PFDV) and diluted (40 up to 
100-fold) with solution I. The internal standard (3,4,5-trimethoxyphenylacetic acid (ISb), 
30 µL 226.23 mg*L-1) were added to 300 µL of this solution. 
 
7.3.1.4.1 Analysis of coffee CGA 
7.3.1.4.1.1 Calibration 
CGA were detected at 320 nm and the IS at 270 nm with the HPLC system I. Due to an 
insufficient chromatographic separation of compounds CQA, FQA and CA were 
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analyzed with condition 1a (see chapter 7.2.1) whereas CQL, FA and diCQA were 
analyzed with condition 1b (see chapter 7.2.1).  
CGA stock solutions (5-CQA (1d), 5-FQA (3c), CA (5a), FA (7a), 3,4-diCQA (4a), in 
solution I) with a maximal concentration range from 333.3 mg*L-1 to 10.2 µg*L-1 were 
used. Solutions were analyzed with the HPLC system I (conditions Ia and Ib in chapter 
7.2.1) in duplicates. For calibration the observed peak area ratios were plotted versus 
the concentration ratios with a correlation coefficient of at least R2 = 0.99. Limit of 
detection (LOD) and limit of quantification (LOQ) were defined as signal to noise (S/N) 
ratios: LOD 1:3 and LOQ 1:10, respectively. On this basis, LOQ was calculated from 
0.68 to 5.42 ng and LOD from 0.20 to 1.62 ng absolute. 
 
7.3.1.4.1.2 Identification and quantification of CGA 
CGA were identified by comparison of retention time, UV spectra and according to the 
fragmentation patterns with references by HPLC system IV, conditions 1a (Table 4-1, 
Results). Quantification was based on the achieved calibration curves of references for: 
FA (7a), CA (5a). CQA and CQL as 5-CQA (1d) equivalents, FQA as 5-FQA (3c) 
equivalents and diCQA as 3,4-diCQA (4a) equivalents (for details see HPLC system I, 
conditions Ia and Ib in chapter 7.2.1). 
 
7.3.1.4.2 Analysis of QA 
For the analysis of QA (10a) a stable isotope dilution method was established with the 
isotopically labeled standard U-13C-D-(-)-QA (Isolife, Wageningen (Netherland)) (Erk et 
al., 2009).  
 
7.3.1.4.2.1 Calibration 
Seven reference solutions of QA (10a) were prepared in triplicate in solution I with 
concentrations ranging from 1.2 to 5,000 ng*mL-1. Solutions were analyzed in the MRM 
mode, and the observed peak area ratios (QA vs. U-13C-D-(-)-QA) were plotted vs the 
concentration ratios. LOD and LOQ were defined with signal-to-noise (S/N) ratios of 1:3 
and 1:10, respectively. On the basis of the lowest calibration concentrations, an LOQ of 
97.7 pg and an LOD of 24.4 pg absolute were calculated. 
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7.3.1.4.2.2 Identification and quantification of QA 
For the quantification of QA (10a) a stable isotope dilution analysis with HPLC-MS/MS 
had been established (Erk et al., 2009). Sample preparation was performed in 
triplicates.  
Coffee solutions were centrifuged (5 min, 5,000 rpm), membrane filtered (0.45 μm 
PVDF), diluted (1600-fold) with solution I, and 50 µL were spiked with 50 µL of the 
labeled standard (200 ng*mL-1) and further analyzed by HPLC system IV (conditions Ic, 
see chapter 7.2.2). For QA quantification the MRM transition from the deprotonated 
molecular ion [M-H]- m/z 191 to m/z 85 was used as the quantifier. Further, the 
characteristic QA fragmentation ions from [M-H]- m/z 191 to m/z 93 and m/z 127 were 
used as qualifier ions to additionally ensure the identity of the detected QA in urine. The 
MRM transition used for quantification of the isotopically labeled standard 
U-13C-D-(-)-QA was m/z 198 to m/z 89 (Figure 7-3). 
 
 
 
Figure 7-3: HPLC-MS/MS chromatogram monitored in the multiple reaction monitoring 
(MRM) mode for a model mixture of D-(-)-quinic acid (A) and U-13C-D-(-)-quinic acid 
(B) at concentrations of 100 ng*mL-1 (HPLC system IV, condition Ic see chapter 
7.2.2).  
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7.3.1.5 Urine samples 
7.3.1.5.1 Preparation of urine samples 
Urine samples were collected before - 24 to 0 and 0, 0.5, 1, 2, 3, 4, 6, 8, 8 to 24 and 
24 to 48 hours after coffee consumption. Urine samples were collected in acid washed 
urine collection flasks containing HCl and ascorbic acid (1 L urine collection flasks 
containing 10 mL 1 M HCl and 2 mL aqueous ascorbic acid at 100 g*L-1). During the 
collection intervals, the flasks were kept at + 4 to + 8ºC. At the end of each collection 
interval the total volume and weight was measured. The pH was adjusted to 3- 4. Five 
aliquots of 25 mL were filled into a 50 mL falcon and stored at - 80°C.  
Unfortunately ileo no. 4 didn’t collect the urine sample correctly at the study trial LOW. 
The sample was collected from 8 to 48 h into one flask. 
 
7.3.1.5.2 Analysis of CGA and metabolites 
Aliquots were thoroughly defrosted, warmed to + 37°C, and 3 mL were acidified with 
H3PO4 to a pH of 1.5. In addition, samples were centrifuged (+ 4°C, 5 min, 5,000 x g) 
and the supernatant (2 mL) was used for solid phase extraction (SPE), (Varian: bond 
elut PH, 500 mg). All solutions were acidified with HCl (0.01%, v/v). The 
SPE - cartridges were preconditioned (2 mL MeOH and 2 mL H2O) using a vacuum 
manifold. After sample application (2.0 mL) on the column, the SPE was washed with 
1 mL H2O, dried carefully and afterwards analytes were eluted using 1.8 mL MeOH. The 
eluate was concentrated in a vacuum centrifuge (60 min), subsequently lyophilized to 
dryness and stored at – 80°C prior analysis.  
Residues were redissolved with 200 µL solution I. To 100 µL of this sample, 10 µL of 
the IS (o-coumaric acid (ISa), 61 µM) was added and mixed well. Extraction efficiencies 
were determined > 90% with test the compounds 5-CQA (1d), CA (5a), FA (7a), DHCA 
(6a), DHFA (8c). 
 
7.3.1.5.2.1 Calibration 
Calibration curves were generated using a mix of 0 h urine samples (CGA free), spiked 
with references (see Table 7-4, maximal concentration range 8.2 mg*L-1 to 5.5 µg*L-1) 
and extracted in duplicate as described above. LOQ was from 0.6 to 43.4 ng and LOD 
was from 0.2 to 13.0 ng (see Table 7-4).  
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Table 7-4: Limit of detection (LOD) and limit of quantification (LOQ) of the HPLC-MS 
multiple ion method for CGA and metabolite detection in urine samples (see 
chapter 7.3.1.5.2.2). 
Compound  LOD LOQ 
   [ng]  [ng] 
   Ferulic acid 4.2 14.1 
Ferulic acid-4´-O-Sulf 1.3 4.4 
Isoferuloylquinic acid-3´-O-GlucA 0.7 2.2 
Dihydroferulic acid-4´-O-Sulf 0.5 1.7 
Dihydroferulic acid-4´-O-GlucA 0.7 2.3 
Caffeic acid 0.2 0.8 
Caffeic acid-3´-O-Sulf 0.7 2.4 
Caffeic acid-3´-O-GlucA 2.8 9.4 
Dihydrocaffeic acid 13.0 43.4 
Dihydrocaffeic acid-3´-O-Sulf 0.7 2.4 
5-O-Caffeoylquinic acid 2.9 9.5 
5-O-Feruloylquinic acid 0.2 0.6 
    
7.3.1.5.2.2 Identification and quantification of CGA and metabolites 
CGA and derivatives identification were achieved on HPLC-system IV, conditions 1a 
(see chapter 7.2.2). Caffeoylquinic acids and metabolites, Caffeoylquinides and 
metabolites, Iso- / feruloylquinic acid and metabolites were identified as already 
reported in chapter 4.3.2.1, Results. Feruloylglycine (7d) was identified by comparison 
of the MS2 fragmentation pattern reported by (Stalmach et al., 2009). Other 
hydroxycinnamic acids such as CA (5a), FA (7a) and derivative compounds were 
identified by co-chromatography and a matching MS2 fragmentation pattern with 
reference compounds provided by NRC. 
 
Quantification of compounds was performed by a multi method (see Figure 10-1, 
Appendix) with the HPLC system IV, conditions Ib (see chapter 7.2.2). For each analyte 
the corresponding deprotonated molecular ions [M-H]- was used as a quantifier in 
duplicates. Quantification was based on the achieved calibration curves of references 
(see Table 7-4). Because calibration curves were generated equal to urine samples it 
was not necessary to use a correction factor for extraction efficacy. Determination was 
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semi-quantitative, since compounds were quantified based on calibration curves of the 
available references: 
CQA, CQL and their corresponding metabolites, as 5-CQA (1d) equivalents; FQA and 
metabolites as 5-FQA (3c) equivalents; FA (7a) and FA-Gly (7d) as ferulic acid 
equivalents; FA-GlucA (7b) derivatives as IFA-GLucA (7e) equivalents; sulfated 
derivatives as FA-Sulf (7c) equivalents. CA- (5a) and DHCA (6a) metabolites were 
quantified using the 3´ conjugated metabolites, respectively. 
 
7.3.1.5.3 Quantification of QA 
For the quantification of QA (10a) in urine the same stable isotope dilution analysis as 
for coffee was used (see chapter 7.3.1.4.2). Urine sample preparation was performed in 
duplicates. After unfreezing in a water bath with + 37°C for short, samples were cooled 
down to room temperature and diluted with bidist. H2O (20 fold maximum dilution for the 
high trial). Consequently 40 µL of this dilution were mixed up with 56 µL of the internal 
standard (U-13C-D-(-)-QA, 200 ng*L-1). To precipitate proteins 16 µL of an acidified 
methanolic solution (0.25 M HCl in MeOH) were added to this mixture followed by a 
centrifugation step (+ 4°C, 30 min, 14,000 x g). Samples were quantified with the HPLC 
system IV, conditions Ic (see chapter 7.2.2) with 20 µL of the received supernatant as 
injection volume. 
 
7.3.1.5.4 Creatinine determination 
Creatinine was measured spectrophotometrically as a colored complex (Knud, 1972). 
For this, duplicate 400 µL aliquots of diluted urine (normally 1:4) were added to 
1,400 µL picric acid solution (9.0 g NaCl, 1.31 g picric acid in 1 L H2O) and mixed in a 
cuvette. The reaction was started with the addition of 400 µL sodium hydroxide solution 
(1 M). Absorption was measured at 510 nm with a UV-VIS spectrophotometer after 
10 and 60 sec to obtain: 
( ) ( ).sec10.sec60 EEE −=∆  
 
This difference value and an equally established calibration curve were used to 
calculate the creatinine concentration. The calibration curve was generated with six 
standard solutions prepared in duplicate with creatinine concentrations ranging from 
34.5 µM to 1105 µM.  
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7.3.1.6 Ileal fluids 
7.3.1.6.1 Preparation of ileal fluid samples 
After freeze drying of the ileal bags, the dry weight was determined and samples were 
carefully homogenized. Aliquots (n = 3) of at least 20 mg were extracted in an 
Eppendorf tube with 1 mL (solution I). Samples were vortexed shortly at 2,700 min-1 and 
sonicated for 5 min. Subsequently, the samples were centrifuged (5 min., + 4°C, 
10,000 x g) and then the supernatant was decanted into a clean Eppendorf tube. The 
pellet was again re-extracted twice. The received supernatants were combined, filtered 
through a membrane filter (0.45 µm PVDF). For HPLC-DAD analysis these ileal fluid 
extract was further diluted (5 up to 20-fold) with solution I. Extraction efficiencies were 
checked by spiking a CGA-free, re-dissolved ileal extract with a physiological 
concentration of 5-CQA (1d), CA (5a) and FA (7a) and treated as described above. 
Recovery rates were determined > 86%. 
 
7.3.1.6.2 Analysis of CGA and metabolites 
7.3.1.6.2.1 Identification 
Identification of CGA and metabolites was achieved as described in chapter 7.3.1.4.1.2 
with HPLC-DAD and chapter 7.3.1.5.2.2 with HPLC-MS/MS. 
 
7.3.1.6.2.2 Quantification of CGA 
The obtained extraction solution (see chapter 7.3.1.6.1) was diluted 20 times (solution I) 
and 30 µL of the IS (3,4,5-trimethoxyphenylacetic acid (ISb), 226.23 mg*L-1) was added 
to 300 µL of this solution. CGA determination was performed with the HPLC system I 
conditions Ia and Ib (see chapter 7.3.1.4.1.1 and 7.2.1). 
 
7.3.1.6.2.3 Quantification of CGA metabolites 
7.3.1.6.2.3.1 Sample Preparation 
In order to clean up and concentrate ileal samples, a SPE method using a phenylic 
phase (Varian: bond elut PH. 500 mg) was used for sample preparation. The ethanolic 
part of the resulting ileal extraction solution (1.0 mL, as described above, see chapter 
7.3.1.6.1) was removed in a vacuum centrifuge and subsequently redissolved with 
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water to 1.0 mL (pH 1.5, acidified with H3PO4). This solution was used for SPE 
extraction as described in chapter 7.3.1.5.2. Residues were redissolved with 200 µL 
solution I. To 100 µL of this sample, 10 µL of the IS (o-coumaric acid (ISa), 61 µM) was 
added and mixed well. Extraction efficiencies were determined > 88% with the test 
compounds 5-CQA (1d) and 5-FQA (3c). 
 
7.3.1.6.2.3.2 Calibration 
Calibration curves were generated using a CGA free ileal extract, spiked with 
references (see Table 7-5, maximal concentration range 6.2 mg*L-1 to 1.3 µg*L-1). 
These calibrations were prepared in duplicate as described above and analyzed in 
duplicate by HPLC system IV conditions 1b (see chapter 7.2.2) in the multiple ion mode. 
The correlation coefficients were > R2 = 0.99. LOQ were from 0.7 to 6.2 ng and LOD 
from 0.2 to 1.9 ng (see Table 7-5). 
 
Table 7-5: Limit of detection (LOD) and limit of quantification (LOQ) of the HPLC-MS 
multiple ion method used for detection of CGA metabolites in ileal fluid samples 
(see chapter 7.3.1.6.2.3.3). 
Compound  LOD LOQ 
   [ng]  [ng] 
   Ferulic acid 0.3 1.2 
Ferulic acid-4´-O-Sulf 0.6 2.0 
Isoferuloylquinic acid-3´-O-GlucA 0.6 2.0 
Dihydroferulic acid-4´-O-Sulf 0.4 1.3 
Caffeic acid-3´-O-Sulf 1.2 4.1 
Caffeic acid-3´-O-GlucA 0.5 1.5 
Dihydrocaffeic acid 1.9 6.2 
Dihydrocaffeic acid-3´-O-Sulf 1.3 4.4 
5-O-Caffeoylquinic acid 0.5 1.7 
3-O-Feruloylquinic acid 0.2 0.7 
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7.3.1.6.2.3.3 Quantification 
Determination was semi-quantitative, since compounds were quantified based on 
calibration curves of the available references equally as described in chapter 
7.3.1.5.2.2. 
 
7.3.1.6.3 Quantification of QA 
For the quantification of QA (10a) in ileal fluid the extraction solution (see chapter 
7.3.1.6.1) was diluted with water (5 up to 400 fold). To 50 µL of this solution 50 µL of the 
isotopically labeled standard U-13C-D-(-)-QA (200 ng*L-1) was added and mixed up well. 
For quantification the HPLC system IV, conditions Ic (see chapter 7.2.2) was used. 
 
7.3.1.7 Plasma analysis 
7.3.1.7.1 Preparation of blood samples 
Blood samples were collected directly before (time point 0 h) and 0.5, 1, 2, 4, 6 and 8 
hours after coffee consumption. Blood samples were collected in 9 mL EDTA monovette 
tubes and were directly centrifuged (3,500 x g, 10 min, + 4°C). To 0.5 mL supernatant 
(plasma) 20 µL of a fresh 'storage solution’ (0.4 M NaH2PO4 buffer containing 20% 
ascorbic acid and 0.1% EDTA) was added and stored at - 80°C. Depending on the 
blood volume at least three aliquots were obtained. 
Unfortunately due to five unsuccessful attempts for placing the needle correctly, two 
volunteers withdrew their permission for blood collections (Ileo 3 at the HIGH trial and 
Ileo 4 at the MEDIUM trial). Additionally, the needle of Ileo 1 was blocked after five 
hours at the MEDIUM trial. Here data for time points six and eight are missing. 
 
7.3.1.7.2 Analysis of CGA and metabolites 
7.3.1.7.2.1 Quantification of CGA an metabolites 
For measurement of CGA, duplicate samples of 100 µL plasma were spiked with an 
isotopically labeled IS (5 µL; 1 µM labeled d13C2-caffeic acid) and protein was 
precipitated (500 µL ethanol) by centrifugation (5 min, + 4°C, 17,500 x g). The residue 
was further twice re-extracted and the combined supernatants dried under N2. After 
evaporation, the residue was incubated at + 37°C for 60 min with β-glucuronidase 
(1,000 units) and sulfatase (60 units) (in pH 5.5, 0.1 M sodium acetate). After adding 
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10 µL perchloric acid (6 M), CGA was extracted twice (30 min at + 4°C) with ACN. The 
supernatants were adjusted to pH 7 with potassium carbonate (0.75 M; 40 µL), pooled, 
dried and re-suspended (water with 1% acetic acid, 5% ACN), and then samples 
(50 µL) were analyzed by HPLC mass spectrometry.  
The selective determination of each target compound was performed by acquisition of 
characteristic product ions of the precursor ion in the selected reaction monitoring 
(SRM) mode with HPLC system V, conditions 1a (see chapter 7.2.2). 
 
7.3.1.7.2.2 Calibration 
Calibration curves were generated for each volunteer and trial by spiking blank plasma 
sample (0 hour collection point) with the labeled CA as IS and a stock solution including 
the compounds described in chapter 7.2.2 with HPLC system V, conditions 1a. The 
concentration range was 10 to 2,400 nM, except for diCQA, which was 30 to 2,400 nM. 
The extracted spiked plasma samples at different known concentrations were used to 
build the calibration curve that corrected at the same time the extraction errors (by ratio 
to IS), the matrix effects and the extraction recoveries. The LOD was ranged from 1.2 to 
13.6 nM, but was set to ~10 nM for all the compounds, except for diCQA where LOQ 
was set to 30 nM.  
Unfortunately the individual calibration curve of ileo 5 at the study trial LOW could not 
be used for quantification. As blank plasma samples were limited CGA plasma 
concentrations of ileo 5 after LOW coffee dose consumption could not be determined. 
 
7.3.1.7.3 Analysis of QA 
For the measurement of QA (10a) a stable isotope dilution analysis was used (see 
chapter 7.3.1.4.2). A volume of 120 µL plasma was mixed with 30 µL of the IS 13C-QA 
(5.1 µM; solution I) and deproteinization with 50 µL of acidified EtOH (0.25 M HCl) were 
added. Samples were vortexed (1 min at 1,600 min-1) and kept at + 4°C for 30 min. 
After these samples were vortexed briefly and centrifuged (14,000 x g at + 4°C for 30 
min). The supernatants were filtered (0.45 µM PVDF), and the extraction was done in 
duplicates. For Quantification 70 µL of each prepared sample was used as injection 
volume and measured with HPLC-system IV conditions Id (see chapter 7.2.2). MS was 
run in the multiple reaction monitoring mode (MRM) and a MRM transition from the 
deprotonated molecular ion [M-H]- m/z 191 to m/z 93 was used as quantifier. Identity of 
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QA in plasma was confirmed by comparison of the retention time and fragmentation 
pattern with a commercial reference. MRM transition used for quantification of the 
isotopically labelled standard U-13C-D-(-)-QA was m/z 198 to m/z 99. 
 
7.3.1.7.3.1 Calibration 
Calibration curve was generated with reference solutions (with concentrations ranging 
from 0.02 µM to 5.2 µM) prepared in triplicates as described for sample extraction (see 
chapter 7.3.1.7.3). LOQ was 273 ng and an LOD 91 ng absolute. 
 
7.3.2 Individual ex vivo structure-absorption relationship (SAR) of coffee CGA and QA 
in the pig jejunal Ussing model  
7.3.2.1 Study design 
The ex vivo transport experiments were performed with pig jejunum, provided by a local 
slaughterhouse (Kuhn & Bolander GmbH, Otterberg, Germany and Haerting GmbH, 
Kaiserslautern, Germany). German landrace pigs were used; both male and female, 
aged between 5 and 6 months, of an average body weight of 100 kg. After slaughtering 
the pigs, the GIT was removed and a 50 cm section of the jejunum was excised 10 cm 
below the ligament of Treitz. The jejunum was stored in a cooled and carbogen gas–
saturated (oxygenated) HBSS buffer and transported immediately to the laboratory. 
 
7.3.2.2 Preparation of the tissue (jejunal epithelium and lamina propria) 
A 10 cm section was then excised and a longitudinal incision made along the 
mesenteric fixation. A cleaning step with HBSS followed in order to remove chymus 
residues. The jejunum was fixed in place with needles and the jejunal epithelium and 
lamina propria were separated carefully from the lamina muscularis mucosae and tela 
submucosa by slide stripping. The separation was monitored with histological 
examinations. Subsequently, the tissue (jejunal epithelium with lamina propria) was 
secured inside the Ussing chamber (K. Mußler, Aachen, Germany; software, Clamp 
2.14; area, 0.78 cm2) and the two chambers were filled with the HBSS buffer (5.0 mL). 
The tissue was used for incubation experiment if reaching a tissue conductance form 9 
to 22 ms*cm-2.  
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7.3.2.3 Incubation transfer experiments 
Physiological conditions were simulated throughout the incubation. The HBSS buffer 
contained glucose (1.0 g*L-1), a physiological salt concentration, and was aerated with 
carbogen gas (95% O2 / 5% CO2) at a temperature of + 37°C. Moistening of carbogen 
gas was achieved by a washing flask. On the mucosal side the HBSS buffer was 
adjusted to the physiological pH of 6.0 with 1 M HCl (Fallingborg, 1999), whereas on the 
serosal side a pH of 7.4 was used (stabilized with 60 mg NaHCO3). The incubation 
experiments were started after a 15 min equilibration period; by adding a DMSO stock 
solution of CGA (2.5 µL, 40 mM stock solution for a final concentration of 20 µM) at the 
mucosal side for absorption experiments and at the serosal side for secretion 
experiments. The final DMSO concentration in the incubation buffer was 0.05%. CGA 
were added to a final concentration of 20 µM on the corresponding side. Approx. 200 µL 
aliquots (HBSS) were taken from both sides each hour during the entire experiment 
(4 hours). Aliquots were immediately stabilized with 1 M HCl and stored at - 80°C. Each 
incubation experiment with a single CGA or different concentrations were performed at 
least in four Ussing chambers, with the jejunum of two different animals. 
 
7.3.2.3.1 Dose-response incubation experiments 
Dose-response experiments were conducted on 5-CQA (1d) in a final concentration 
range of 0.02 to 3.5 µM in the compartments. The transepithelial flux (nmol*h-1*cm-2) 
was calculated on the basis of the serosal 5-CQA concentration 2 h after the experiment 
had started. Aliquots and tissues were taken and stored as described above. Linearity 
of the transepithelial flux (nmol*h-1*cm-2) plotted against concentration (mM) was 
checked by means of the coefficient of determination (R2) (see Figure 4-24, Results).  
 
7.3.2.3.2 Inhibition of transfer with NaN3  
Inhibition of a potential active transport of CGAs via ABC-transporters was investigated 
with NaN3. The influence of NaN3 on absorption or secretion was determined by co-
incubating 10 mM NaN3 in both chambers with 20 µM 5-CQA. Aliquots and tissues were 
taken and stored as described above.  
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7.3.2.4 CGA analysis of incubation buffer 
The incubation-buffer samples (200 µL) were thawed quickly, membrane filtered 
([PVDF, 0.45 µm), and used for HPLC–DAD analysis. For HPLC analysis, 15 µL of the 
internal standard (IS), 3,4,5-trimethoxyphenylacetic acid (226.2 mg L−1), was added to 
150 µL of the received solution. The mixture was analyzed in duplicate with HPLC-DAD 
at 320 nm. 
CA (5a), 5-CQA (1d), 5-FQA (3c) and 4,5-diCQA (4c) were analyzed with HPLC system 
I condition 1a (see chapter 7.3.1.4.1 and 7.2.1). 
 
The compounds 4-FQA (3b), 3-FQA (3a), 3,4-diCQA (4a) and 3,5-diCQA (4b) were 
analyzed with HPLC system II, condition 1a (see chapter 7.2.1). The absolute LOQ was 
calculated in the range 0.61 to 0.72 ng and an LOD in the range 0.15 to 0.18 ng. 
Quantification was based on the calibration curves of references. For FQA, the 
3-feruloylquinic acid and for diCQA, the 3,5-diCQA were used for quantification and the 
results are presented as 3-FQA and 3,5-diCQA equivalents. 
 
7.3.2.5 QA analysis in incubation buffer 
Determination of QA (10a) was done with 50 µL filtered buffer mixed up with 50 µL of 
isotopically labeled standard U-13C-D-(-)-QA equal to chapter 7.3.1.4.2. 
 
7.3.2.6 Extraction and analysis of tissue (jejunal epithelium and lamina propria) 
After the incubation experiment, the remaining tissue was exhaustively washed and 
covered with 1.5 mL buffer solution (0.4 M Na2HPO4, pH 4). Samples were briefly 
vortexed and homogenized with a Potter. To precipitate proteins, 1.0 mL of the 
generated suspension was mixed with 200 µL of an acidified ethanol solution 
(EtOH/formic acid, 96.5% / 3.5%, v/v). Samples were centrifuged (10 min, 16,500 x g, 
+ 4°C) and the supernatants were filtered (PVDF membrane, 0.45 µM) and used for 
HPLC-DAD analysis. CGA analysis was performed as described in chapter 7.3.2.4. and 
QA analysis was performed as described in chapter 7.3.2.5. 
 
7.3.2.7 Identification of CGA metabolites 
Identification of metabolites was performed as described in chapter 7.3.1.5.2.2.  
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7.3.3 Identification of the transport proteins MDR 1 and MPR 2 in the pig jejunum 
For tissue analysis, samples were thawed in 1.5 mL homogenization buffer (6.057 g Tris 
and 146.12 mg EDTA in 500 mL bidist. H2O, pH 7.6) and 25 µL protease inhibitor 
cocktail. Samples were homogenized, centrifuged (15 min at + 4°C and 6,500 x g) and 
the supernatant were centrifuged (30 min at + 4°C and 100,000 x g). The received 
pellets were re-suspended as per the manufacturer’s instructions and the protein 
content was determined with the bicinchoninic acid assay (Kit Uptima, KMF 
Laborchemie, Darmstadt, Germany). The suspensions were diluted with loading buffer 
[50 mL of 0.5 M Tris/HCl (pH 6.8), 1.24 g SDS, 40 mL glycerin, 0.16 g 
bromophenolblue, and 5 mL mercaptoethanol in 100 mL bidist. H2O], resulting in a final 
protein content of 14 to 40 µg per 15 µL sample. After 15 min at room temperature (RT), 
lysis was performed (+ 95°C, 5 min) and samples were centrifuged (15 min at RT and 
13,000 rpm). The samples (15 µL) were loaded in the gel wells [stacking gel: 2.54 mL 
H2O, 1.23 mL Tris (1.5 M, pH 8.8), 1.15 mL acrylamide (30%), 49.2 μL SDS (10%), 
24.6 μL APS (10%), and 2.46 μL TEMED; separation gel: 1.1 mL H2O, 0.5 mL Tris 
(0.5 M, pH 6.8), 0.25 mL acrylamide (30%), 20 μL SDS (10%), 20 μL APS (10%), and 
2 μL TEMED] and molecular weight marker (10 µL) was loaded in the first lane of every 
gel. Proteins were separated by gel electrophoresis [100 V, 1 to 2 h] and then 
transferred to a polyvinylidene fluoride membrane. This was performed in a semi-dry 
blot apparatus at 45 mA for 90 min (Hoefer TE 77, Amersham Biosciences, Muenchen, 
Germany). Membranes were blocked by storing for 1 h in blocking buffer (100 mL TBS-
T, 5% milk powder) and then incubated overnight at + 4°C with the primary antibodies, 
mAb C219, mAb M2 III-6, and mouse mAb (each diluted 200-fold with TBS-T). After 
washing twice with TBS-T, the membranes were incubated for 1 h with the secondary 
antibody, goat anti-mouse IgG-HRP (diluted 5,000-fold with TBS-T). Bands were 
visualized by stirring in a detection solution [10 mL A (50 mg luminol in 200 mL 0.1 M 
Tris/HCl), 1 mL B (11 mg p-coumaric acid in 10 mL DMSO, and 100 µL C (50 µL H2O2 
in 1 mL Tris/HCl)] and using a Lumi-Imager (Lumi-Analyst 3.1, Roche, Mannheim, 
Germany). 
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7.3.4 Stability measurements of CGA in ileal fluid 
7.3.4.1 Study design and volunteers 
In order to determine the stability of CGA in the ileal fluids we performed an ex vivo 
incubation model. Therefore, we sampled ileal effluents and incubated it with instant 
coffee (same as in the intervention study) in the anaerobic chamber. The experiment 
lasted 8 hours and was performed under physiological conditions with a coffee 
concentration (132.2 µM CGA) that could easily be reached after coffee consumption.  
CGA free ileal effluents were provided by five ileostomist (7.3.1.2); which were 
remaining in CGA-free diet 48 hours before sampling. The ileal fluids were stored by 
volunteers in gas proof boxes containing an anaerobic atmosphere created by Anaero 
GenTM under cooled conditions and were in this kind transported to the laboratory. 
 
7.3.4.2 Incubation buffer 
Ex vivo simulation of CGA stability in ileal effluent was performed with an 
carbonate-phosphate buffer according to Lebet et al. (Lebet et al., 1998). Following the 
instructions in Table 7-6 the trace element solution was prepared first with bidist. water 
and 10 mL of it was added to the carbonate-posphate buffer (Table 7-6) in 1 L. The pH 
of buffer was adjusted to 6.3 (1 M HCl) and oxygen was removed in a first step by 
heating in a water bath (30 min at + 80°C).  
 
Table 7-6: Composition of the anaerobic incubation buffer (carbonate-phosphate buffer) 
in bidist. water according to (Lebet et al., 1998). 
Carbonate-phosphate buffer  Trace element solution 
Compound Unit  Compound Unit 
     
NaHCO3 9.24 g*L-1  FeSO4 x 7 H2O  368.0 mg*100 mL-1 
Na2HPO4 2.83 g*L-1  MnSO4 x 1 H2O  115.9 mg*100 mL-1 
NaCl 0.47 g*L-1  ZnSO4 x 7 H2O  44.0 mg*100 mL-1 
KCl 0.45 g*L-1  CoCl2 x 6 H2O  12.0 mg*100 mL-1 
Urea 0.40 g*L-1  NiCl2  10.0 mg*100 mL-1 
CaCl2 x 2 H2O  0.07 g*L-1  CuSO4 x 5 H2O  9.8 mg*100 mL-1 
Na2SO4, waterfree  0.10 g*L-1  Mo7(NH4)6O24 x 4 H2O 1.7 mg*100 mL-1 
MgCl2 x 6 H2O  0.10 g*L-1    
Trace element solution 10 mL*L-1    
Resazurin (1 mg*mL-1) 1 mL*L-1    
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After cooling to room temperature 5 mL of cysteine hydrochloride (0.1 g*mL-1) was 
added and remaining oxygen was removed in a second step by gassing with helium 
until a color change from blue to a weak pink was observed (approx. 3 hours). 
 
7.3.4.3 Incubation of CGA 
The following steps were performed in an anaerobic chamber (Figure 7-4) continuously 
flushed with N2 : CO2 gas mixture (80/20, v/v) according to the work of Knaup et al. 
2007 (Knaup et al., 2007).  
 
 
Figure 7-4: Anaerobic chamber for ex vivo incubation experiments.  
 
The incubation experiments were performed in duplicates for each volunteer. The pH 
values of the ileal fluids were measured and the ileal fluids were mixed with the same 
volume of the pre-gassed anaerobic incubation buffer. Coarse particles of this mixture 
were removed by filtration using a riddle. The filtrate was used as inoculum. For the 
incubation aliquots of 1.950 µL inoculum were added to the incubation vessels 
containing a 50 µL aliquot of the coffee DMSO stock solution (800 mg of instant coffee 
powder in 20 mL DMSO and 20 mL bidist. water, which corresponds to 104.7 µM CQA; 
12.0 µM FQA; 6.3 µM CQL; 8.4 µM diCQA; 0.9 µM CA). Vessels were mixed up well, 
closed and incubated at + 37°C for 4 min, 2, 4, 6 and 8 hours in a drying oven. The 
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incubation was stopped by adding 10 µL 1 M HCl, vortexed and was subsequently 
placed in liquid nitrogen. In order to determine the influence of ileal fluid on coffee CGA 
stability, a further stability study was performed according to the procedure described 
above using only the anaerobic carbonate-phosphate buffer (blank = without ileal fluid).  
As control, a blank value with 50 µL DMSO/bidist. water (1/1, v/v, without coffee CGA) 
and inoculums of each volunteer were prepared and subjected to the procedure 
described above. 
 
7.3.4.4 Sample extraction and analysis 
After freeze drying the inoculum and blank samples were extracted. For this 1.2 mL 
EtOH (with 1% formic acid) was added to the incubation vessels, vortexed for short 
(2,700 min-1) and sonicated for 5 min. Subsequently, samples were centrifuged (5 min, 
+ 4°C, 5,000 x rpm) and then the supernatants were decanted into a clean Eppendorf 
tube. The pellets were re-extracted three times. The received supernatants were 
combined, concentrated in a vacuum centrifuge, subsequently lyophilized to dryness 
and stored at – 80°C prior to analysis. Recovery rate was determined with 93% for the 
test compound 5-CQA (5a) in a spiked CGA-free ileal fluid. Nevertheless, the overall 
recovery of CGA at time point 0 h in the incubation experiment was 22.8% when 
incubated with inoculum and 58.4% when incubated with buffer solution. 
 
7.3.4.5 Quantification of CGA 
The dried extract was redissolved in 1 mL solution I, filtered through a membrane filter 
(0.45 µm PVDF) and analyzed as described in 7.3.1.4.1. 
 
7.3.4.6 Enzyme activity of ileal fluid 
To determine enzymatic activities of ileostomy fluids, the semi-quantitative 
micro-method Api® ZYM (BioMeriéux, Marcy-l`Etoile (France)) was performed in 
triplicates for each volunteer. Therefore, volunteers (who were still remaining in 
CGA-free diet) additionally collected CGA free ileostomy fluid 48 hours after coffee 
consumption.  
 
The ileal fluids were stored by volunteers in gas tight boxes containing an anaerobic 
atmosphere created by AnaeroGenTM under cooled conditions and in this way 
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transported to the laboratory. All following steps were performed in an anaerobic 
chamber aerated with ALIGAL gas (CO2/ N2, 80/20, v/v). Preparation of the inoculums 
were performed by opening the ileal bags and mixing 3.0 mL of ileal fluid with 6.0 mL 
sterile water. After vortexing for short and centrifuging (10 min, 3,500 x g), the 
supernatants were used as inoculum. The micro-wells of the enzymatic test stripes were 
inoculated with 65 µL inoculum or 65 µL sterile water as control. Subsequently, the 
samples were proofed and incubated for 4 hours at + 37°C. At the end of incubation one 
drop of ZYM A reagent and one drop of ZYM B reagent were added to each micro-well 
and after five minutes test stripes were put under a powerful light source (500 W) for 
about 20 sec with the bulb placed approximately 10 cm above it. Metabolic products 
formed during incubation time were detected through colored reactions compared to 
control incubations.  
 
7.3.4.7 Determination of microflora in ileal fluids 
The microflora content was determined with the Enterosan-test technique performed 
with ileal fluid through the L&S AG (Bad Bocklet, Germany).  
Therefore, ileal fluids were sampled on study day two immediately before coffee 
consumption (sampling point 0 hours) and were stored under cooled conditions (+ 4°C) 
prior to analysis at the L&S laboratory. 
 
7.3.5 Synthesis and isolation of single CGA 
7.3.5.1 Preparation of 3- and 4-caffeoylquinic acid 
The preparation of 3-CQA (1b) and 4-CQA (1c) was achieved by interesterification of 
5-CQA (1d) using the method of Trugo and Macrae (Trugo and Macrae, 1984a). A 
10 g*L-1 solution of 5-CQA in water was compounded (200 mg 5-CQA in 20 mL H2O) 
and the pH was adjusted to 8 with 4 M NH3. This solution was heated for 30 min to 
+ 100°C and subsequently cooled down to room temperature. Interesterification was 
stopped by adding 4 M HCl in order to obtain a pH of 3. The formed CQA mixture 
(3-CQA, 4-CQA, 5-CQA) was separated using HPLC system III condition 1a (see 
chapter 7.2.1). Due to obtain pure solid compounds eluates with an individual CQA 
were combined and lyophilisized. The Purity of the received 3-CQA (99%) and 4-CQA 
(95%) were examined with HPLC system III condition 1a. Identification was performed 
with HPLC system IV conditions 1a (see chapter 7.2.2).  
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7.3.5.2 Preparation of 3- and 4-caffeoylquinide 
A freeze dried mixture of 3-CQA, 4-CQA and 5-CQA was generated (Trugo and 
Macrae, 1984a). This mixture was used to achieve quinides according to the published 
protocol of (Rúveda et al., 1964).  
The CQA mixture (200 mg) was dissolved in 150 mL acetic acid (water free) and were 
constantly stirred at a temperature of + 100°C for 6 hours. Acetic acid was almost 
completely removed and 7 mL of solution I was added. Isolation was carried out by 
HPLC system I condition 1c (see chapter 7.2.1). Identification of the obtained pure 
compounds (purity > 95%) was performed by comparison of the fragmentation pattern 
with HPLC system IV conditions 1a (see chapter 7.2.2) and literature data. Further NMR 
spectroscopy data was used for differentiating 3-CQL (2a) and 4-CQL (2b). For this, 
compounds were dissolved in deuterated methanol (CD3OD) and NMR spectra were 
obtained. In Figure 7-5 the main NMR spectra characteristics of 3-CQL and 4-CQL are 
shown. A Bruker AMX – 600 apparatus with WIN – NMR v6.0 software was used. 
  
 
Figure 7-5: Detailed view of the main characteristics of a 1H-NMR spectra of 
3-caffeoylquinide (A) and 4-caffeoylquinide (B) in deuterated methanol (CD3OD). 
Chemical structure = quinide, R = caffeic acid moiety. For details see Table 7-7.  
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The achieved 1H-NMR data for 3-CQL (2a) and 4-CQL (2b) (Table 7-7) were in 
accordance with literature data (Bennat et al., 1994). 
 
Table 7-7: 1H-NMR data of 3-caffeoylquinide (3-CQL) and 4-caffeoylquinde (4-CQL) in 
deuterated methanol (CD3OD) at 600 MHz. The reference signals for 1H were 
δ = 3.35 ppm for CHD2OD and δ = 4.8 ppm for HDO. 
Position* 3-CQL 4-CQL 
   C-2-H ax 2.12 (dd) 2.00 (dd) 
C-2-H eq 2.19 (m) 2.19 (m) 
C-3-H ax 4.95 (ddd) 4.01 (ddd) 
C-4-H eq 4.31 (dd) 5.33 (dd) 
C-5-H ax 4.77 (dd) 4.83 (dd) 
C-6-H ax 2.59 (d) 2.43 (m) 
C-6-H eq 2.32 (ddd) 2.43 (m) 
C-2'-H 7.11 (d) 7.10 (d) 
C-5'-H 6.84 (d) 6.82 (d) 
C-6'-H 6.99 (dd) 7.01 (dd) 
C-7'-H 7.65 (d) 7.67 (d) 
C-8'-H 6.34 (d) 6.39 (d) 
   *see Figure 7-5. 
 
7.3.6 Statistics 
Each experiment was repeated multiple times and results are expressed as means 
± SD. The reported n values represented the number of independent repeated 
experiments. Excel 2007 (Microsoft, Unterschleißheim, Germany) was used for 
statistical evaluations (two-sample T-test of significance) and differences were 
considered significantly with *p ≤ 0.05, **p ≤ 0.01 or ***p ≤ 0.001. Data achieved in the 
Ussing chamber experiment was additionally analysed with Nalimov test for outlier 
detection. 
Deviation was calculated on the basis of the following formula: 
𝑆𝑆𝑆𝑆𝑆 = �∑(𝑥 − ?̅?)2
𝑛
 
Where x is the sample mean average and n is the sample size.  
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8 Overview of chemical structures 
Table 8-1: Naming of chemical structures and numbering of chlorogenic acids (CGA), 
its metabolites and D-(-)-QA. 
No Substance No Substance 
    
 
Caffeoylquinic acids 
 
diCaffeoylquinic acids 
1a 1-O-Caffeoylquinic acid 4a 3,4-O-diCaffeoylquinic acid 
1b 3-O-Caffeoylquinic acid 4b 3,5-O-diCaffeoylquinic acid 
1c 4-O-Caffeoylquinic acid 4c 4,5-O-diCaffeoylquinic acid 
1d 5-O-Caffeoylquinic acid 
  1e 3-O-Caffeoylquinic acid-3´-O-GlucA 
 
Hydroxycinnamic acids 
1f 4-O-Caffeoylquinic acid-3´-O-GlucA 5a Caffeic acid 
1g 3-O-Caffeoylquinic acid-3´-O-Sulf 5b Caffeic acid-4´-O-GlucA 
1h 4-O-Caffeoylquinic acid-3´-O-Sulf 5c Caffeic acid-3´-O-GlucA 
1i 5-O-Caffeoylquinic acid-3´-O-Sulf 5d Caffeic acid-4´-O-Sulf 
  
5e Caffeic acid-3´-O-Sulf 
 
Caffeoylquinides 6a Dihydrocaffeic acid 
2a 3-O-Caffeolyquinide 6b Dihydrocaffeic acid-3´-O-GlucA 
2b 4-O-Caffeoylquinide 6c Dihydrocaffeic acid-4´-O-Sulf 
2c 3-O-Caffeolyquinide-3´-O-GlucA 6d Dihydrocaffeic acid-3´-O-Sulf 
2d 4-O-Caffeolyquinide-3´-O-GlucA 7a Ferulic acid 
2e 3-O-Caffeoylquinide-3´-O-Sulf 7b Ferulic acid-4´-O-GlucA 
2f 4-O-Caffeoylquinide-3´-O-Sulf 7c Ferulic acid-4´-O-Sulf 
  
7d Feruloylglycine 
 
Iso-/ Feruloylquinic acids 7e Isoferulic acid-3´-O-GlucA 
3a 3-O-Feruloylquinic acid 7f Isoferulic acid-3´-O-Sulf 
3b 4-O-Feruloylquinic acid 7g Isoferulic acid 
3c 5-O-Feruloylquinic acid 8a Dihydroferulic acid -4´-O-GlucA 
3d 3-O-Feruloylquinic acid-4´-O-GlucA 8b Dihydroferulic acid-4´-O-Sulf 
3e 4-O-Feruloylquinic acid-4´-O-GlucA 8c Dihydroferulic acid 
3f 5-O-Feruloylquinic acid-4´-O-GlucA 9a Dimethoxycaffeic acid 
3g 3-O-Feruloylquinic acid-4´-O-Sulf 9b Dimethoxydihydrocaffeic acid 
3h 4-O-Feruloylquinic acid-4´-O-Sulf 10a D-(-)-Quinic acid 
3i 3-O-Isoferuloylquinic acid-3´-O-GlucA 
  3j 4-O-Isoferuloylquinic acid-3´-O-GlucA 
 
Standards 
  
ISa o-Coumaric acid 
  
ISb 3,4,5-trans-Trimethoxyphenylacetic acid 
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Table 10-1: Anthropometric data achieved from each individual ileostomist (Ileo 1 to 
Ileo 5) participating in the human coffee intervention studies. 
  Ileo 1 Ileo 2 Ileo 3 Ileo 4 Ileo 5 
      Age 40 47 40 36 42 
Size (cm) 163 158 166 175 170 
Bodyweight (kg) 65.0 73.5 82.7 79.5 79.0 
Bodyfat (%) * 29.1 35.6 36.4 33.1 35.2 
Bodyfat (kg) * 18.9 26.2 30.1 26.3 27.8 
Body Mass Index (BMI)  24.5 29.4 30.0 26.0 27.3 
Fat free body mass (kg) * 46.1 47.3 52.6 53.2 51.2 
Fat free body mass (%) * 70.9 64.4 63.6 66.9 64.8 
Water content (L) * 33.7 34.6 38.5 38.9 37.5 
Water content (%) * 51.8 47.1 46.6 48.9 47.5 
Basic metabolism (kcal) * 1351 1324 1440 1483 1420 
 
 
    Primary disease Morbus 
Crohn 
Morbus 
Crohn 
Morbus 
Crohn 
Morbus 
Crohn 
Ulcerative 
Colitis  
Time point of colectomy 2002 1986 2001 2002 1996 
      *measured with bioimpedance instrument (Maltron BodyFat-Instrument BF-906, Gauting 
(Germany)) 
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Figure 10-1: HPLC-MS molecular ion [M-H]- chromatograms of chlorogenic acids and 
corresponding metabolites detected in urine and ileal fluid of an ileostomist 2 h 
after coffee consumption. Internal standard a (ISa) – o-coumaric acid. HPLC 
system IV, conditions 1b (see chapter 7.2.2). For identification of peaks and 
peak numbers see Table 8-1, Overview of Chemical Structures, (* conjugation 
position was suspected at 3´). 
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Table 10-2: Recovery rates (in % of the initial measured concentration at time point 
0 h) of CGA from instant coffee 8 hours after ex vivo incubation with inoculum 
(ileal fluid/buffer, 1/1, v/v, n = 5) or buffer (n = 2) with the anaerobic chamber 
indicating interesterification and degradation during incubation (data 
expressed as mean values ± SD). Details see chapter 7.3.4. 
Compound Inoculum Buffer 
   
1-O-Caffeoylquinic acid 48 ± 31 43 ± 11 
3-O-Caffeoylquinic acid 93 ± 17 47 ± 16 
4-O-Caffeoylquinic acid 89 ± 11 41 ± 11 
5-O-Caffeoylquinic acid 74 ± 18 35 ± 10 
3-O-Caffeolyquinide 44 ± 20 13 ± 7 
4-O-Caffeoylquinide 56 ± 30 8 ± 6 
3-O-Feruloylquinic acid 107 ± 25 107 ± 11 
4-O-Feruloylquinic acid 97 ± 27 76 ± 58 
5-O-Feruloylquinic acid 68 ± 14 11 ± 11 
3,4-O-diCaffeoylquinic acid 97 ± 10 17 ± 12 
3,5-O-diCaffeoylquinic acid 86 ± 11 19 ± 12 
4,5-O-diCaffeoylquinic acid 94 ± 10 16 ± 7 
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Table 10-3: Enzyme activity of ileal fluid of each ileostomist (Ileo 1 to Ileo 5) 
determined versus bidist. water (blank) using Api®-ZYM test (BioMeriéux); n = 
3. 
No.  Enzyme assayed for: Ileo 1 Ileo 2 Ileo 3 Ileo 4 Ileo 5 Blank 
        1 Control - - - - - - 
2 Alkaline phosphatase        + + + + + - 
3 Esterase (C4) - (+) - + - - 
4 Esterase Lipase (C8) + + + + (+) - 
5 Lipase (C14) - - - + - - 
6 Leucine arylamidase + + + + + - 
7 Valine arylamidase + + + + + - 
8 Cystine arylamidase - - - - - - 
9 Trypsin + + + + + - 
10 α-chymotrypsin - - - - - - 
11 Acid phosphatase + + + + + - 
12 Naphtol-AS-BI-phosphohydrolase + + + + + (+) 
13 α-galactosidase - - - - - - 
14 β-galactosidase - + (+) (+) + - 
15 β-glucuronidase (+) (+) + + - - 
16 α-glucosidase + + + + + - 
17 β-glucosidase - - - - - - 
18 N-acetyl-β-glucosaminidase + + + + + - 
19 α-mannosidase - - - - - - 
20 α-fucosidase - - - - - - 
        Legend: + = positive; (+) = weak positive; - = negative 
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Table 10-4: Amounts of microflora determined in ileostomy effluents of each volunteer 
as colony forming unit per g [CfU/g]. 
Microflora Ileo 1 Ileo 2 Ileo 3 Ileo 4 Ileo 5 
      Aerobic 
     E. coli 1x108 1x108 8x107 1x108 1x105 
E. coli-variant --- < 104 < 104 < 104 --- 
E. coli-variant lact.-neg. 1x106 --- --- --- --- 
E. coli-variant haem. --- --- --- --- 6x103 
Klebsiella sp. --- 8x107 --- --- --- 
Proteus sp. --- 7x103 --- --- --- 
Enterobacteriaceae < 104 --- < 104 < 104 < 104 
Enterococcus sp. 1x108 1x106 7x107 6x105 5x105 
Other aerobics < 104 < 104 < 104 < 104 < 104 
      Anaerobic 
     Bacteroides sp. < 108 < 108 1x103 5x103 1x103 
Clostridium sp. < 106 < 106 7x107 < 106 1x108 
Bifidobacterium sp. 1x108 1x106 1x107 1x106 3x107 
Lactobacillus sp. 1x106 6x105 1x106 1x106 1x106 
Other anaerobis < 106 < 106 < 106 < 106 < 106 
      Fungi 
     Candida sp. < 102 1x102 5x102 1x103 4x103 
Geotrichum sp. < 102 < 102 < 102 < 102 < 102 
Other fungi < 102 < 102 < 102 < 102 < 102 
      Analysis was performed by L+S AG, Bad Bocklet (Germany). 
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Table 10-5: Amounts of coffee CGA and QA consumed in each trial in µmol (data 
expressed as mean values ± SD; n = 5) 
Compound HIGH MEDIUM LOW 
    
  1-O-Caffeoylquinic acid 29.2 ± 2.7 14.3 ± 2.2 8.0 ± 0.6 
  3-O-Caffeoylquinic acid 877.5 ± 73.2 451.8 ± 59.2 230.9 ± 21.0 
  4-O-Caffeoylquinic acid 868.8 ± 72.5 431.3 ± 53.1 208.7 ± 17.3 
  5-O-Caffeoylquinic acid 1262.0 ± 106.2 621.5 ± 75.3 298.4 ± 24.1 
Total Caffeoylquinic acids 3037.3 ± 148.0 1519.1 ± 109.6 746.0 ± 36.4 
    
  3-O-Caffeolyquinide 480.6 ± 31.6 218.2 ± 15.7 84.3 ± 12.0 
  4-O-Caffeoylquinide 248.8 ± 20.9 109.7 ± 8.7 40.8 ± 8.1 
Total Caffeoylquinides 729.4 ± 37.8 327.9 ± 18.0 125.1 ± 14.6 
    
  3-O-Feruloylquinic acid 121.6 ± 10.8 63.3 ± 8.3 33.5 ± 3.8 
  4-O-Feruloylquinic acid 121.6 ± 9.5 60.1 ± 7.8 29.5 ± 2.8 
  5-O-Feruloylquinic acid 192.8 ± 15.5 90.5 ± 11.3 45.7 ± 4.3 
Total Feruloylquinic acids 436.0 ± 21.1 213.9 ± 16.1 108.7 ± 6.4 
    
  3,4-O-diCaffeoylquinic acid 112.2 ± 6.8 55.8 ± 5.2 25.7 ± 1.7 
  3,5-O-diCaffeoylquinic acid 77.1 ± 6.4 38.3 ± 3.9 19.4 ± 1.4 
  4,5-O-diCaffeoylquinic acid 105.0 ± 5.7 50.5 ± 4.3 21.6 ± 1.5 
Total diCaffeoylquinic acids 294.3 ± 10.9 144.6 ± 7.8 66.8 ± 2.7 
    
  Caffeic acid 28.1 ± 2.4 13.3 ± 1.2 6.5 ± 0.5 
    
Total chlorogenic acids 4525.0 ± 154.6 2218.8 ± 112.5 1053.1 ± 39.8 
    
  D-(-)-Quinic acid 2546.5 ± 275.9 1372.9 ± 128.9 695.3 ± 62.6 
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Table 10-6: Ileal amounts of CGA and corresponding metabolites excreted after 
ingestion of a HIGH- , MEDIUM- and LOW- coffee dose (in % of initial coffee 
concentration) indicating interesterification during the passage of the 
gastrointestinal tract, ileostomist n = 5 (data expressed as mean values ± SD; 
n = 5). 
Compound HIGH MEDIUM LOW 
    1-O-Caffeoylquinic acid 55.1 ± 8.8 67.9 ± 5.8 63.7 ± 6.9 
3-O-Caffeoylquinic acid* 76.5 ± 8.6 80.0 ± 4.3 81.9 ± 7.4 
4-O-Caffeoylquinic acid* 72.8 ± 8.2 77.8 ± 4.8 81.4 ± 8.9 
5-O-Caffeoylquinic acid* 68.4 ± 8.3 73.4 ± 5.0 76.5 ± 8.7 
    
Caffeolyquinides* 26.7 ± 9.9 19.5 ± 8.4 47.2 ± 17.2 
    
3-O-Feruloylquinic acid* 71.4 ± 10.5 72.5 ± 3.9 74.9 ± 8.5 
4-O-Feruloylquinic acid* 80.4 ± 9.2 71.2 ± 7.5 79.7 ± 8.7 
5-O-Feruloylquinic acid* 57.5 ± 8.1 67.6 ± 5.4 69.8 ± 8.3 
    
3,4-O-diCaffeoylquinic acid 68.1 ± 7.2 68.1 ± 6.1 72.2 ± 9.0 
3,5-O-diCaffeoylquinic acid 64.6 ± 7.3 65.1 ± 5.3 63.0 ± 7.6 
4,5-O-diCaffeoylquinic acid 67.7 ± 8.3 72.4 ± 7.2 83.1 ± 8.4 
 
   
D-(-)-Quinic acid 76.3 ± 22.9 70.3 ± 24.3 64.6 ± 30.4 
    * including corresponding metabolites (sulfates and glucuronides). 
  
202   Appendix 
 
Table 10-7: Ileal amounts of CGA and metabolites excreted after ingestion of a HIGH- , 
MEDIUM- and LOW- coffee (in µmol), ileostomist n = 5. (data expressed as mean 
values ± SD; n = 5) 
Compound HIGH MEDIUM LOW 
    
1-O-Caffeoylquinic acid 16.1 ± 4.8 9.8 ± 3.8 5.1 ± 2.1 
3-O-Caffeoylquinic acid 637.7 ± 182.6 341.9 ± 128.8 178.6 ± 68.9 
4-O-Caffeoylquinic acid 592.8 ± 169.7 312.3 ± 121.4 157.1 ± 61.6 
5-O-Caffeoylquinic acid 861.6 ± 246.1 455.0 ± 174.6 227.6 ± 88.6 
3-O-Caffeoylquinic acid-O-GlucA 4.3 ± 1.6 2.1 ± 1.0 1.2 ± 0.4 
4-O-Caffeoylquinic acid-O-GlucA 5.2 ± 1.8 2.7 ± 1.2 1.5 ± 0.6 
3-O-Caffeoylquinic acid-O-Sulf 30.3 ± 10.4 18.6 ± 8.2 9.7 ± 3.8 
4-O-Caffeoylquinic acid-O-Sulf 35.2 ± 11.9 21.7 ± 9.7 12.0 ± 4.6 
5-O-Caffeoylquinic acid-O-Sulf 1.6 ± 0.7 1.3 ± 0.7 0.8 ± 0.3 
    
3-O-Caffeolyquinide 132.0 ± 63.1 38.5 ± 19.5 15.5 ± 8.0 
4-O-Caffeoylquinide 55.8 ± 27.6 22.1 ± 10.9 9.3 ± 4.8 
3-/4-O-Caffeolyquinide-O-GlucA 16.3 ± 5.5 8.5 ± 3.8 3.0 ± 1.5 
3-/4-O-Caffeoylquinide-O-Sulf 125.3 ± 35.5 75.8 ± 27.7 33.1 ± 16.2 
    
3-O-Feruloylquinic acid 86.4 ± 24.9 45.6 ± 17.1 25.0 ± 9.5 
4-O-Feruloylquinic acid 97.5 ± 28.5 43.0 ± 16.8 23.4 ± 8.7 
5-O-Feruloylquinic acid 110.9 ± 31.6 61.1 ± 23.9 31.9 ± 12.4 
3-O-Feruloylquinic acid-O-Sulf 0.2 ± 0.1 0.2 ± 0.1 0.1 ± 0.0 
4-O-Feruloylquinic acid-O-Sulf 0.3 ± 0.1 0.2 ± 0.1 0.1 ± 0.0 
3-O-Feruloylquinic acid-O-GlucA 0.2 ± 0.1 0.1 ± 0.1 0.1 ± 0.0 
4-O-Feruloylquinic acid-O-GlucA < LOQ < LOQ < LOQ 
    
3-O-Isoferuloylquinic acid-O-GlucA 0.4 ± 0.1 0.2 ± 0.1 0.1 ± 0.0 
4-O-Isoferuloylquinic acid-O-GlucA 0.9 ± 0.3 0.6 ± 0.2 0.5 ± 0.2 
    
Caffeic acid 27.0 ± 8.0 16.2 ± 5.6 13.4 ± 4.4 
Caffeic acid-3´-O-GlucA 1.3 ± 0.5 1.2 ± 0.7 0.2 ± 0.1 
Caffeic acid-3´-O-Sulf 26.4 ± 9.4 17.0 ± 8.1 11.3 ± 4.7 
Caffeic acid-4´-O-Sulf 6.0 ± 2.0 4.1 ± 2.1 2.8 ± 1.1 
    
Dihydrocaffeic acid 7.8 ± 3.1 4.3 ± 1.2 2.2 ± 0.9 
Dihydrocaffeic acid-3´-O-Sulf 1.2 ± 0.5 0.9 ± 0.4 0.5 ± 0.2 
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Compound HIGH MEDIUM LOW 
    
Ferulic acid 5.0 ± 1.7 3.2 ± 1.0 2.9 ± 1.1 
Ferulic acid-4´-O-Sulf 2.0 ± 0.6 1.6 ± 0.4 1.7 ± 0.5 
Feruloylglycine 0.9 ± 0.3 0.3 ± 0.1 0.2 ± 0.1 
    
Isoferulic acid-3´-O-Sulf 0.3 ± 0.1 0.2 ± 0.1 0.2 ± 0.1 
    
Dihydroferulic acid-4´-O-Sulf 3.7 ± 1.0 1.8 ± 0.5 0.9 ± 0.4 
    
3,4-O-diCaffeoylquinic acid 76.4 ± 22.6 38.0 ± 14.5 18.6 ± 7.3 
3,5-O-diCaffeoylquinic acid 49.9 ± 14.7 24.9 ± 9.3 12.3 ± 4.8 
4,5-O-diCaffeoylquinic acid 71.1 ± 21.5 36.5 ± 14.2 18.0 ± 6.9 
    
    
∑ 3093.7 ± 317.0 1598.4 ± 110.7 816.6 ± 88.9 
% of ingested amount 68.8 ± 9.0 72.4 ± 4.7 77.4 ± 4.3 
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Table 10-8: Ileal excretion of CGA and metabolites given in Tmax (hours) after ingestion 
of a HIGH- , MEDIUM- and LOW- coffee, ileostomist n = 5. (data expressed as 
mean values ± SD; n = 5). 
Compound HIGH MEDIUM LOW 
    1-O-Caffeoylquinic acid 1.2 ± 1.4 1.8 ± 2.1 2.1 ± 1.3 
3-O-Caffeoylquinic acid 1.2 ± 1.4 1.8 ± 2.1 2.1 ± 1.3 
4-O-Caffeoylquinic acid 1.2 ± 1.4 1.8 ± 2.1 2.1 ± 1.3 
5-O-Caffeoylquinic acid 1.2 ± 1.4 1.8 ± 2.1 2.1 ± 1.3 
3-O-Caffeoylquinic acid-O-GlucA 2.2 ± 1.0 3.0 ± 1.5 2.6 ± 1.0 
4-O-Caffeoylquinic acid-O-GlucA 2.4 ± 1.0 2.8 ± 1.6 2.6 ± 1.0 
3-O-Caffeoylquinic acid-O-Sulf 2.1 ± 1.3 3.0 ± 1.7 2.4 ± 1.0 
4-O-Caffeoylquinic acid-O-Sulf 2.2 ± 1.2 3.0 ± 1.8 2.4 ± 1.0 
5-O-Caffeoylquinic acid-O-Sulf 3.3 ± 1.9 4.5 ± 1.5 3.4 ± 1.5 
    3-O-Caffeolyquinide 1.2 ± 1.4 1.2 ± 0.9 1.3 ± 1.3 
4-O-Caffeoylquinide 1.2 ± 1.4 1.2 ± 0.9 1.3 ± 1.4 
3-/4-O-Caffeolyquinide-O-GlucA 2.0 ± 1.1 2.2 ± 1.9 2.6 ± 1.0 
3-/4-O-Caffeoylquinide-O-Sulf 1.5 ± 1.3 2.1 ± 2.0 2.6 ± 1.0 
    3-O-Feruloylquinic acid 1.2 ± 1.4 1.8 ± 2.1 2.1 ± 1.3 
4-O-Feruloylquinic acid 1.2 ± 1.4 1.8 ± 2.1 2.1 ± 1.3 
5-O-Feruloylquinic acid 1.2 ± 1.4 1.8 ± 2.1 2.1 ± 1.3 
3-O-Feruloylquinic acid-O-Sulf 3.0 ± 0.9 3.6 ± 1.4 3.0 ± 0.6 
4-O-Feruloylquinic acid-O-Sulf 3.0 ± 1.5 3.2 ± 1.5 2.8 ± 0.8 
3-O-Feruloylquinic acid-O-GlucA 3.0 ± 1.7 3.6 ± 1.4 2.5 ± 0.5 
4-O-Feruloylquinic acid-O-GlucA 2.3 ± 0.9 4.0 ± 1.4 3.0 ± 0.0 
    3-O-Isoferuloylquinic acid-O-GlucA 3.2 ± 0.7 3.6 ± 1.4 2.8 ± 0.7 
4-O-Isoferuloylquinic acid-O-GlucA 2.8 ± 1.2 3.0 ± 0.6 2.8 ± 0.7 
    Caffeic acid 1.2 ± 1.4 1.2 ± 0.9 1.2 ± 1.4 
Caffeic acid-3´-O-GlucA 1.6 ± 1.3 1.6 ± 1.0 1.8 ± 1.4 
Caffeic acid-3´-O-Sulf 2.2 ± 1.2 3.0 ± 1.9 2.4 ± 1.0 
Caffeic acid-4´-O-Sulf 2.2 ± 1.2 2.3 ± 2.0 2.4 ± 1.0 
    Dihydrocaffeic acid 1.2 ± 1.4 1.8 ± 2.1 2.2 ± 1.4 
Dihydrocaffeic acid-3´-O-Sulf 3.6 ± 2.4 2.7 ± 2.0 2.4 ± 1.0 
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Compound HIGH MEDIUM LOW 
    Ferulic acid 1.2 ± 1.4 2.7 ± 1.9 2.8 ± 0.7 
Ferulic acid-4´-O-Sulf 3.2 ± 1.2 4.0 ± 1.7 3.1 ± 1.9 
Feruloylglycine 2.6 ± 0.8 3.2 ± 1.5 3.4 ± 1.4 
    Isoferulic acid-3´-O-Sulf 4.6 ± 2.2 3.8 ± 1.9 3.0 ± 0.6 
    Dihydroferulic acid-4´-O-Sulf 1.3 ± 1.4 2.9 ± 2.2 2.5 ± 1.1 
    3,4-O-diCaffeoylquinic acid 1.2 ± 1.4 1.8 ± 2.1 2.1 ± 1.3 
3,5-O-diCaffeoylquinic acid 1.2 ± 1.4 1.8 ± 2.1 2.1 ± 1.3 
4,5-O-diCaffeoylquinic acid 1.2 ± 1.4 1.8 ± 2.1 2.1 ± 1.3 
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Table 10-9: Ileal excretion of CGA and metabolites given in Cmax (in nmol*g-1ileal fluid) 
after ingestion of a HIGH- , MEDIUM- and LOW- coffee, ileostomist n = 5, (data 
expressed as mean values ± SD; n = 5). 
Compound HIGH MEDIUM LOW 
    1-O-Caffeoylquinic acid 72 ± 38 123 ± 118 48 ± 17 
3-O-Caffeoylquinic acid 3011 ± 1668 4601 ± 4682 1771 ± 713 
4-O-Caffeoylquinic acid 2801 ± 1516 4180 ± 4163 1583 ± 625 
5-O-Caffeoylquinic acid 4070 ± 2235 6014 ± 6029 2278 ± 902 
3-O-Caffeoylquinic acid-O-GlucA 30 ± 15 21 ± 10 11 ± 7 
4-O-Caffeoylquinic acid-O-GlucA 39 ± 21 26 ± 12 12 ± 9 
3-O-Caffeoylquinic acid-O-Sulf 206 ± 95 187 ± 121 100 ± 57 
4-O-Caffeoylquinic acid-O-Sulf 215 ± 98 276 ± 245 125 ± 63 
5-O-Caffeoylquinic acid-O-Sulf 18 ± 19 16 ± 9 8 ± 6 
    3-O-Caffeolyquinide 756 ± 392 677 ± 631 159 ± 73 
4-O-Caffeoylquinide 350 ± 243 451 ± 498 91 ± 42 
3-/4-O-Caffeolyquinide-O-GlucA 118 ± 84 76 ± 48 29 ± 23 
3-/4-O-Caffeoylquinide-O-Sulf 509 ± 332 812 ± 644 305 ± 148 
    3-O-Feruloylquinic acid 403 ± 225 610 ± 621 241 ± 97 
4-O-Feruloylquinic acid 468 ± 239 569 ± 594 239 ± 114 
5-O-Feruloylquinic acid 523 ± 296 794 ± 799 316 ± 127 
3-O-Feruloylquinic acid-O-Sulf 2 ± 1 2 ± 1 1 ± 1 
4-O-Feruloylquinic acid-O-Sulf 2 ± 1 1 ± 1 1 ± 1 
3-O-Feruloylquinic acid-O-GlucA 1 ± 1 1 ± 1 1 ± 0 
4-O-Feruloylquinic acid-O-GlucA < LOQ < LOQ < LOQ 
    3-O-Isoferuloylquinic acid-O-GlucA 3 ± 1 2 ± 1 1 ± 1 
4-O-Isoferuloylquinic acid-O-GlucA 5 ± 3 5 ± 3 3 ± 2 
    Caffeic acid 134 ± 93 301 ± 419 134 ± 87 
Caffeic acid-3´-O-GlucA 5 ± 2 7 ± 8 2 ± 1 
Caffeic acid-3´-O-Sulf 166 ± 90 208 ± 177 124 ± 85 
Caffeic acid-4´-O-Sulf 42 ± 31 54 ± 58 28 ± 18 
    Dihydrocaffeic acid 33 ± 25 39 ± 41 18 ± 12 
Dihydrocaffeic acid-3´-O-Sulf 7 ± 4 9 ± 7 5 ± 4 
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Compound HIGH MEDIUM LOW 
    Ferulic acid 24 ± 13 36 ± 33 22 ± 14 
Ferulic acid-4´-O-Sulf 12 ± 7 20 ± 27 10 ± 7 
Feruloylglycine 6 ± 4 2 ± 2 2 ± 1 
    Isoferulic acid-3´-O-Sulf 2 ± 1 2 ± 2 1 ± 1 
    Dihydroferulic acid-4´-O-Sulf 16 ± 8 23 ± 24 8 ± 4 
    3,4-O-diCaffeoylquinic acid 371 ± 186 502 ± 506 179 ± 68 
3,5-O-diCaffeoylquinic acid 242 ± 120 320 ± 315 117 ± 42 
4,5-O-diCaffeoylquinic acid 344 ± 163 461 ± 441 174 ± 72 
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Table 10-10: Renal excretion of chlorogenic acids and metabolites (in µmol) after 
ingestion of a HIGH-, MEDIUM- and LOW- coffee, ileostomists n = 5 (data 
expressed as mean values ± SD; n = 5). 
Compound HIGH MEDIUM LOW 
    
3-O-Caffeoylquinic acid 26.2 ± 27.8 14.6 ± 0.6 8.2 ± 0.5 
4-O-Caffeoylquinic acid 14.6 ± 8.0 8.6 ± 0.7 6.7 ± 1.2 
5-O-Caffeoylquinic acid 9.4 ± 7.9 6.7 ± 0.5 4.4 ± 0.4 
3-O-Caffeoylquinic acid-O-GlucA 8.3 ± 5.6 4.8 ± 0.2 1.6 ± 0.1 
4-O-Caffeoylquinic acid-O-GlucA 23.3 ± 18.2 13.3 ± 0.9 5.5 ± 0.2 
3-O-Caffeoylquinic acid-O-Sulf 5.3 ± 2.1 4.0 ± 0.2 2.2 ± 0.2 
4-O-Caffeoylquinic acid-O-Sulf 5.1 ± 1.8 3.8 ± 0.2 2.7 ± 0.2 
    
3-O-Caffeolyquinide 2.8 ± 3.0 0.8 ± 0.1 0.2 ± 0.0 
4-O-Caffeoylquinide 4.6 ± 4.7 1.5 ± 0.1 0.7 ± 0.1 
Caffeoylquinide-O-GlucA 4.1 ± 3.0 2.2 ± 0.1 0.6 ± 0.0 
Caffeoylquinide-O-Sulf 24.1 ± 6.9 23.5 ± 1.6 10.3 ± 0.6 
    
3-O-Feruloylquinic acid 33.3 ± 19.5 20.8 ± 1.4 12.3 ± 0.9 
4-O-Feruloylquinic acid 22.2 ± 17.0 14.9 ± 0.5 7.1 ± 0.8 
5-O-Feruloylquinic acid 17.0 ± 16.1 12.0 ± 0.6 7.1 ± 0.7 
3-O-Feruloylquinic acid-O-Sulf 0.3 ± 0.3 0.1 ± 0.0 < LOQ 
4-O-Feruloylquinic acid-O-Sulf 0.8 ± 0.7 0.4 ± 0.0 0.1 ± 0.0 
3-O-Feruloylquinic acid-O-GlucA 2.2 ± 1.4 1.8 ± 0.3 1.0 ± 0.1 
4-O-Feruloylquinic acid-O-GlucA 1.3 ± 1.8 0.5 ± 0.1 0.2 ± 0.1 
    
3-O-Isoferuloylquinic acid-O-GlucA 6.1 ± 3.8 3.9 ± 0.3 1.9 ± 0.1 
4-O-Isoferuloylquinic acid-O-GlucA 19.7 ± 13.8 12.9 ± 0.9 6.2 ± 0.3 
    
Caffeic acid 14.1 ± 17.8 4.6 ± 0.3 3.9 ± 0.7 
Caffeic acid-3´-O-GlucA 1.6 ± 1.3 0.5 ± 0.1 < LOQ 
Caffeic acid-4´-O-GlucA 0.6 ± 0.6 n.d. n.d. 
Caffeic acid-3´-O-Sulf 12.8 ± 3.6 11.7 ± 0.7 10.9 ± 0.7 
Caffeic acid-4´-O-Sulf 2.1 ± 0.8 1.8 ± 0.1 1.5 ± 0.2 
    
Dihydrocaffeic acid 5.1 ± 6.2 1.4 ± 0.1 1.1 ± 0.2 
Dihydrocaffeic acid-3´-O-Sulf 3.4 ± 1.3 5.4 ± 0.2 3.0 ± 0.2 
Dihydrocaffeic acid-4´-O-Sulf 0.2 ± 0.1 < LOQ < LOQ 
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Compound HIGH MEDIUM LOW 
    
Ferulic acid 17.1 ± 21.3 4.6 ± 0.6 2.8 ± 0.8 
Ferulic acid-4´-O-GlucA 14.6 ± 9.3 12.3 ± 0.7 9.9 ± 0.5 
Ferulic acid-4´-O-Sulf 17.5 ± 6.9 23.1 ± 1.2 23.8 ± 1.6 
Feruloylglycine 16.5 ± 13.3 19.3 ± 0.6 5.6 ± 0.5 
    
Isoferulic acid-3´-O-GlucA 23.7 ± 13.1 15.9 ± 1.2 11.8 ± 0.5 
Isoferulic acid-3´-O-Sulf < LOQ n.d. n.d. 
    
Dihydroferulic acid -4´-O-GlucA 2.6 ± 1.4 4.5 ± 0.7 1.1 ± 0.2 
Dihydroferulic acid-4´-O-Sulf 0.3 ± 0.2 0.2 ± 0.1 0.1 ± 0.1 
    
    
∑ 363.0 ± 223.3 256.7 ± 141.8 154.5 ± 72.1 
% of ingested amount 8.0 ± 4.9 12.1 ± 6.7 14.6 ± 6.8 
    
n.d. = not detected (< LOD) 
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Table 10-11: Renal excretion of CGA and metabolites given in Tmax (hours) after 
ingestion of a HIGH- , MEDIUM- and LOW- coffee, ileostomist n = 5. (data 
expressed as mean values ± SD; n = 5). 
Compound HIGH MEDIUM LOW 
    3-O-Caffeoylquinic acid 2.0 ± 0.0 2.0 ± 0.0 2.6 ± 1.2 
4-O-Caffeoylquinic acid 2.6 ± 1.2 2.0 ± 0.0 2.6 ± 1.2 
5-O-Caffeoylquinic acid 2.0 ± 0.0 2.0 ± 0.0 2.6 ± 1.2 
3-O-Caffeoylquinic acid-O-GlucA 3.2 ± 0.3 3.8 ± 1.5 3.2 ± 1.5 
4-O-Caffeoylquinic acid-O-GlucA 2.6 ± 1.2 2.6 ± 1.2 2.6 ± 1.2 
3-O-Caffeoylquinic acid-O-Sulf 2.0 ± 0.0 2.0 ± 0.0 2.0 ± 0.0 
4-O-Caffeoylquinic acid-O-Sulf 2.0 ± 0.0 2.0 ± 0.0 2.0 ± 0.0 
    3-O-Caffeolyquinide 2.6 ± 1.2 2.0 ± 0.0 2.0 ± 0.0 
4-O-Caffeoylquinide 3.2 ± 1.5 2.0 ± 0.0 2.0 ± 0.0 
3-/4-O-Caffeolyquinide-O-GlucA 2.0 ± 0.0 2.8 ± 1.3 2.0 ± 0.0 
3-/4-O-Caffeoylquinide-O-Sulf 2.0 ± 0.0 2.0 ± 0.0 2.0 ± 0.0 
    3-O-Feruloylquinic acid 2.0 ± 0.0 2.0 ± 0.0 2.0 ± 0.0 
4-O-Feruloylquinic acid 2.0 ± 0.0 2.0 ± 0.0 2.0 ± 0.0 
5-O-Feruloylquinic acid 2.0 ± 0.0 2.0 ± 0.0 2.0 ± 0.0 
3-O-Feruloylquinic acid-O-Sulf 3.0 ± 1.4 2.0 ± 0.0 2.0 ± 0.0 
4-O-Feruloylquinic acid-O-Sulf 2.8 ± 1.3 2.0 ± 0.0 3.0 ± 1.4 
3-O-Feruloylquinic acid-O-GlucA 2.8 ± 1.3 3.2 ± 1.5 3.8 ± 1.5 
4-O-Feruloylquinic acid-O-GlucA 3.5 ± 1.5 3.2 ± 1.5 3.8 ± 1.5 
    3-O-Isoferuloylquinic acid-O-GlucA 3.8 ± 1.5 4.4 ± 1.2 3.2 ± 1.5 
4-O-Isoferuloylquinic acid-O-GlucA 3.2 ± 1.5 3.8 ± 1.5 3.8 ± 1.5 
    Caffeic acid 2.6 ± 1.2 3.5 ± 1.5 3.2 ± 1.5 
Caffeic acid-3´-O-GlucA 2.0 ± 0.0 2.0 ± 0.0 2.0 ± 0.0 
Caffeic acid-4´-O-GlucA 3.5 ± 1.5 5.0 ± 0.0 n.d. 
Caffeic acid-3´-O-sulfate 2.0 ± 0.0 2.0 ± 0.0 2.0 ± 0.0 
Caffeic acid-4´-O-Sulf 2.0 ± 0.0 2.0 ± 0.0 2.0 ± 0.0 
    Dihydrocaffeic acid 2.0 ± 0.0 2.0 ± 0.0 2.0 ± 0.0 
Dihydrocaffeic acid-3´-O-Sulf 2.0 ± 0.0 2.0 ± 0.0 2.0 ± 0.0 
Dihydrocaffeic acid-4´-O-Sulf 2.0 ± 0.0 2.0 ± 0.0 2.0 ± 0.0 
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Compound HIGH MEDIUM LOW 
    Ferulic acid 2.0 ± 0.0 2.0 ± 0.0 7.5 ± 9.5 
Ferulic acid-4´-O-GlucA 2.6 ± 1.2 2.0 ± 0.0 2.0 ± 0.0 
Ferulic acid-4´-O-Sulf 2.0 ± 0.0 2.0 ± 0.0 3.2 ± 2.4 
Feruloylglycine 2.0 ± 0.0 2.0 ± 0.0 2.0 ± 0.0 
    Isoferulic acid-3´-O-GlucA 2.6 ± 1.2 2.0 ± 0.0 2.6 ± 1.2 
Isoferulic acid-3´-O-Sulf 2.0 ± 0.0 2.0 ± 0.0 2.0 ± 0.0 
    Dihydroferulic acid -4´-O-GlucA 25.4 ± 19.9 20.0 ± 17.1 32.7 ± 21.7 
Dihydroferulic acid-4´-O-Sulf 2.8 ± 1.3 2.0 ± 0.0 11.8 ± 18.1 
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Table 10-12: Concentrations of CGA and metabolites in urine given in 
nmol*g-1creatinine (Cmax) after ingestion of a HIGH- , MEDIUM- and LOW- coffee 
dose, ileostomist n = 5, (data expressed as mean values ± SD; n = 5). 
Compound HIGH MEDIUM LOW 
    3-O-Caffeoylquinic acid 1643 ± 1692 961 ± 635 646 ± 404 
4-O-Caffeoylquinic acid 1088 ± 809 613 ± 433 536 ± 245 
5-O-Caffeoylquinic acid 592 ± 550 463 ± 330 264 ± 170 
3-O-Caffeoylquinic acid-O-GlucA 406 ± 296 270 ± 210 117 ± 80 
4-O-Caffeoylquinic acid-O-GlucA 1303 ± 1232 680 ± 393 370 ± 176 
3-O-Caffeoylquinic acid-O-Sulf 327 ± 162 296 ± 170 123 ± 33 
4-O-Caffeoylquinic acid-O-Sulf 266 ± 115 239 ± 118 124 ± 29 
    3-O-Caffeolyquinide 222 ± 252 64 ± 51 12 ± 26 
4-O-Caffeoylquinide 313 ± 324 116 ± 91 59 ± 49 
3-/4-O-Caffeolyquinide-O-GlucA 354 ± 357 141 ± 67 56 ± 37 
3-/4-O-Caffeoylquinide-O-Sulf  2029 ± 723 1969 ± 582 945 ± 326 
    3-O-Feruloylquinic acid 2282 ± 1468 1442 ± 868 1002 ± 477 
4-O-Feruloylquinic acid 1273 ± 1022 812 ± 584 580 ± 416 
5-O-Feruloylquinic acid 919 ± 859 731 ± 425 588 ± 364 
3-O-Feruloylquinic acid-O-Sulf 38 ± 31 12 ± 3 < LOQ 
4-O-Feruloylquinic acid-O-Sulf 86 ± 72 38 ± 37 7 ± 8 
3-O-Feruloylquinic acid-O-GlucA 114 ± 47 100 ± 61 57 ± 37 
4-O-Feruloylquinic acid-O-GlucA 27 ± 8 24 ± 14 13 ± 7 
    3-O-Isoferuloylquinic acid-O-GlucA 241 ± 105 201 ± 146 138 ± 87 
4-O-Isoferuloylquinic acid-O-GlucA 887 ± 594 697 ± 500 475 ± 267 
    Caffeic acid 671 ± 775 412 ± 415 390 ± 381 
Caffeic acid-3´-O-GlucA 158 ± 156 43 ± 19 < LOQ 
Caffeic acid-4´-O-GlucA 45 ± 32 n.d. n.d. 
Caffeic acid-3´-O-Sulf 657 ± 284 629 ± 304 541 ± 195 
Caffeic acid-4´-O-Sulf 148 ± 71 134 ± 56 75 ± 20 
    Dihydrocaffeic acid 415 ± 548 122 ± 112 111 ± 112 
Dihydrocaffeic acid-3´-O-Sulf 202 ± 98 256 ± 139 184 ± 81 
Dihydrocaffeic acid-4´-O-Sulf 45 ± 51 < LOQ < LOQ 
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Compound HIGH MEDIUM LOW 
    Ferulic acid 981 ± 1145 333 ± 206 240 ± 181 
Ferulic acid-4´-O-GlucA 596 ± 379 394 ± 183 287 ± 141 
Ferulic acid-4´-O-Sulf 684 ± 352 630 ± 281 383 ± 190 
Feruloylglycine 979 ± 753 694 ± 365 308 ± 169 
    Isoferulic acid-3´-O-GlucA 1315 ± 649 791 ± 397 763 ± 379 
Isoferulic acid-3´-O-Sulf < LOQ n.d. n.d. 
    Dihydroferulic acid -4´-O-GlucA 35 ± 26 52 ± 56 10 ± 8 
Dihydroferulic acid-4´-O-Sulf 24 ± 16 15 ± 2 5 ± 5 
    n.d. not detectable < LOD 
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Table 10-13: Maximum plasma concentrations (Cmax), corresponding time point (Tmax) and AUC of CGA, (after enzyme hydrolysis) and 
quinic acid for probands after consumption of HIGH-, MEDIUM- and LOW- coffee (data expressed as mean values ± SD; n = 4). 
 
HIGH 
 
MEDIUM 
 
LOW 
Compound Cmax (nM) AUC(nM*0-8h-1) Tmax (h) 
 
Cmax (nM) AUC(nM*0-8h-1) Tmax (h) 
 
Cmax (nM) AUC(nM*0-8h-1) Tmax (h) 
            3-CQA  43 ± 10 129 ± 48 0.6 ± 0.2 
 
33 ± 13 89 ± 27 0.8 ± 0.3 
 
14 ± 6 38 ± 19 1.3± 0.4 
4-CQA 73 ± 7 222 ± 61 0.8 ± 0.3 
 
57 ± 24 156 ± 68 0.8 ± 0.3 
 
20 ± 7 64 ± 24 0.9 ± 0.2 
5-CQA 44 ± 7 125 ± 38 0.8 ± 0.3 
 
30 ± 12 85 ± 32 0.9 ± 0.2 
 
14 ± 5 43 ± 13 0.6 ± 0.2 
            3-FQA 96 ± 39 251 ± 85 0.9 ± 0.2 
 
56 ± 26 131 ± 53 0.9 ± 0.2 
 
23 ± 10 61 ± 24 1.0 ± 0.0 
4-FQA 117 ± 36 317 ± 85 1.0 ± 0.0 
 
62 ± 24 167 ± 62 0.9 ± 0.2 
 
32 ± 10 94 ± 24 0.9± 0.2 
5-FQA 45 ± 8 160 ± 51 1.1 ± 0.5 
 
41 ± 23 119 ± 66 0.9 ± 0.2 
 
16 ± 5 45 ± 6 0.8 ± 0.3 
            CA 214 ± 22 605 ± 176 0.6 ± 0.2 
 
162 ± 52 445 ± 172 0.9 ± 0.2 
 
77 ± 12 243 ± 71 0.5 ± 0.0 
DHCA 63 ± 18 153 ± 65 0.5 ± 0.0 
 
35 ± 11 77 ± 30 0.5 ± 0.0 
 
53 ± 13 51 ± 70 0.8 ± 0.3 
FA  518 ± 76 937 ± 157 0.5 ± 0.0 
 
214 ± 39 453 ± 93 0.5 ± 0.0 
 
147 ± 27 377 ± 84 0.5 ± 0.0 
IFA 262 ± 91 559 ± 249 0.5 ± 0.0 
 
110 ± 6 190 ± 43 0.5 ± 0.0 
 
76 ± 27 344 ± 315 0.7 ± 0.2 
DHFA 85 ± 12 173 ± 27 0.6 ± 0.2 
 
34 ± 12 78 ± 50 0.9 ± 0.2 
 
22 ± 16 64 ± 55 0.5 ± 0.0 
            DiMeCA 305 ± 63 824 ± 154 0.6 ± 0.2 
 
129 ± 55 357 ± 117 0.8 ± 0.2 
 
58 ± 21 88 ± 48 0.6 ± 0.2 
DiMeDHCA 67 ± 55 208 ± 185 0.3 ± 0.2 
 
28 ± 22 42 ± 25 0.8 ± 0.2 
 
59 ± 15 213 ± 186 0.8 ± 0.3 
            
 
Cmax (µM) AUC(µM*0-8h-1) Tmax (h) 
 
Cmax (µM) AUC(µM*0-8h-1) Tmax (h) 
 
Cmax (µM) AUC(µM*0-8h-1) Tmax (h) 
            D-(-)-QA 4.2 ± 0.4 24.4 ± 5.6 5.0 ± 1.0 
 
2.5 ± 0.6 14.8 ± 5.0 4.5 ± 0.9 
 
1.2 ± 0.1 8.0 ± 0.5 5.2 ± 1.0 
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Table 10-14: Distribution of coffee polyphenols and D-(-)-quinic acid after 4 h 
incubation with pig mucosa in an Ussing chamber (mean ± SD as a percentage 
of the initial concentration; n = 4). 
 Compartment 
 Mucosal Serosal Tissue 
Mucosal application (20 µM)       
    
1-O-Caffeoylquinic acid* 97.2 ± 8.6 1.4 ± 0.7 1.3 ± 0.5 
3-O-Caffeoylquinic acid* 98.8 ± 6.3 1.0 ± 0.3 1.0 ± 0.5 
4-O-Caffeoylquinic acid* 95.0 ± 7.4 1.0 ± 0.3 1.1 ± 0.6 
5-O-Caffeoylquinic acid* 95.4 ± 6.8 0.87 ± 0.19 1.4 ± 0.8 
    
Caffeic acid 97.7 ± 6.7 1.4 ± 0.8 1.3 ± 0.3 
    
D-(-)-Quinic acid 103.1 ± 11.5 3.9 ± 1.3 1.5 ± 0.6 
    
3-O-Feruloylquinic acid 100.9 ± 15.1 2.6 ± 1.4 1.4 ± 0.3 
4-O-Feruloylquinic acid 83.9 ± 3.9 2.0 ± 0.3 1.1 ± 0.5 
5-O-Feruloylquinic acid 98.6 ± 2.9 2.6 ± 0.5 1.6 ± 0.5 
    
3,4-O-diCaffeoylquinic acid 84.4 ± 4.2 < LOQ 0.16 ± 0.05 
3,5-O-diCaffeoylquinic acid 61.8 ± 20.0 < LOQ 0.18 ± 0.04 
4,5-O-diCaffeoylquinic acid 95.2 ± 10.0 < LOD < LOD 
    
5-O-Caffeoylquinic acid (100 µM)* 118.5 ± 13.1 1.6 ± 0.2 1.4 ± 0.7 
5-O-Caffeoylquinic acid (500 µM)* 130.9 ± 30.5 1.8 ± 0.5 0.6 ± 0.1 
5-O-Caffeoylquinic acid (1000 µM)* 98.7 ± 6.5 1.1 ± 0.5 1.0 ± 0.8 
5-O-Caffeoylquinic acid (2000 µM) 106.6 ± 9.9 1.8 ± 1.0 1.3 ± 0.4 
5-O-Caffeoylquinic acid (3500 µM) 94.7 ± 8.8 1.3 ± 0.5 1.9 ± 0.6 
    
Serosal application (20 µM)       
    
5-O-Caffeoylquinic acid 2.3 ± 0.6 100.7 ± 14.0 0.5 ± 0.3 
5-O-Caffeoylquinic acid + NaN3 1.3 ± 0.5 77.1 ± 14.4 0.8 ± 0.3 
    
*data was achieved in cooperation with Johanna Hauser 
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Table 10-15: Permeation rates of individual CGA and QA through the pig jejunal tissue (in nmol*cm-2) during the incubation experiments 
in the Ussing chamber at 1, 2, 3 and 4 h. Permeation was determined from mucosal to serosal direction (muc application) or from 
serosal to mucosal direction (ser application) in concentrations from 20 up to 3500 µM. 
Compound Application Conc. (µM) 1 h 2 h 3 h 4 h 
       Caffeoylquinic acids 
      1-CQA* muc 20 0.02 ± 0.04 0.24 ± 0.15 0.46 ± 0.26 0.71 ± 0.43 
3-CQA* muc 20 0.04 ± 0.07 0.24 ± 0.15 0.43 ± 0.20 0.68 ± 0.29 
4-CQA* muc 20 0.11 ± 0.09 0.38 ± 0.22 0.70 ± 0.33 1.06 ± 0.43 
5-CQA ser 20 0.16 ± 0.05 0.66 ± 0.17 1.57 ± 0.67 2.86 ± 1.02 
           5-CQA + NaN3 ser 20 0.07 ± 0.06 0.42 ± 0.29 0.88 ± 0.46 1.33 ± 0.81 
5-CQA* muc 20 0.12 ± 0.06 0.35 ± 0.16 0.56 ± 0.29 0.78± 0.39 
5-CQA* muc 100 0.44 ± 0.04 2.07 ± 0.18 4.51 ± 0.24 6.47± 0.66 
5-CQA* muc 500 2.60 ± 0.89 10.91 ± 1.74 22.96 ± 4.4 34.9 ± 8.4 
5-CQA* muc 1000 4.05 ± 2.73 16.95 ± 8.77 34.60 ± 16.60 59.12 ± 28.20 
5-CQA muc 2000 10.47 ± 4.81 42.80 ± 15.48 95.73 ± 20.40 175.50 ± 31.67 
5-CQA muc 3500 9.54 ± 3.98 59.52 ± 21.83 114.08 ± 40.25 218.37 ± 82.52 
       Feruloylquinic acids 
      3-FQA muc 20 0.10 ± 0.13 0.66 ± 0.27 2.03 ± 1.38 3.65 ± 2.63 
4-FQA muc 20 0.17 ± 0.10 0.67 ± 0.28 1.60 ± 0.58 2.60 ± 0.66 
5-FQA muc 20 0.12 ± 0.08 0.73 ± 0.25 1.95 ± 0.60 3.88± 0.92 
       Caffeic acid muc 20 0.09 ± 0.04 0.37 ± 0.20 0.80 ± 0.43 1.28 ± 0.72 
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Compound Application Conc. (µM) 1 h 2 h 3 h 4 h 
       D-(-)-Quinic acid muc 20 0.32 ± 0.37 1.25 ± 0.71 2.01 ± 1.24 5.40 ± 2.20 
       *data was achieved in cooperation with Johanna Hauser 
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Table 10-16: Jejunal tissue conductance (in % of initial value 0 hours) during the incubation in the Ussing chamber after 1 h, 2 h, 3 h and 
4 h with CGA and D-(-)-QA from coffee. Application of compounds was performed on mucosal (muc) or serosal (ser) compartment 
of the Ussing chamber with concentrations form 20 up to 3500 µM. 
Compound Application  Conc. (µM) 1 h 2 h 3 h 4 h 
       Caffeoylquinic acids 
      1-CQA* muc 20 125.4 ± 27.8 146.9 ± 30.4 186.0 ± 26.5 234.8 ± 30.7 
3-CQA* muc 20 133.4 ± 36.2 170.5 ± 39.6 218.3 ± 45.9 283.1 ± 44.3 
4-CQA* muc 20 123.9 ± 25.5 138.1 ± 31.8 178.4 ± 43.3 209.7 ± 52.8 
5-CQA   ser 20 149.7 ± 18.5 176.7 ± 14.9 210.0 ± 19.7 356.2 ± 62.2 
           5-CQA + NaN3 ser 20 140.8 ± 29.8 196.3 ± 54.9 228.7 ± 63.6 274.6 ± 88.8 
5-CQA* muc 20 124.7 ± 27.1 143.6 ± 31.1 176.6 ± 44.8 231.4 ± 49.8 
5-CQA* muc 100 129.8 ± 26.1 138.3 ± 25.5 156.9 ± 28.7 184.5 ± 33.0 
5-CQA* muc 500 151.9 ± 31.0 185.5 ± 35.1 246.5 ± 40.1 423.7 ± 52.5 
5-CQA* muc 1000 137.0 ± 15.8 156.2 ± 17.7 191.0 ± 26.4 282.9 ± 40.4 
5-CQA muc 2000 125.9 ± 34.8 141.4 ± 29.1 156.2 ± 31.2 168.9 ± 17.2 
5-CQA muc 3500 149.9 ± 18.8 165.0 ± 23.8 193.6 ± 35.6 294.4 ± 86.7 
       Feruloylquinic acids 
      3-FQA muc 20 153.5 ± 25.5 171.1 ± 26.8 189.0 ± 32.0 210.8 ± 37.1 
4-FQA muc 20 139.4 ± 10.1 146.4 ± 14.7 166.1 ± 21.5 185.4 ± 28.2 
5-FQA muc 20 149.0 ± 8.8 184.0 ± 11.6 248.4 ± 21.0 274.7 ± 13.5 
       Caffeic acid muc 20 142.1 ± 13.7 172.8 ± 12.6 196.1 ± 12.5 243.0 ± 23.9 
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Compound Application  Conc. (µM) 1 h 2 h 3 h 4 h 
       D-(-)-Quinic acid muc 20 133.2 ± 21.8 168.9 ± 24.8 212.0 ± 46.3 245.7 ± 56.1 
       diCaffeoylquinic acids 
     3,5-diCQA muc 20 124.5 ± 28.7 120.5 ± 18.5 168.4 ± 24.4 212.3 ± 21.8 
3,4-diCQA muc 20 157.5 ± 44.7 161.5 ± 38.5 190.6 ± 41.6 232.6 ± 50.4 
4,5-diCQA muc 20 125.8 ± 30.3 151.3 ± 30.6 157.3 ± 28.9 184.6 ± 30.0 
       *data was achieved in cooperation with Johanna Hauser 
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